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In this work, novel oral drug delivery formulations were developed for the administration 
of hydrophobic therapeutics, with the overarching goal of improving their solubility and 
permeability in the gastrointestinal tract. We have developed a set of four nanoscale hydrogels, 
formulated by incorporating different hydrophobic monomer components, and screen them for 
optimal physicochemical properties, drug loading and release, and ability to modulate intestinal 
permeability and P-glycoprotein related drug efflux. Here, we employ an evolved paradigm of in 
vitro tests to gauge the potential of these novel nanoscale carriers for the specific application of 
improving oral solubility and permeability of poorly water-soluble and less permeable 
therapeutics. 
All the responsive nanoscale hydrogels are capable of undergoing a transition in size in 
response to change in pH. We capitalize on the interplay between the incorporated hydrophobic 
monomer choices and screened resulting physicochemical properties to determine an optimal 
nanoscale formulation. Depending upon the selection of the hydrophobic monomer, the sizes of 
the nanoparticles vary widely from 120 nm to about 500 nm at pH 7.4. We also evaluate 
cytocompatibility of the nanoparticle formulations in vitro in the presence of an intestinal 
epithelial cell mode to find that all formulations are reasonably cytocompatible. Subsequently, 
we discuss some of the key findings and results of characterization studies that validate the 
success of achieving desired molecular architecture and physicochemical properties of the 
formulation. We then confirm the capacity of the nanocarrier to be able to load and release 
hydrophobic therapeutics in gastrointestinally relevant environments. Further, the ability of the 
nanocarriers to transport the hydrophobic therapeutic doxorubicin is determined by evaluating 
permeability of doxorubicin with intestinal epithelial cell monolayers. Furthermore, demonstrate 
functional abilities desired from a therapeutically relevant, oral delivery system is tested. 
Specifically, to overcome problems associated with P-glycoprotein related efflux and reduced 
drug permeability in the small intestine, we evaluated the ability of the nanoformulation to 
achieve therapeutic success in relevant and characteristic in vitro cancer cell lines. Finally, we 
make concluding remarks on the ability of the nanoparticles to function as improved 
formulations of hydrophobic therapeutics capable of performing and achieving the end-goal of 
delivering hydrophobic therapeutics orally for the treatment of cancer.  
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Chapter 1:  Introduction  
Despite momentous achievements in the field of tumor biology, cancer diagnosis and 
treatment, cancer continues to be the second leading cause of death in the US. Cancer continues 
to remain  the lives of over half a million Americans each year, with one in every 4 deaths 
resulting from cancer. It is responsible for about 5 million hospitalizations among adults in a 
year.   
Cancer begins as a localized, malignant tumor that can be successfully removed if 
detected at that stage. However, about 80% of the cancer cases are detected after cancer has 
spread to other organs of the body. Usually, the patient undergoes surgical resection of the 
primary tumor followed by chemotherapy or radiation therapy to eliminate any metastases or 
secondary tumor. Chemotherapy may be also used for shrinking the tumor to surgical 
proportions. While such therapies show increased success rates over the last decade, post-
surgical cancer metastasis is responsible for 90% of all cancer-related deaths
 
reflecting upon the 
need to develop more effective treatment modalities.  
Primary and metastasized cancer hospitalizations alone account for a whopping $58 
billion in costs, a number $15 billion higher than the combined costs for septicemia, 
osteoarthritis and atherosclerosis. Cancer-related surgeries specifically, account for an estimated 
25% of the hospitalization costs, while intravenous, in-patient chemotherapy accounts for 
approximately 14%. At the present rate of cancer incidence, the financial burden associated with 
cancer is expected to increase by 39% in the next decade, primarily, due to establishment of 
specialized, targeted treatments requiring in-patient hospitalization.  
The high direct and indirect costs associated with cancer treatment in addition to the 
discomfort incurred as a result of chemotherapy and subsequent loss of productivity; indicate the 
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need for further improvements in cancer treatment technologies. It is of critical importance that 
we address the shortcomings of the current treatment regimens for cancer or even find 
alternatives. Oral chemotherapeutic delivery can alleviate some of the side effects associated 
with intravenous chemotherapeutic administration and even supplant surgery as a treatment 
option, if the bioavailability of the cancer drug following intestinal absorption is good.  
An inherent setback of small molecule cancer drugs is their hydrophobicity. Most cancer 
drugs are developed by modifying drug leads based on natural compounds. For example, 
doxorubicin, a commonly used cancer drug is obtained by modifying an antibiotic secreted by 
Streptomyces peucetius). Similarly, a lot of focus is devoted to develop anticancer drugs that 
selectively target cancerous cells, through high-throughput drug target screening and related 
technologies. Drug molecules that result from such a screening processes are rarely ever efficient 
in terms of deliverability, with about 60% of them being hydrophobic. Moreover, it is 
economically unfeasible to simply discard these recalcitrant, yet effective drugs and continue 
looking for hydrophilic drugs that can be easily delivered to the tumor target. Although there is 
an increasing trend to synthesize analogues of existing antineoplastic agents (eg. daunorubicin 
from doxorubicin) in a manner similar to that used to treat arteriosclerosis (eg. everolimus from 
sirolimus), the hydrophobicity issue remains to be resolved. There is no doubt that development 
of drug delivery systems capable of effectively delivering hydrophobic drug molecules for 
cancer and other diseases is the need of the hour. Such advancements in cancer therapy are 
imperative not only for increasing patient survival rates but also improving the quality of life of 
patients.   
In this proposed thesis, we focus on the development, characterization and optimization 
of nanoscale hydrogels for the oral delivery of hydrophobic agents. Our overall goal is to 
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examine polymeric nanoparticles for their ability to load hydrophobic therapeutic agents, retain 
the drug during gastric transit, and release it in the small intestine. Such carriers can permit 
superior control over physicochemical properties that determine the fate of substance in the GI 
tract. Parameters such as the constituent hydrophobic monomer, cross linking density, and the 
hydrophobic monomer content will be controlled to exploit GI tract conditions for enhancing 
delivery of the hydrophobic drugs doxorubicin and tamoxifen, in vitro, across Caco-2 cell 
monolayers.  Consequently, such oral drug delivery systems have the potential to overcome the 
innate drawbacks imposed by the molecular structure of hydrophobic chemotherapeutics.    
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Chapter 2:  Objectives of Proposed Research  
In this work, we propose the development of a novel oral drug delivery system for the 
administration of hydrophobic therapeutics. We first describe the motivation and rationale 
behind the design of such a system, and underline the need for the desired molecular 
architecture. We then move onto delineating the actual facile synthesis method used to produce 
such a system. Subsequently, we discuss some of the key findings and results of characterization 
studies led to examine and validating the success of achieving desired molecular architecture and 
physicochemical properties of the formulation. We then confirm the capacity of the nanocarrier 
to be able to load and release hydrophobic therapeutics in gastrointestinally relevant 
environments. Further, the ability of the nanocarriers to demonstrate functional abilities desired 
from a therapeutically relevant, oral delivery system is tested. Specifically, we establish the 
ability of the nanoformulation to achieve therapeutic success in relevant and characteristic cancer 
cell lines, with the overarching goal of corroborating hydrophobic drug delivery in an in vitro 
cell model. Finally, we make concluding remarks on the ability of the nanoparticles to function 
as improved formulations of hydrophobic therapeutics capable of performing and achieving end-
goal of delivering hydrophobic therapeutics orally for the treatment of cancer; while, 
summarizing the results from our studies, and touching upon some of the inherent, ineluctable 
limitations of the system and enunciating modifications to design parameters and experimental 
studies for future reference. Here, we employ an evolved paradigm of in vitro tests to gauge the 
potential of these novel nanoscale carriers for the specific application of improving oral 
solubility and permeability of poorly soluble and less permeable therapeutics. We develop a set 
of four nanoscale hydrogels, formulated by incorporating different hydrophobic monomer 
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components, and screen them for optimal physicochemical properties, drug loading and release, 
and ability to modulate intestinal permeability.  
In this proposed PhD thesis, we focus at achieving the following goals:  
 To design, synthesize and characterize polyanionic nanoscale hydrogels that are capable 
of efficiently loading and release of hydrophobic therapeutics such as chemotherapeutics; 
 To examine and compare the loading and release behaviors of different formulations and 
arrive at an optimal formulation 
 To evaluate their in vitro cytocompatibility and transport properties across an intestinal 
epithelial model 
 
We propose to design and develop methacrylic acid based nanoscale hydrogels, which will 
be optimized by varying hydrophobic monomer component, hydrophobic monomer percentage 
content and the cross linking density of the polymeric networks. We hypothesize that the use of 
hydrogels, which are optimized for better loading and release of hydrophobic therapeutics, can 
enhance the intestinal transport of such drugs and open up a window of opportunity for orally 
treating diseases that can be accessed through the blood stream. Finally, we intend to test the 
capacity of our oral drug delivery system to modulate intestinal permeability. 
  
The specific aims of this research are: 
 To synthesize and characterize methacrylic acid based polyanionic, nanoscale hydrogel 
networks for the oral delivery of hydrophobic therapeutic agents 
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 To design and develop a loading and release protocol for encapsulating hydrophobic 
drugs within the nanoscale hydrogels, and examine modulation of hydrophobic solute 
permeation through the gels 
 To evaluate and compare the in vitro biocompatibility and transport properties of the 
developed nanoscale hydrogels  
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Chapter 3:  Cancer  
Cancer starts as a malignant tumor that has genetically lost its ability to undergo 
controlled growth and cellular division owing to mutations leading to overexpression of 
oncogenes and underexpression of tumor suppressor genes [11]. This malignant tumor 
dangerously and dramatically evolves into a pervasive disease with an intricate vasculature, by 
facile adoption of a set of principles commonly known as the hallmarks of cancer. Malicious 
tumor cells acquire self-sufficiency in growth signals and insensitivity to antigrowth signaling to 
conveniently overcome inherent growth regulatory constraints, which would otherwise limit 
normal cell growth and ensure homoeostasis. In fact cancer cells and adjacent normal cells rely 
on each other to acquire remarkable control of mitogenic growth signaling and the eventual 
growth factor independence [12,13].  
Furthermore, cancer progresses by avoiding apoptosis, a characteristic that allows them 
to replicate uncontrollably and limitlessly. These burgeoning, aberrant cells explicably require 
unprecedented amounts of oxygen and nutrition to flourish. In a state of hypoxia, the tumorigenic 
tissue activates an otherwise dormant endothelium through proangiogenic factors and start 
building their own vascular network using proliferating and elongating endothelial cells [14]. 
Particularly, when a tumor reaches 2mm in diameter, oxygen is unable to diffuse throughout all 
cancer cells within the tumor [15]. Hypoxic cancer cells start a pro-angiogenic signaling process 
that ultimately translates into secretion of growth factors and extracellular matrix components 
(ECM) that induce the angiogenic process [16]. Angiogenesis sustains the continued growth of 
malignant tumors by providing oxygen and nutrients and disposing of waste products over the 
period of disease progression. These newly formed small blood vessels are critical for the 
survival and metastasis of the primary tumor to other organs of the body, spreading the 
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malignancy and advancing the stage of the disease. Compelling evidence in numerous mouse 
models of inhibition of the customary “angiogenic switch” that triggers the resilient foray of 
primary tumor cells to other body organs, has indicated halt of tumor growth and metastatic 
spread [17,18].  
The process of angiogenesis is as complex as cancer itself, comprising of several steps 
and ancillary diffusible factors that facilitate the development of a supportive vascular network. 
As expected, cancer cells are equipped to escalate the production of proangiogenic factors and 
downregulating angiogenesis inhibitors, thus thwarting the natural balance of angiogenic factors. 
The initiation of angiogenesis involves extravasation of plasma proteins, degradation of 
extracellular matrix to allow migration of cells, followed by actual endothelial cell proliferation 
and migration, and capillary tube formation. Anti-angiogenic therapy is an approach, which 
circumvents the issue of metastasis by choking out overgrown tumors and enhances the 
therapeutic benefit achieved by anti-cancer drugs.  
Eventually, tumor cells emigrate to other distant organs through such capillary sprouts 
and colonize those locations by adapting to the surrounding milieu over time [19]. Sometimes, 
these immigrating “micrometastases” (i.e., a small number of cancer cells that have spread 
beyond the original tumor) are able to camouflage themselves from diagnosis and detection by 
remaining dormant and not displaying the characteristic “hallmarks” evidenced by cancer cells 
[20]. These cells lack the potential to vigorously grow and replicate or activate angiogenesis 
when initially circulating systemically or settling in other organs. After several cycles of 
replication and evolution, ranging over a period of days to decades, they achieve enhanced 
survival capabilities and resume their cancerous behavior with unparalleled metastatic fury 
leading to unexpected tumor regression [21,22].            
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3.1 CURRENT STATE OF CHEMOTHERAPY  
Intravenous administration of chemotherapeutics continues to be the beacon of hope for a 
majority of cancer malignancies, with the obvious caveat of systemic toxicity morbidly lining the 
therapeutic benefits earned. Success in chemotherapy requires dosage of hydrophobic 
therapeutics over sufficiently long exposure time periods and at concentrations that are above the 
therapeutic limit and lower than the toxic limit. In fact, a common strategy is to attack cancerous 
cells with a high payload of cytotoxic drug at one go, thereby not allowing cancer cells to build 
immunity for the drug or its structural analogues [23].  
Systemic drug delivery has a merit in these regards, since it helps achieve high systemic 
concentrations of the drug after intravenous infusion permit cytotoxic drugs to reach distant 
organs at efficacious concentrations. Moreover, administration of a drug directly into the blood 
flow has the unique benefit of accessibility to a number of remote organs and tissues enabling 
eradication of micrometastases. With access to remote tissues and organs, a therapeutic luxury 
unavailable to other modes of treatment such as surgery or loco-regional drug delivery, 
intravenous administration has emerged to be the practical route of administering 
chemotherapeutics.  
A pronounced increase in the concentration of the drug in the bloodstream also implies 
increased risk of normal cell and tissue drug exposure, thus, greatly limiting the cogency of the 
treatment. Thus, a major stumbling block in the employment of this ostensibly simple strategy is 
the off target effect of potentially cytotoxic chemotherapeutic drugs that persist in the 
bloodstream for prolonged time periods. In addition to serious side effects as result of exposure 
to normal cells and tissues, the actual procedure of intravenous administration of 
chemotherapeutics itself is accompanied by distinct challenges. The highly invasive procedure 
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uses major veins to distribute drugs effectively and can subject the patient to the perils of local 
complications resulting from the extravasation of drugs into proximate tissues [24].  
Hydrophobic drugs are contrived into an intravenous formulation by utilizing surfactants 
(such as Cremophor EL) for enhancing their solubility in the saline fluid as well as blood stream 
[25]. Such surfactants have been known to stimulate hypersensitivity reactions at tissues close to 
the point of injection. Moreover, since many anticancer drugs dosages tenuously rely on the cell 
cycle and are schedule dependent, they require continuous administration; thereby eliminating 
the possibility of outpatient IV administrations. Although hospital admissions systemic 
administration is an invasive treatment modality, requiring hospital admissions, infusion 
supplies, surfactants and implantation of catheters in major blood vessels. These patent 
disadvantages reveal that intravenous administration is not only sophisticated but also cost 
prohibitive.  
Other routes of administration such as oral or topical delivery are used only for a select 
number of cancers at specific stages of tumor growth [26]. Approaches such as topical (loco-
regional) therapy rely on the premise of selective impingement of anticancer drugs to the 
diseased area eliminate the need for surgery or intravenous treatment while optimizing the 
benefits offered by both. However, this mode of application is excessively complex and requires 
highly skilled technical professionals [26].  
Despite the obvious off-target effects of intravenous anticancer drug administration, one 
of the main reasons this potentially lethal strategy continues to dominate cancer treatment 
modalities is the lack of development in the sector of oral formulations for most hydrophobic 
cancer drugs [27].  Problems such as lack of availability of bioequivalent oral formulations for 
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most drugs, poor absorption of drugs across the epithelial layer and into the bloodstream, 
cytotoxic effects to the gastric inner lining and inconsistency in the tissue/plasma concentration 
of the drug transported across the GI tract beset the oral delivery of hydrophobic drugs [27]. 
Despite possessing the clear advantage of being the most convenient and comfortable mode of 
administration for cancer patients, the absence of innate mechanisms that can boost the ability of 
hydrophobic drugs to infiltrate the bloodstream after transit through the GI tract has been a 
fundamental impediment to the widespread applicability of this treatment modality.  
3.2 LIVER CANCER 
Liver cancer is defined as the uncontrolled, abnormal growth of hepatocytes in the liver. Owing 
to the ease of access that hepatocytes have to blood flow, liver cancer is typically diagnosed in its 
late metastatic stage, after the spread of cancerous cells to distant organs of the body through 
blood circulation. The causes of liver cancer are purported to be hepatitis B or C virus infection 
and even alcoholic cirrhosis. Liver cancer is the fifth most common cancer in the world and the 
third most common cancer-related cause of death with a five-year survival rate of less than 5% 
[28,29]. Advanced hepatocellular carcinoma (HCC), the metastatic form of the disease is known 
for the over-expression of p-glycoprotein and the resultant multidrug resistance [30-32]. Hence, 
liver cancer can serve as a multidrug resistant cancer model in addition to being a metastatic 
cancer model.  Moreover, first pass metabolism in the liver is similar to intestinal first pass 
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metabolism owing to the presence of such efflux transporters [33]. As a result, drugs that can 
permeate through intestinal enterocytes may also be transported into hepatocytes. Liver cancer is 
an example disease model that can use an effective oral delivery system that can deliver the drug 
directly to the liver subsequent to intestinal absorption.  Specifically, the nanoscale hydrogels 
will be used to enhance intestinal permeability of a chemotherapeutic drug, and the effect of the 
nanoscale hydrogel on modulation of P-gp will be studied.  
In addition to chemotherapy, treatment for metastatic liver cancer involves dosage of 
Nexavar
® 
(sorafenib), an orally active multikinase inhibitor that blocks the action of Vascular 
endothelial growth factor receptors (VEGFR) and hinders angiogenesis. However, sorafenib is 
used in conjunction with regular intravenous chemotherapy and is not an alternative to it. 
Recently, doxorubicin loaded poly(isohexyl cyanoacrylate) nanoparticles showed great promise 
against liver cancer. This nanoparticle formulation of doxorubicin, called as LivaTag
®
 , is 
currently undergoing clinical trials and is administered intravenously.  
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Chapter 4:  Oral Delivery of Hydrophobic Therapeutics 
4.1 CLASSIFICATION OF HYDROPHOBIC DRUGS  
Classification standards proposed for orally delivered drugs declassified their common 
characteristics, enabling the pharmaceutical industry to develop strategies to deliver them more 
effectively. These classification systems afford a representation of the in vivo bioavailability of 
these drugs, based solely on the in vitro evaluation of properties such as solubility, 
permeability/metabolism and even dissolution rate. It is important to note that this classification 
system applies not just to pure drugs, but also to formulations/excipients containing the drug. 
Excipients/formulations that can reclassify the drug owing to their overall solubility/metabolic 
properties open up the opportunity to avoid in vivo bioequivalence studies. As a result, 
enhancement of solubility and permeability (or inhibition of efflux transporters) can be used as a 
guide to develop suitable oral drug delivery systems for chemotherapeutics. At present, the 
classification system and the related FDA policies are restricted to pure drugs or immediate 
release oral solid dosage forms (Excipient + active pharmaceutical ingredient). However, in the 
future, we foresee such a classification system and the FDA policies to serve as a basis in order 
to govern the outcomes of carriers delivering the drugs orally. 
4.2 HYDROPHOBIC BEHAVIOR BASED ON THE BIOPHARMACEUTICS CLASSIFICATION 
SYSTEM 
The biopharmaceutics classification system (BCS) identifies aqueous solubility and 
intestinal permeability as the two fundamental parameters controlling drug absorption and 
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bioavailability following oral intake [1]. All drugs can be classified into four classes, namely: (i) 
 Class I (high solubility, high permeability),  
(ii)  Class II (low solubility, high permeability),  
(iii) Class III (high solubility, low permeability), and  
(iv)  Class IV (low solubility, low permeability).  
Currently, the United States Food and Drug Administration (U.S. FDA) utilizes the BCS 
(which was developed by an academic, Prof. Gordon Amidon of the University of Michigan, and 
an FDA researcher, Dr. Vinod Shah during Amidon’s sabbatical leave at FDA about twenty 
years ago) to waive in vivo bioequivalence studies and simplify regulatory pathways for BCS 
Class I drugs and/or solid dosage formulations incorporating the drug, if they display high 
solubility, and high intestinal permeability in vitro [2,3]. FDA’s BCS guidance also recommends 
the use of Caco-2 cell monolayer transport studies to predict absorption of drugs in humans [4]. 
This oral drug delivery guidance system recognizes the intestinal jejunum to be the predominant 
site of drug absorption into the blood stream as it presents the largest surface area for 
permeation.  
In addition to Class I drugs, Class II (low solubility, high permeability) drugs may stand a 
chance of getting waivers if their solid oral dosage is formulated to possess in vivo dissolution 
rates faster than the gastric emptying time or the GI transit time [2]. In general, Class II drugs 
have high permeability into intestinal enterocytes mainly due to high lipid solubility, which 
enhances partitioning of the drug into intestinal epithelial membranes and makes permeation 
through the lipophilic cell membranes rather easy.  
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4.3 HYDROPHOBIC BEHAVIOR BASED ON THE BIOPHARMACEUTICS DRUG DISPOSITION 
CLASSIFICATION SYSTEM  
The Biopharmaceutics Drug Disposition Classification System (BDDCS) system developed by 
Wu and Benet further expands the concept of intestinal permeability to include metabolism in the 
intestine and liver [1]. Prof. Les Benet of the University of California at San Francisco was the 
original pioneer who analyzed drug transport in the GI tract but was omitted during the 
development of the BCS. He responded by providing a deep and thorough molecular and cellular 
evaluation of drug transport that corrected some of the shortcomings of the Amidon-Shah 
development. It is interesting that Benet and Amidon finally published an article together in 2008 
[5]. In fact just this month, Benet and associates [6] published the most comprehensive analysis 
of drug transport in tissues and cells with a detailed understanding of the transport mechanisms 
and the various methods. Indeed, lipophilic compounds that permeate through the membrane of 
epithelial cells (in a transcellular manner) also exhibit affinity for metabolizing enzymes/efflux 
transporter related enzymes present in the intestine and liver [7,8].  
BDDCS stipulates additional insight into mechanisms governing gastrointestinal 
permeability of drugs; mainly, efflux and absorptive transporters, metabolic routes of drug 
elimination, and the effect of concurrent food intake. This modified criteria for bioequivalence 
evaluation, thus, better envisages drug absorption, distribution, metabolism and excretion. Such 
classification gains unprecedented relevance in the case of cancer drugs, which display meager 
bioavailability subsequent to oral administration owing to efflux transporters.  
BDDCS identifies and accounts for the fact that the more permeable lipophilic drugs are 
good substrates for cytochrome P450 enzymes (CYP) enzymes [9]. It notes that Class I high 
solubility/high permeability drugs avoid efflux transporters by saturating them, thereby ensuring 
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high bioavailability.  For hydrophobic cancer drugs, however, which belong to Class II and 
Class IV owing to their low solubility, the concentrations entering intestinal enterocytes is 
severely limited, making saturation of efflux transporters and enzymes impossible and leading to 
low bioavailability. According to BDDCS, high-fat meals may enhance bioavailability of Class 
II and Class IV therapeutics. This increase in bioavailability is explained by inhibition of P-
glycoprotein transporters after a high-fat meal and additional solubilization of the drugs in the 
intestinal lumen due to micelle formation [10].      
4.4 GASTROINTESTINAL TRACT PHYSIOLOGY FOR ORAL DELIVERY 
Drug delivery systems can enable protection of therapeutics from the highly variable, 
dynamic milieu encountered during transit through the GI tract [11]. The GI tract spans from the 
mouth to the large intestine, and is sub-divided into an “upper” region (comprising of the mouth, 
esophagus, and stomach) and a “lower” region (comprising of the small intestine- duodenum, 
jejunum, ileum, and, the large intestine- caecum, colon, rectum). Throughout its extent, the GI 
tract is covered with mucus-lined epithelial cells that tightly and selectively regulate the 
movement, retention and uptake of orally ingested therapeutics based on solubility, surface 
properties and intermolecular interactions [12-18].  
In addition, the harsh environment of the GI tract has been programmed to safely and 
fastidiously absorb materials into the blood stream. For instance, the highly acidic setting of the 
stomach (~pH 2 in a state of fasting) and the bevy of enzymes (lipases, proteases, etc.) released 
to facilitate digestion can potentially degrade or deactivate the therapeutic function of most 
agents. Even doxorubicin, a relatively stable anthracycline, may be susceptible to degradation 
under gastric conditions, although the deleterious activity of doxorubicin against the gastric 
lining and encompassed enzymes is a bigger concern [19]. Also, retention of substances in the 
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stomach is subject to dietary and individual inconsistencies making transit times through the 
stomach highly variable [20].  Moreover, the gastric lining enclosing this acidic environment 
does not provide an opportunity for absorption into the bloodstream, precluding the stomach as a 
potential target for enhancing drug release into the bloodstream [21].  
The highly digestive environment of the stomach is followed by the duodenum in the 
small intestine, wherein pancreatic enzymes and bile salts are released in a timely manner to 
further scavenge and effectively breakdown nutrients from foodstuffs.  It is also important to 
note, that the pH of the GI tract lumen increases from a value of ~2 in the stomach to value of 5-
6 in the duodenum and further to a value of 7 in the jejunum and ileum.  
Conditions of drug stability are more favorable in the neutral pH of the small intestine 
than the acidic conditions of the stomach. However, the absorptive enterocytes of the small 
intestine are covered by a highly viscoelastic mucosal layer capable of clearing any drug released 
to the mucosal lumina through mucus clearance mechanisms [22]. Such clearance mechanisms 
are designed to proactively trap and efficiently expel any foreign bodies or particles that do not 
interact well with the mucosal layer [23].  Consequently, our drug carrier would be required to 
diffuse through the mucus layer or even adhere to it, in order to ensure retention of the drug at 
the release location. 
Moreover, most hydrophobic anticancer drugs such as doxorubicin, paclitaxel, etc., are 
known to act as substrates for p-glycoprotein efflux pumps expressed on most intestinal 
epithelial cells [24]. Located on the apical side of the intestinal epithelium, these transporter 
proteins, selectively and actively transport certain molecules out of the intestinal epithelial cells 
[25,26]. Understandably, this natural detoxification mechanism primarily designed for purging 
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immunosuppressants, malevolently foils any advantage conferred by strategies to improve 
solubility and permeability of chemotherapeutics [27-29].  
Despite the number of challenges faced by orally delivered therapeutics, the 8m long 
lower region of the GI tract does present 300-400 m
2 
of surface area for drug absorption into the 
bloodstream owing to the presence of villi in the intestinal region [30]. Increasing the retention 
time of the drug in this region can facilitate drug absorption into systemic circulation. Improved 
retention of entities in the intestinal region can, in turn, be accomplished by encouraging 
interactions between the drug carrier and the mucus layer secreted by goblet cells. As a result, 
there has been increased focus on technologies that develop mucoadhesive carriers that can 
release therapeutics specifically in the intestinal region.    
4.5 NANOTECHNOLOGY FOR ORAL DELIVERY OF HYDROPHOBIC DRUGS 
4.5.1 Use of surfactants 
 
Low molecular weight surfactants such as polyoxyethylated castor oil (Cremophor EL 
~1200-1600 Da) are commonly used to facilitate the solubilization of hydrophobic drugs in the 
bloodstream during intravenous administration. On similar lines, Cremophor EL formulations of 
paclitaxel (a mitotic drug used to treat breast and lung cancers) called Paxoral™ have been tested 
in clinical studies to determine their efficacy at delivering the poorly water soluble payload 
orally [32]. However, severe toxicity of Cremophor EL at early stages of the transit through the 
GI tract (mouth and esophagus) has deterred widespread acceptance of surfactant-based 
formulations in oral cancer treatments. Moreover, surfactant-based micelles displayed premature 
release of paclitaxel in the upper GI tract posing a significant risk of cell and tissue damage to 
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the gastric lining [32,33].  
4.5.2 Drug Nanocrystal Formation 
Formulating nanocrystals of pure lipophilic drugs is a rapidly emerging pharmaceutical 
processing technology to greatly improve their surface area and, in turn, lead to increased 
dissolution velocity and saturation solubility in the intestinal lumen [34,35]. Also, these 
nanocrystals have demonstrated increased bioadhesion to the intestinal mucosal wall, thereby 
increasing retention time of the drug and maintaining high enough local drug concentrations to 
sustain a concentration gradient across the wall [36]. A combination of these factors translates 
into improved bioavailability of the drugs in the bloodstream.  
Nanocrystals can be produced by precipitation and aggregation of drug solutions 
(“bottom up”) or by reducing the particle size down to the nanoscale (“top down”). Nanocrystals 
can be precipitated out of solution by adding the drug solution to an organic solvent [37], 
although the use of organic solvents is considered discouraging. “Top down” approaches 
physically break down large particles into nanocrystals by milling and high-pressure 
homogenization, and are more amenable to scale-up for large scale processing.     
Despite these advantages promoting widespread pharmaceutical use, it is important to 
note that this approach uses surfactants such as Tween 80, Tween 20, to stabilize the 
nanocrystals. The use of such hypersensitivity inducing surfactants in addition to the enhanced 
exposure of pure drug to the gastric lining can be a major cause of concern, especially for oral 
delivery of cytotoxic chemotherapeutics [32]. Furthermore, high bioavailability of such drugs 
implies higher systemic exposure to possibly toxic concentrations of anticancer drugs. Active 
targeting or passive targeting using the enhanced permeation and retention effect (EPR) to 
specific diseased organs can address this issue. 
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4.5.3 Beta Casein Nanoparticles 
Synthetic or natural materials that can acquire an amphiphilic structure or can be 
combined with other components to possess an inner hydrophobic core have been a major focus 
of study. Beta-casein is one particular material that is interesting from the standpoint of oral 
delivery of hydrophobic drugs. A protein found in bovine milk, beta casein can be fashioned into 
forming a self-assembled micellar structure under environmental conditions contingent upon the 
pH, temperature, and ionic strength [38,39]. Previous studies have demonstrated the ability of 
beta-casein to preferentially associate to lipid-soluble entities such as vitamin D3, vitamin A and 
sucrose esters by way of van der Waals interactions [40-42]. Effective delivery of a drug 
involves interplay of factors such as rate of release as well as the stability of the molecular 
association between the carrier and the entrapped drugs, so as to avoid premature release. It is of 
utmost importance to retain potentially cytotoxic drugs until they reach the desired site of release 
suggesting the need to design systems that can accommodate and release hydrophobic drugs in a 
stable and timely manner. Thermodynamics of the binding between beta-casein and lipophilic 
molecules and the stability of the micelles in aqueous has previously been verified [33], 
endorsing the use of beta-casein based micelles for such applications. 
Shapira et al. [42] have investigated the utility of beta-casein micellar nanoparticles as 
enzymatically degradable drug delivery systems that can deliver hydrophobic drugs such as 
mitoxantrone for the treatment of gastric cancer. Beta-casein nanoparticles in the size range of 
100-300 nm were formed by continuous addition of hydrophobic drug molecule to an aqueous 
solution of beta-casein in Phosphate Buffered Saline (PBS) at concentrations above and below 
the critical micellization concentration (CMC). Intermolecular hydrophobic interactions between 
the beta-casein molecules and amongst beta-casein-hydrophobic drug molecules are responsible 
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for entrapment of drug within the hydrophobic micellar core. Blocking contact amid the 
hydrophobic agent and the external hydrophilic environment in such a manner holds promise for 
solubilization of many cancer drugs. Versatility of beta-casein micelles in solubilizing a number 
of hydrophobic cancer drugs possessing diverse functional groups has also been demonstrated 
[43]. Once formed, beta casein nanoparticles retained the drug until they were subjected to 
degradative enzymatic conditions similar to the gastric environment indicating their utility for 
treatment of gastric malignancies. Under simulated gastric conditions, about 85-90% of the drug 
was released within 10-20 min of incubation [44], suggesting the prevalence of fast release 
kinetics. Tuning degradation rate by coating pure beta-casein nanoparticles with dietary fibers 
can facilitate targeting to other organs down the GI tract such as the colon. Despite great 
promise, the use of beta casein is restricted to gastric tumors mainly due to their degradability in 
the harsh enzymatic environment of the stomach.  
4.5.4 Chitosan-based oral delivery systems 
Chitosan is a naturally derived macromolecule that can be leveraged for improving drug 
solubility and loading while fulfilling the imperative requirement of biocompatibility. A rich 
body of work has focused on synthetically enhancing the properties of chitosan to tailor its 
ability to target specific cells or release drugs in a site-specific and controlled manner [45]. Two 
important parameters that can be controlled to modify the properties of chitosan particles are the 
molecular weight and the degree of deacetylation [46]. In addition, chitosan has a number of 
amine, hydroxyl and carboxylic groups that can be chemically modified to vary its 
physicochemical properties and influence drug deliverability. 
Chitosan nanoparticles can be covalently crosslinked to cancer drugs, superparamagnetic 
oxides by using multifunctional agents such as glutaraldehyde, polyethylene glycol (PEG) 
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dicarboxylic acid, and acrylate-based molecules [47,48]. Free radical polymerization has been 
used to create chitosan hydrogel nanoparticles with distinct physical properties and achieve 
consistency in molecular weight distribution and particle size. De Moura et al. [49] achieved 
deliberate conformity in random polymerization by using equivalent amounts of poly(methyl 
methacrylate) that could match up to the amine functionality existing in chitosan.  
Similarly, thiolated chitosan was used to increase solubility of hydrophobic 
polyalkylcyanoacrylates (PACA) by using a random free radical emulsion polymerization 
technique that led to the formation of hydrophobic core characterized by PACA and hydrophilic 
shell of chitosan [50]. The hydrophobic shell can possibly entrap hydrophobic drugs while the 
presence of thiolated chitosan can improve therapeutic level of the drugs owing to increased 
mucoadhesion.     
A crucial touchstone for prolific oral delivery in the small intestine is the mucoadhesion 
of the drug carrier. Hydroxyl and amine groups in the glycoproteins predominant in intestinal 
mucus can establish strong hydrogen bonds with functional groups of chitosan leading to 
significantly higher retention times of the nanoparticles within the GI tract [23,51]. Improved 
mucoadhesive properties typically correlate with higher bioavailability of drugs in the 
bloodstream as the drug gets longer time periods to diffuse across the GI tract. Significantly 
improved mucoadhesion due to increased charge density in the case of chitosan, can however, 
also be a cause of concern since a longer contact time with epithelial cells can be potentially 
deleterious [52].   
4.5.5 Dendrimers  
Dendrimers are another important class of polymeric carriers that can solubilize 
hydrophobic anticancer drugs and enable transport of the covalently linked drug across the 
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intestinal epithelium. Chemically, dendrimers are nanoscale macromolecules possessing a unique 
functional architecture consisting of branches that can attach to drugs or targeting moieties for 
improved therapy. The layers of polymeric branches former after every generation form an 
external barrier that can retain the drugs captured within the inner core [52-56]. Polyamido 
amine (PAMAM) dendrimers have been reported to show superior transport properties across the 
mucosal GI tract into the bloodstream [57-59] and significantly improved biodistribution 
subsequent to intestinal absorption. These synthetic are able to permeate through intestinal 
barriers through passive transcellular and paracellular transport owing to sizes in the range of 1-5 
nm [60-62]. 
Previous research work utilizing generation 4 (G4) PAMAM dendrimers for oral drug 
delivery exposed their instability in harsh acidic environments of pH 5 and were even shown to 
be toxic to intestinal epithelial cells restricting the concentrations of the dendrimer (and 
consequently, the drug too) that could be used [63]. Slow release kinetics, with only 40% of the 
drug releasing within 24 hours of incubation at a pH of 7.4, indicated a further barrier to their use 
[64]. More recently, Goldberg and coworkers [65] have conjugated the extremely lipophilic and 
cytotoxic campothecin to PAMAM dendrimers to increase solubility and reduce toxicity of DNA 
topoisomerase inhibitor, 7-ethyl-10-hydroxy campothecin. Modification in the number of 
conjugated molecules resulted in moderation of the surface charge on these dendrimers.  
Previous studies have shown a tangible impact of surface charge of the dendrimers on the 
intestinal absorption of the polymer-drug conjugate in addition to the opening of tight junctions 
and the mechanism of transport [66]. It is hypothesized that a reduction in the surface charge of 
the dendrimer, typically by PEGylation, followed by an increase in the hydrophobicity of the 
polymer, leads to a decrease in the opening of tight junctions, and restricts transport to a 
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transcellular mechanism. Transport studies completed by Goldberg and associates [65] were able 
to demonstrate a notable increase in the uptake of the dendrimer-drug conjugate as opposed to 
the drug alone. This increase in uptake across the intestinal epithelium suggests synergy between 
transcellular, receptor mediated endocytosis and paracellular, diffusive mechanisms to facilitate 
transport of these generation 3.5 dendrimers across the intestine.  
Thus, this class of polymers shows great promise for oral delivery although the need to 
covalently conjugate drugs to the polymer may chemically restrict certain drugs to be used in 
such formulations. The lack of any in vivo studies may limit discussions regarding any immune 
response that may be elicited by these polymers. Moreover, no insight was provided for only 50-
60% release in the “simulated” target organ environment (liver) by enzymatic cleavage of the 
covalent bond between the drug and the polymer. Reliance on enzymatic cleavage and the slow 
release kinetics could potentially restrict practical application of these nanoscale delivery 
systems despite their remarkable ability to travel across intestinal barriers. 
4.5.6 Self-nanoemulsifying drug delivery systems  
One way of improving the prospects of oral delivery of hydrophobic drugs is the increase 
in the dissolution rate of the drug. Self-nanoemulsifying drug delivery system (SNEDDS) is an 
emulsification technology that increases the surface area available for a given volume of drug 
solution to diffuse out, thereby augmenting the dissolution rate of such pharmaceutics. Such 
systems are capsules fabricated using biopolymers such as gelatin and hydroxypropylmethyl 
cellulose (HPMC) and incorporate a dry mixture of oil and surfactant within. Upon absorption of 
gastric fluids, a stable oil-in-water emulsion results owing to stabilization by surfactants present 
in the encompassing capsule. These 150-200 nm nanoemulsion colloids have demonstrated 
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significantly high bioavailability of lipophilic drugs such as simsvastatin, atorvaststin, ezetimibe 
and exetimibe [67,68].     
Hydrophobic molecules used in these devices are typically glycerides such as oleic acid, 
caprylic acid, glycerol monooleate, which are known to facilitate association with lipophilic 
drugs, enhance membrane permeation and even intestinal lymphatic transport [67,68]. 
Components such as these address metabolism-related issues impairing intestinal transport of 
lipophilic drugs by inhibiting gastric enzymes and hindering activity of the efflux transporter 
cytochrome p450. This increases overall permeability of the drug nanoemulsion across the 
intestine and justifies the subsequent high bioavailability of the drug.  
These systems have, however, drawn criticism for their use of hypersensitivity inducing 
surfactants in their formulations. Surfactants such as Tween 80, Cremophor EL, and poloxamer 
188 are known to induce severe hypersensitivity reactions when in contact with tissues [69-71]. 
Moreover, these nanoemulsions show significantly higher uptake in lymphoid tissues, suggesting 
their use may be restricted only to immune related diseases or the HIV/herpes-related cancers 
affecting the immune system such as Kaposi’s sarcoma. 
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Figure 1:  Efflux and uptake transporters present on the apical and basolateral sides of the 
small intestine. Adapted from [31]. 
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Figure 2: Schematic representation of pathways for intestinal transport: (a) transcellular active 
transport, (b) transcellular passive transport, and (c) paracellular transport through 
tight junctions. Adapted from [7]. 
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Chapter 5:  Delivery of Chemotherapeutics using Nanotechnology  
5.1  INTRODUCTION  
It is well understood that the size, charge and surface properties of nanomaterials will 
determine their physiological fate.  In order to effectively design nanomaterials for cancer 
therapy, these parameters must be tailored to traverse the restrictions imposed by human and 
cancer physiology. While chemical synthesis and facile design procedures are widely reviewed, 
the precise effect of modulating these three key parameters to direct their biological fate in the 
context of cancer treatment is refreshed regularly. These properties can chemically engineered 
nanomaterials to increase likelihood of therapeutic success. 
 Rational design and engineering of nanomaterials requires elucidation of verifiable 
design criteria, which in the case of nanomaterial product development have historically been 
their size, charge and surface properties. The diverse physiological barriers presented by primary 
tumors, organs affected by metastasis, and tumor interstitium prevent universal design 
considerations. As such, nanoscale therapeutics for cancer therapy face unique challenges in that 
they must integrate features to propagate across diverse physiological barriers and cater to 
changing disease states, expression levels of molecular targets, and vasculature, in a scalable and 
economical manner. Here is a review of recent work in the development of nanoscale 
therapeutics for cancer therapy with a specific focus on delivery to primary, metastatic, and 
multi-drug resistant cancers.  
 Literature is abound in research highlighting the successful implementation of engineered 
nanomaterials for cancer treatment, despite modest overall survival benefits. Marginal 
improvements arising from nanotechnological solutions, have raised concerns emphasizes the 
need to reflect back on the chemical and molecular design of materials led by recent reveals of 
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primary tumor and metastatic cancer physiology. Elegance in design criteria that may appear to 
simplify nanomaterial product development, has been offset by the challenges that are 
concomitant with a diverse target range of physiochemical barriers presented in myriad cancers, 
organs, and cell lines. Hence, here are some of the recent efforts to understand the impact of 
chemical and molecular design on the ultimate biological fate of engineered nanomaterials to 
enable engineers to develop more potent and clinically efficacious nanoscale formulations. It is 
important to note that just as one therapeutic may not be effective against all cancers; one 
nanoparticle design may not be suitable to treat all cancer types. Chemical and molecular 
engineering of nanoformulations should reflect on and learn from reveals in the knowledge of 
tumor cell, tissue and microenvironment related biochemical features and entities. 
5.2.  CURRENT STANDARD OF CARE  
 Nanotechnology has been chiefly leveraged to compliment chemotherapeutic treatment 
that ensues surgical resection of tumor and/or radiotherapy. The likelihood of two therapeutic 
events is facilitated by nanotechnology- passively funneling to disease site/ targeting (based on 
size/epr) and active targeting (physiological goals based on organ-specific, cellular, or 
subcellular targets). Identification of molecular targets has advanced the development of 
nanomedicine design through established drugs/more potent drugs/peptides/RNA 
molecules/biologics). Newer nanoparticles are being developed and investigated to Emerging 
research in nanotechnology aims at developing novel platforms that can improve the efficacy of 
such potent drugs/biologics by specifically transporting them to the site of action. NCI intitiative 
recently highlighted some of the progress that has been made in conjunction with associated 
researchers. Recent approaches in nanotechnology rely on passive targeting to accumulate within 
the tumor area, and exploit active targeting of molecular targets to achieve drug delivery to the 
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site of action. Successful formulations will need to sustain relevant circulation concentration, 
navigate to the tumor tissue area based on physicochemical properties, and finally effect delivery 
under specific conditions. 
 Reaching the tumor tissue subsequent to circulation in the blood, is largely a passive 
process unless the nanoparticle is designed to be targeted to the specific tumor vasculature. This 
process is dependent chiefly on the size of the nanoparticles so that it avoids clearance prior to 
accumulation within tumor tissue by enhanced permeation and retention effect (EPR). It is also 
possible to elongate circulation time by minimizing interaction of the formulation with blood 
constituents. This can be done reducing surface charge by using PEG tethers thereby avoiding 
opsonization. Active targeting is of immense relevance once the nanoparticle has extravasated 
into tumor tissue. Such targeting is based on the principal that extravsated nanoparticles can be 
induced into anti-cancer action upon activation by tumor microenvironment or external 
triggering.  
 One unique challenge is manufacturing nanoparticle platforms that can integrate features 
to propagate successfully through the diverse physiological barriers to cater to changing disease 
states, expression levels of molecular targets, and vasculature, in a scalable and economical 
manner. 
5.2.  NANOMATERIALS USED IN CANCER THERAPY  
 Nanomaterials for use in therapeutic applications must be designed to navigate the 
challenges presented by cancer physiology.  The most commonly employed nanomaterials in 
research for cancer therapy are polymers, inorganic nanoparticles such as gold, iron oxide and 
mesoporous silica, and carbon based materials such as carbon nanotubes or graphene. Polymer 
nanoparticles have been researched extensively for various drug delivery applications and have 
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well characterized synthesis methods including solvent evaporation, nanoprecipitation, emulsion 
polymerization, and controlled/living radical polymerizations as shown in Fig. 1.[1],[2]
 
Both 
degradable and non-degradable nanoparticles have been utilized for cancer therapies, with the 
most commonly employed polymeric material being PLGA due to relatively non-toxic 
degradation products and FDA approval [3, 4]. Gold and iron oxide nanoparticles have been of 
great interest as nanomaterials for cancer therapy because of their ability to be remotely heated 
by IR light and magnetic fields respectively [5, 6]. In the past decade, mesoporous silica based 
nanotherapeutics for cancer have increased in popularity because of the ability to tailor surface 
functionality and load drugs into pores [7-9]. Carbon based materials such as carbon nanotubes 
and graphene have also emerged as promising candidates for cancer therapy due to high surface 
area and ability to be used in photothermal therapies [10, 11].   
5.3.1 Size 
 Based upon current knowledge of cancer physiology, nanomaterials in the range of 100-
200nm have the highest chance of reaching cancerous tissues through passive targeting methods.  
However, many variables can influence the ability of a drug delivery system to reach these tumor 
cells.  A single step assembly of PLGA-lecithin-PEG nanoparticles loaded with doxorubicin and 
indocyanine green for a chemotherapy photothermal combination therapy for cancer by a single 
step sonication method was recently reported by Zheng et al.  Loaded particles had a 
hydrodynamic radius 97.6nm and demonstrated a synergistic effect compared to monotherapies 
in inducing apoptosis in both doxorubicin sensitive and doxorubicin resistant MCF-7 cell lines in 
vitro while suppressing tumor growth in vivo [12].  Mitragotri and colleagues recently 
demonstrated that rod shaped nanoparticles conjugated with the targeting antibody trastuzumab 
demonstrated higher specific uptake and decreased nonspecific uptake in a series of breast cancer 
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cell lines in comparison to spherical nanoparticles [13].  In addition, the antibody conjugated 
rod-shaped nanoparticles demonstrated an enhanced ability to inhibit growth BT-474 breast 
cancer cells in-vitro.  
5.3.2 Charge 
 The charge on polymeric nanomaterials is a result of functional groups incorporated 
during polymerization.  Cationic polymers result from the incorporation of amine containing 
monomers, while anionic polymers typically result from acid containing monomers.  New 
advances controlled/living radical polymerization by Matyjaszewski and colleagues, have 
allowed for enhacned control over polymer architecture with a reduction in catalyst required with 
techniques by ARGET ATRP [14-16]. Forbes et al. recently employed an ARGET ATRP 
emulsion polymerization technique to synthesize cationic nanogels composed of 
diethylaminoethyl methacrylate with poly(ethylene glycol) tethers that could be complexed with 
siRNA and loaded with a small molecule drug.  Particle sizes were 120nm with pH dependent 
drug release, and have potential for local delivery to colon cancer or to multi-drug resistant 
cancer cells by intravenous injection [17].  
5.3.3 Functionality 
Graphene and graphene oxide have recently surfaced in the field of intelligent drug 
delivery as drug and gene carriers.   One such carrier is a nanosized chitosan-functionalized 
graphene oxide, which served to enhance biocompatibility and solubility.  Further, the authors 
demonstrated the ability to effectively load camptothecin as a result of pi-pi stacking and 
hydrophobic interaction and transfect HeLa cells using luciferase as a gene reporter [18]. Liu et 
al. synthesized polyion complexes with passive and active targeting, cell membrane 
 60 
translocation, pH dependent drug release, and co-delivery capabilities.  TAT was conjugated to 
the distal end of PEG in poly(ethylene imine)-poly(ethylene)glycol copolymers, and  
doxorubicin was chemically conjugated to amino group of the PEI with a hydrazone linkage. 
Electrostatic interactions were then used to bind DNA to the PEI backbone, and a NGR 
functionalized virus mimetic shell to the surface of the polyion complex [19].    
5.4  DELIVERY TO PRIMARY CANCERS 
 Primary cancers can be described as tumors that have not shown growth of carcinogenic 
entities in sites other than the organ of origin. For most primary cancers, surgical resection of 
tissue remains as the first mode of therapeutic action, especially in colon cancer. This is usually 
followed by radiation therapy and chemotherapy to ensure complete elimination of cancerous 
cells and possible metastases. Both these treatments are not without undesirable side effects. 
Hence, considerable research focus has been devoted to minimizing off-target effects and 
making treatment more targeted to cancerous cells and tissues. Examples of targeted radiation 
therapy include. Approaches modulating particle size, charge and active targeting continue to 
dominate targeted therapy in primary cancer treatment.   
 Primary tumors usually vary in size and microenvironmental characteristics depending on 
progression of growth, thereby presenting unique challenges for delivery of therapy. On the basis 
of steps taken to accomplish intracellular delivery of therapeutics, the following barriers are 
exhibited in the case of primary cancers – (1) Blood vessels and the circulatory system (as the 
therapeutic is transported through blood flow to the region of therapeutic action) (2) Tumor 
interstitium (Upon penetration through blood vessel wall, the therapeutic will encounter the 
interstitial space or extracellular matrix filling the blood vessel margin and cancer cells, (3) 
Target cancer cells [20]. Complex, multilayered problems are presented by the metastatic version 
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of cancer, expanding the target area of therapy to organs other than the primary site of disease, 
along with the possible presence of metastases in the blood or lymph.  Furthermore, multidrug 
resistance occurs in cancer cells when cells develop mechanisms to resist chemotherapeutic 
agents [19]. Each step presents its own unique set of challenges that have informed design 
considerations in cancer nanomedicine. To demonstrate efficacy, most anti-cancer drugs have to 
be present in the correct dosage and appropriate activity level, within the nucleus of the cancer 
cells, and in the case of monoclonal antibodies, sometime to the cell surface receptors. Loss or 
inability of active pharmaceutical ingredients to reach their final destination results in ineffective 
treatment, or sometimes worse- off-target side effects. Understanding the physiochemical 
intricacies of each environment is crucial to achieve this. Here is a review of the most recent 
findings that may inform rational design of nanomedicine, or highlight work that has 
demonstrated successful delivery in vitro or in vivo. 
 Nanoscale therapeutics are typically administered intravenously, and spends most of its 
biological presence traversing through thse blood circulation. This presents the most challenges 
to the delivery efficacy, which if not addressed, could lead to rapid and significant clearance of 
the therapeutic before it can even reach the relevant site. Fortunately, design considerations to 
evade circulatory clearance have received tremendous, well-deserved attention.  
 Size is an important consideration post interstitial/ intravenous administration of 
nanotherapeutics, as the appropriate size can enable preferential uptake in the lymph and avoid 
drainage back into the blood. Experimental evidence shows that particles with size <10nm are 
uptaken rapidly by lymph nodes, but are at higher risk of resorption back into the blood flow [20, 
21]. On the other hand, particles >100nm may remain accumulated at the injection site instead of 
being transferred into the lymphatic circulation [22, 23]. In general, smaller nanoparticles have 
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faster clearance kinetics from the blood as well as the lymphatic system. Renal clearance occurs 
if the size of the nanomedicine is smaller than 10 nm [3]. On the other end of the scale, however, 
if the size is increased beyond a certain threshold, the nanoscale entity can more readily adsorb 
proteins and undergo opsonization in blood flow, subsequently becoming vulnerable to uptake 
by macrophages and reticuloendothelial clearance [4].  
 Studies investigating surface charge effects show that the uptake of neutral or positively 
charged nanoparticles by macrophages/lymphocytic bodies is drastically low as compared to 
negatively charged nanoparticles. While modulating surface charge has not demonstrated any 
relief from renal/hepatobiliary clearance, neutral or positively charged particles are known to 
avoid uptake by macrophages/lymphocytic bodies. Similarly, the influential role played by 
poly(ethylene glycol) (PEG) in avoiding non-specific protein adsorption and thus improving 
circulation time, has driven numerous preclinical studies and engendered the widely accepted 
DOXIL- a PEGylated liposomal formulation of doxorubicin.  
 Other surface coatings that hold immense promise in masking nanotherapeutics from the 
typical clearance mechanisms in the body are red blood cells/erythrocytes themselves and 
polysaccharides such as cyclodextrin, heparosan and hyaluronic acid owing to properties such as 
biocompatibility, biodegradability, and ability to be chemically modified. There is a growing 
body of work enunciating the exemplary effects of coating nanoparticles with erythrocytes to 
enhance circulation time, as well as improve intracellular concentration of drugs. Self-assembly 
micelles based on heparosan and deoxycholic acid conjugate have been reported to show 
superior DOX loading (into the hydrophobic deoxycholic acid core) and release, and enhanced 
cellular uptake in HeLa cells [24]. One reason to seek other surface modification alternatives 
over PEG is the reported activation of the complement immune pathway by PEGylated 
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liposomes. Negatively charged heparosan avoided adsorption of serum protein components and 
extended intravenous circulation time of the formulation, and could be a potential substitute for 
the popular alternative PEG. The use of PEG has also been reported to create several problems 
such as reduced cellular uptake (due to the hydrophilicity of PEG) and poor endosomal escape 
subsequent to endocytosis (due to minimal interaction with endosomal lipids) [25]. Neutral or 
negatively charged nanoparticles seeking access to the lymphatics avoid electrostatic interaction 
with negatively charged glycosaminoglycans, and are able to enter the lymphatic system more 
readily. Cationic nanoparticles can form high molecular weight aggregates with interacting 
proteins precluding absorption from the injection site. Lymph node retention of drug delivery 
devices is commonly increased by using an increased size (physical filtration) or increased 
hydrophobicity/receptor interactions. By contrast, drainage into the lymphatics from the blood 
necessitates opposing properties [26]. 
 Solving the problem of short circulation times, leads us to our next challenge; permeating 
the blood vessel at the appropriate location and entering the tumor interstitial matrix. While this 
seems rather intuitive and easy, the complexity of myriad tumors and the high interstitial 
pressure in the surrounding microenvironment makes this a force to reckon with. Research 
suggests that small molecules and particles, will prominently extravasate in normal tissues 
instead of the tumor tissues, owing to relatively higher interstitial fluid pressures in tumors [27]. 
Pores in normal vessels have an average cross-section of, while that in tumor associated vessels 
are. Evidence also indicates that increasing the size above may exclude extravasation into tumor 
interstitium surrounded by the lower threshold of blood vessel pore diameter, and negate the gain 
in selectivity. Particle size will have to be balanced and optimized to cater to individual tumor 
and microenvironments. Even if penetration into the interstitial space is achieved, the tumor 
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environment itself is spatially heterogeneous, further impeding transport of particles of certain 
size. Furthermore, surface charge and shape of nanoparticles can also influence extravasation and 
interstitial transport. Jain et al. have revealed that cationic particles permeate better through 
tumor endothelial cells and blood vessel in relation to neutral or anionic particles. But, there is no 
doubt that neutral particles undergo minimal interaction with components of the interstitial 
matrix and diffuse faster through the interstitium than cationic or anionic particles. Linear, 
polymeric particles are supposed to diffuse faster than spherical, rigid particles although there is 
no consensus on the reason behind this observation.        
 One reason to seek other surface modification alternatives over PEG is the reported 
activation of the complement immune pathway by PEGylated liposomes. Drawing inspiration 
from LDL receptors that dissociate in response to the intracellular environment, PEGylated 
nanocarriers can be designed to respond to stimuli such as pH, reducing agents, cathepsins, 
esterases or matrix metalloproteinases to shed/dissociate the PEG coating entailing 
biodistribution in the tumor site [28-32].  
 Strategies relying on the EPR effect typically involve a hydrophobic core and a coating 
with PEG polymer for biocompatibility, which is good for small molecule hydrophobic drugs 
which otherwise exhibit a dismal pharmacokinetic profile.  Fig. 2 illustrates the intravenous 
administration of nanotherapeutics that utilize the EPR for passive targeting to tumor tissues.  An 
emerging class of nanomaterials is being constructed using single-walled carbon nanotubes with 
the overarching aim of improving tumor uptake in intravenously injected nanoparticles by means 
of the EPR effect. To gain a deeper understanding of how SWNTs may be internalized by cells, 
Smith et al. performed in vivo studies in mice and compared internalization of SWNT by blood 
cells to that of PEG, and found that SWNTs were rapidly internalized by cells [33]. Conversely, 
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SWNTs were not uptaken by phagocytic cells, in addition to not activating monocytes 6 hours 
past uptake. Intriguingly, monocytes containing SWNTs were found to increasingly penetrate the 
tumor interstitium and vasculature as compared to other circulating monocytes. This leads into 
insight indicating that SWNTs may further infiltrate the tumor interstitium by entering 
circulatory cells employing a “Trojan Horse mechanism”, in addition to the EPR effect.  
 In contrast to passive targeting, active targeting approaches can be used to further 
improve effectiveness and minimize off-target effects. Because of their specificity, peptides are a 
natural choice for use as targeting ligands [34]. It has been a long standing obstacle to deliver 
nanocarriers with peptidic ligands that may be susceptible to enzymatic degradation and lower 
affinity compared to antibodies. This can be resolved by introducing D-amino acids or 
multivalent sequences into the peptide sequence. Most commonly used peptidic sequences 
include cyclic RGD sequences that recognize ανβ3 integrin receptors, CSNIDARAC peptides for 
lung tumors, EPPT peptides for tumor-specific antigen underglycosylated mucin-1, F3 peptides 
that target endothelial cells lining the tumor vasculature, and also a wide range of membrane 
receptors for cholecystokinin, GRP and somatostatin [35]. 
 Aptamers have gained considerable popularity as targeting ligands because of their high 
specificity, low cost, lower toxicity and immunogenicity, and smaller size. Development of 
aptamers by the systematic evolution of ligands through exponential enrichment allows for an 
elegant way to produce a more robust group of targeting biomolecules as opposed to protein-
based ones [36]. So far, aptamer ligands have been prepared for IgG receptors, tyrosine kinase 
receptors, E-selectin, nucleolin, and other tumor molecules and cells.  
 To demonstrate efficacy in treatment of primary cancers, most anti-cancer drugs have to 
be present in the correct dosage and appropriate activity level, inside the cancer cells, or in the 
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case of monoclonal antibodies, at the cell surface. Loss or inability of active pharmaceutical 
ingredients to reach their final destination results in ineffective treatment, or sometimes worse- 
off-target side effects. 
 The facility to selectively compartmentalize drug molecules makes liposomes, vesicles, 
and micelles lucrative from a drug delivery standpoint. Such nanocarriers are constructed with a 
precise control over the molecular architecture, permitting loading of a variety of anticancer 
drugs such as hydrophobic small molecules, proteins, siRNAs, and even plasmids [29]. 
Sequential addition of individual layers complemented with external triggers based on pH, light, 
and temperature can release drugs in a site-specific manner. Of noteworthy mention is the use of 
PEG as the outermost layer of such multi-layered nanoformulations, primarily for achieving the 
benefit of biocompatibility and minimization of non-specific interactions upon intravenous 
administration.     
 Block copolymers have traditionally been the synthetic constructs/building blocks of 
these composite nanocarriers. Block copolymers have traditionally been the synthetic 
constructs/building blocks of these composite nanocarriers and have been reviewed elsewhere 
[37]. Of notable mention, is the recent use of polyion complex vesicles (PICsomes) synthesized 
from block copolymers, with the aim of delivering hydrophobic as well as hydrophilic anticancer 
drugs. Kishimura and group mixed oppositely charged diblock copolymers to attain self-
assembly of PICsomes [38]. One unit of PICsome (uPICsome) was made from a block of PEG 
and a segment of charged poly(amino acid)s for the diblock copolymer uPICsome. Modulating 
the concentration of uPICsomes allowed for tunability of size and drug release kinetics.       
 For selective delivery of plasmid DNA (pDNA) to tumor cell nuclei, Nomoto et al. 
synthesized PEG-PAsp(DET)-PLys triblock copolymers and added them to a pDNA solution to 
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fabricate self-assembled three-layered polyplex micelles in a bottom-up fashion [39]. Longer 
circulation times, a prerequisite for effective intravenous anticancer therapy, were achieved 
through the use of a PEG shell compartment. Selectivity was obtained by including a 
photosensitizer in the design, which allowed intracellular gene delivery only after infrared 
irradiation subsequent to accumulation of micelles within the tumor. Inactivation of the pDNA 
by oxidative damage from the photosensitizer – a major hurdle in this scheme, in addition to 
enzymatic degradation  – was largely avoided by spatially compartmentalizing pDNA within the 
core PLys (condensation of pDNA with anionic PLys), and complexing the photosensitizer with 
the cationic PAsp(DET). In-vivo success with this light-sensitive gene transfer scheme was 6-
fold in photoirradiated tumors vs non-photoirradiated ones. Despite the promising selective gene 
transfection results within tumor cells, it is important to note that the roughly 100nm long 
nanocarriers, also accumulated in other highly vascularized normal organs like lungs, liver, 
spleen, and kidney, resulting in off-target gene expression.        
 Another approach exploiting the compartmentalization ability of polymeric micelles, was 
illustrated by Synatschke and associates, who used interpolyelectrolyte complexation between 
positively charged PLL-b-PEG and negatively charged BVqMAA to yield a neutral 
multicompartmental core-shell-corona structure [40]. By orchestrating a PEG corona, they were 
able to observe longer circulation times and improved tumor accumulation in vivo, while the 
polybutadiene core was able to preferentially load a hydrophobic model drug. 
 Uncontrolled, off-target drug release from Pegylated liposomal formulations such as 
DOXIL can be surmounted by externally-triggered drug release as demonstrated by 
thermoresponsive phosphatidylcholine-based liposomal carriers that rely on gel-to-liquid phase 
transitions, such as ThermoDox (dipalmitoylphosphatiylcholine (DPPC): 
 68 
monostearoylphosphatidylcholine (MSPC)/PEG 2000- distearoylphosphatidylethanolamine 
(DSPE)=90:10:4 molar ratio) [41]. These 150 nm size lysolipid formulations respond 
specifically to mild hyperthermia, but suffer from relatively poor stability in blood plasma 
subsequent to intravenous administration. Chen et al. recently re-engineered this liposomal 
formulation, by encapsulating ammonium bicarbonate within the core leading to generation of 
CO2 bubbles in response to a mild hyperthermia trigger (~41
o
C), thereby opening up pores to 
enable fast, tumor-specific DOX release [41].  
 In another recent study, degradable DNA cages were complexed with hydrophobic drugs 
for intracellular delivery. Single DNA strands are complexed with smaller strands to create 
unique structures with sites available for attaching functional groups/targeting 
agents/biomolecules [42]. Formation of DOX-DNA complexes is rather intuitive given the 
planar structure of DOX allows efficient intercalation within the DNA molecules. In studies 
performed in nude nice with a human orthotopic breast tumor, triangular structures with 120 nm 
long sides, endocytosed within tumor cells, and were transferred into lysosomes providing 
sustained delivery and tumor reduction.    
5.4  DELIVERY TO METASTATIC CANCERS 
 A large unmet need in the treatment of cancer that has metastasized, is the lack of 
chemotherapeutic options for bone metastases, which conduce an aggressive form of cancer 
typically conferred with a selective advantage [43]. Complex problems are especially presented 
by the metastatic version of cancer, as they expand the target area of therapy to organs other than 
the primary site of disease, along with the possible presence of metastases in the blood or lymph. 
As a result, significant co-operation is necessary from clinicians, and may rely heavily on the 
ability to elucidate the organs to which the metastases have spread to. Tackling metastatic cancer 
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with the aid of the nanotechnological toolbox has been reviewed in remarkable detail by 
Schroeder et al [44]. Researchers designing nanomaterials for treating metastatic cancers must 
consider delivering to a wide range of physiology based on the organs the cancer has 
metastasized to, in addition to ensuring delivery to the cancer cell/ subcellular organelle. While 
design considerations remain similar, physiological heterogeneity of the organs may exclude the 
use of a single nanoparticle and may necessitate utilization of a variety of diverse nanomaterials 
to individually tackle metastases in each organ and changing tumor landscape, based on the stage 
of development.   
 One approach that can be readily used for targeted delivery to bone/skeletal tissue, a 
common site of metastasis, utilizes high affinity apatite binding molecules like bisphosphonates 
and oligopeptides. Unfortunately, the negative charge conferred by these targeting moieties can 
exclude the nanocarriers from the negatively charged cell membranes/cytosol [45]. Solid phase 
synthesis of peptides allows for rational design of multifunctional peptides that allow for 
inclusion of diversely charged elements in the same targeting moiety. Applying this method, 
Wang et al. generated a custom trifunctional peptide that consisted of an anionic targeting 
element (for apatite targeting), a cathepsin-cleavable linker (to respond to a metastatic 
microenvironment), and a cationic element (for supporting cellular uptake). The peptide-b-PEG-
PTMC (poly(trimethylene carbonate)) polymer self-assembles into nanomicelles that 
demonstrated up to 90% DOX loading efficiencies into the PTMC hydrophobic core [46].  
Further, the 75 nm nanoparticles were able to avoid clearance owing to the presence of PEG, 
selectively targeted to bone metastases and even displayed a prolonged survival rate in mice 
compared to control groups, thereby highlighting the overall attractiveness of this approach.   
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 Another hotspot for the accumulation of metastases is the lymph nodes. Poorly developed 
lymphatic vessels surround metastasizing cancers, and expose gaping holes between adjacent 
lymphatic cells that eventually facilitate invasive spread of cancer cells. In fact, the excessively 
permeable network of lymphatic vessels is touted to be the primary means of cancer metastasis 
[47]. Surgical and radiological treatments for lymph node metastases are accompanied with side 
effects and inefficiencies as well, presenting another urgent need that can be treated with 
nanotechnology. To target and inhibit cancer cells that have gained access to lymph nodes would 
require the use of nanoparticles that can also circulate in the lymph nodes and empower drugs to 
exert their therapeutic effect.  
 Understanding what triggers and supports lymph node metastasis can enable development 
of appropriate nanomedicine. Spread of cancer cells via lymph nodes typically advances through 
vascular endothelial growth factors- C and –D (VEGF-C and VEGF-D) [43] [31,34] and integrin 
ανβ3 levels [57,58], and consequentially, VEGF inhibitors are good targeting moieties for halting 
metastatic spread. Chemokine receptor expression-level is another determinant of the site of 
metastasis, and potential receptor targets include chemokine receptors CXCR4 and CCR7 [44]. 
PLGA Nanocapsules with size ~300nm and a negative charge, containing docetaxel at >95% 
nanocapsulation efficiency were largely distributed in the mesenteric lymph node [45]. While the 
precise mechanism by which this happens remains largely unknown, it is believed that 
nanoparticles were coated with apoproteins and phospholipids, thereby facilitating delivery to the 
lymphatic system.  
 Size is an important consideration post interstitial/ intravenous administration of 
nanotherapeutics, as the appropriate size can enable preferential uptake in the lymph and avoid 
drainage back into the blood. Experimental evidence shows that particles with size <10nm are 
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uptaken rapidly by lymph nodes, but are at higher risk of resorption back into the blood flow [20, 
21]. On the other hand, particles >100nm may remain accumulated at the injection site instead of 
being transferred into the lymphatic circulation [22, 23]. In general, smaller nanoparticles have 
faster clearance kinetics from the blood as well as the lymphatic system. Neutral or negatively 
charged nanoparticles seeking access to the lymphatics avoid electrostatic interaction with 
negatively charged glycosaminoglycans, and are able to enter the lymphatic system more readily. 
Cationic nanoparticles can form high molecular weight aggregates with interacting proteins 
precluding absorption from the injection site. By subcutaneously delivering a polycationic 
dextran with their liposomal formulation, Feng et al. were able to increase interstitial pressure as 
the positively charged dextran bound to the interstitium and the increased pressure was able to 
drive their liposomal DOX formulation into the lymphatics. Lymph node retention of drug 
delivery devices is commonly increased by using an increased size (physical filtration) or 
increased hydrophobicity/receptor interactions. By contrast, drainage into the lymphatics from 
the blood necessitates opposing properties [9]. In particular, PEG which is coated on most 
nanocarriers to increase hydrophilicity, blood retention time, and avoid opsonisation and 
phagocytosis, drains rapidly from the blood into the lymphatics, but is not retained within the 
lymphatics owing to its hydrophilicity and minimal phagocytic engulfment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 Newer strategies to ascertain chemotherapeutic delivery within cancer cells include the 
use of ATP triggered nanoparticles. To achieve increased accumulation within the tumor mass, 
Mo et al. leveraged an anionic hyaluronic acid coating/shell that remains stable in blood 
circulation and allows functionalization with targeting moieties, and undergoes degradation only 
in the presence of tumor extracellular matrices and tumor cellular endocytic 
vesicles/endolysosomes [34-36]. Within the HA shell, they used the cationic protein protamine, 
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which enables active cellular uptake, endosomal escape, and nuclear targeting [33]. Protamine is 
complexed with an ATP-responsive DNA motif that is itself complexed with DOX, a planar 
molecule and model chemotherapeutic drug. DOX is released in the vicinity of ATP because the 
DNA motif forms a complex structure with the ATP, dissociating the intercalated DOX. 
Concentration differences between extracellular ATP (<0.4 mM) and intracellular ATP (1-
10mM) displayed selective release of DOX within the cytosol, both in vivo and in vitro. 
 Remodeling the tumor microenvironment to essentially discourage cancer cells from 
proliferating has been the focus of several anti-cancer combination therapies. Nanomedicine can 
play a pivotal role in this by encapsulating multiple drugs in appropriate dosage ratios. By 
inhibiting antiangiogenic activity in a xenograft tumor model, Leaf Huang and group revalidate 
this attractive strategy to halt the metastatic spread of cancer cells [48]. By loading DOPA-
cisplatin cores into PLGA nanoparticles, they increased the core hydrophobicity of PLGA, 
further facilitating improved loading of the hydrophobic anti-angiogenic drug - rapamycin (a 
VEGF and Tumor associated fibroblasts inhibitor). Co-encapsulation within the same 
nanoparticle is crucial as it can help maintain the desired dose ratio, giving better control over 
the release and synergistic therapeutic effect; while ensuring a lower IC50 value than co-
treatment of rapamycin and cisplatin as a result of distinct in vivo pharmacokinetics and 
biodistribution.  
 Because anti-angiogenic therapy can normalize tumor vasculature and improve drug 
delivery to metastasizing cancers, researchers have delivered siRNA to vascular endothelial cells 
in metastatic lung cancer models [49]. An epoxide-terminated lipid was reacted with PEI600 , a 
commonly used siRNA delivery agent, to tune size and charge for efficient particle uptake by 
target endothelial cells, reduce particle accumulation and subsequent undesirable gene 
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expression in the liver, along with the achieving the overarching goal of multi-gene silencing in 
vivo. The lipid formulation called 7C1 forms multilamellar vesicles having a size range of 35-60 
nm and has a neutral charge at pH 7.4. Carrying a neutral or slightly lower cationic surface 
charge at pH 7.4 is a desirable property to ensure appropriate biodistribution and endosomal 
escape [50]. While the exact mechanism by which 7C1 succeeds at targeted delivery to 
endothelial cells remains unknown, it is believed to promote delivery to endothelial cells by 
favorably interacting with serum proteins.  
 Strictly speaking, the central core of a tumor that is metastasizing has immense interstitial 
pressure that can drive nanoparticles out before a desired therapeutic outcome is achieved using 
the popular EPR effect. To combat this vascular permeability issue, nanoparticles are usually 
targeted to be delivered directly to the tumor site, or co-delivered with biomolecules (VEGF, 
TGFβ inhibitors) that normalize the vasculature [47]. Improved biocompatibility confers these 
particles with a prolonged half-life that has extend the elimination half-life of drugs like 
doectaxel from 2.2-4.5h in normal tissue to 22h in tumors. It is important to note, however, that 
PEGylated nanoparticles that simply rely on EPR effect are most likely to release their payload 
outside the cancer cell/extraceullarly, owing to poorer cellular uptake arising from steric 
hindrance/ hydrophilicity due to PEG. Extracelullar delivery is desirable for treatment of 
metastasizing tumors/ micrometastases since modulating the tumor microenvironment can 
substantially improve accompanying chemotherapy. Interestingly, improved circulation and 
biodistribution had also been suggested to explain the success of Abraxane (albumin bound 
paclitaxel) – the first-ever FDA approved intravenous, passive nanomedicinal treatment of 
metastatic breast cancer. However, albumin lipid nanoparticle technology did not significantly 
improve drug pharmacokinetics. In fact, it is suggested that simply using albumin instead of 
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cremophor EL, the toxic excipient previously used to formulate paclitaxel for the treatment, can 
lead an increase in the therapeutic index and maximum tolerated dose of Paclitaxel owing to 
lowered systemic toxicity in the absence of cremophor EL.    
 PEGylated formulations that make use of block compolymer chemistry yield micelles 
that have been carefully tailored to modulate drug loading and release profile. PEG-PLA 
nanoparticles have especially received widespread attention, and Genexol-PM formulation is 
currently undergoing Phase II clinical trials in the USA for treatment of metastatic cancer. Better 
control over characteristics of PEGylated block copolymers can overcome current immunogenic 
limitations associated with PEG [51], burst release related issues, and even extracellular anti-
cancer drug release within the tumor microenvironment instead of cell interior.    
 Similarly, albumin-manganese dioxide nanoparticles have been used to regulate the 
tumor microenvironment with the aim of improving prognosis with radiation therapy [48]. MnO2 
nanoparticles can specifically catalyzed and reacted with hydrogen peroxide produced in a 
growing tumor microenvironment to sustainably generate oxygen to counteract hypoxia and 
improve cytotoxic effect of radiation, in addition to increase the acidic extracellular pH in a 
responsive manner. The core MnO2 was coated with the cationic polyelectrolyte poly(allylamine 
hydrochloride), followed by conjugation with bovine serum albumin to produce ~50nm particles, 
which can be delivered locally and displayed excellent retention in tumors. Polyelectrolyte 
complexes like these can resist enzymatic degradation by proteases, and undergo endocytotic 
uptake by cells [52].   
 Leaf Huang and group have also examined the utility of nanomedicine enabled cancer 
immunotherapy to combat metastatic disease [49]. Most combination therapies rely on loading 
multiple therapeutics within the same nanomaterial to better modulate the tumor 
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microenvironment and cytotoxicity. In the aforementioned study, the antigen-specific response 
of a therapeutic vaccine against melanoma was boosted by the use of a separately delivered 
siRNA that reversed the immunosuppressive microenvironment found in an advanced melanoma 
mouse model. To elicit an immune response, immunogenic self-antigen tyrosinase-related 
protein 2 (Trp2) peptide was encapsulated within mannose-modified lipid-calcium phosphate 
nanoparticles having a size of 30 nm as observed under electron microscopy. As an adjuvant, 
CpG oligonucleotides were loaded into the same nanoparticle to evoke a strong immunogenic 
response from the cytotoxic T lymphocyte (CTL) towards the tumor. In order to address the 
microenvironmental changes concomitant with metastasis, a separately delivered TNF β siRNA 
nanoformulation performed the task of normalizing the tumor microenvironment and enabling 
improved vaccine performance. For siRNA delivery, considerations for design were slightly 
different requiring another nanocarrier. Firstly, a cationic liposome coated with PEG was used to 
overcome challenges associated with biodistribution and opsonization. Then, anisamide, a ligand 
targeting the sigma receptor in cancer cells was conjugated to the cationic lipsome. Finally, 
siRNA and hyaluronic acid were condensed together to yield a negatively charged complex that 
is coated on the cationic liposomes via electrostatic interactions.  
5.5  DELIVERY FOR ANTI-ANGIOGENIC THERAPY 
5.5.1 Introduction 
Angiogenesis is a biological phenomenon that promotes formation of blood vessels 
(hemoangiogenesis) and lymphatic vessels (lymphangiogenesis) from pre-existant vessels [53]. 
Angiogenesis entails the outgrowth of new capillaries from the prevailing endothelial cells in 
blood vessels in order to nourish the primary tumor [54]. When a tumor reaches 2mm in 
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diameter, oxygen is unable to diffuse throughout all cancer cells within the tumor [55]. Hypoxic 
cancer cells start a pro-angiogenic signaling process that ultimately translates into secretion of 
growth factors and extracellular matrix components (ECM) that induce the angiogenic process 
[56]. Angiogenesis sustains the continued growth of malignant tumors by providing oxygen and 
nutrients and disposing of waste products over the period of disease progression. These newly 
formed small blood vessels are critical for the survival and metastasis of the primary tumor to 
other organs of the body, spreading the malignancy and advancing the stage of the disease.  
Compelling evidence in numerous mouse models of inhibition of the customary “angiogenic 
switch” that triggers the resilient foray of primary tumor cells to other body organs, has indicated 
halt of tumor growth and metastatic spread [57-59]. The process of angiogenesis is as complex as 
cancer itself, comprising of several steps and ancillary diffusible factors that facilitate the 
development of a supportive vascular network. Cancer cells are equipped to escalate the 
production of proangiogenic factors and downregulate angiogenesis inhibitors, thus thwarting the 
natural balance of angiogenic factors. The initiation of angiogenesis involves extravasation of 
plasma proteins, degradation of extracellular matrix to allow migration of cells, followed by 
actual endothelial cell proliferation and migration, and capillary tube formation. 
5.5.1.1  Proangiogenic factors 
Among proangiogenic factors there are several types of growth factors, such as Vascular 
Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Epidermal Growth 
Factor (EGF), Fibroblast Growth Factor (FGFs), and extracellular matrix (ECM) components 
such as adhesion molecules [60-62]. 
5.5.2.1 Growth factor related proangiogenic factors 
5.5.2.1.1 VEGF or VPF(Vascular Endothelial Growth Factor or Vascular Permeability Factor) 
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Most notable of the army of proangiogenic signals that aid in the spread of tumor cells is the 
Vascular Endothelial Growth Factor. VEGF is programmed to be released by an oxygen-
deprived tumor cell for adjusting the vessel blood flow to fulfill its higher oxygen demands for 
rapid growth and proliferation [mo. The VEGF signal causes the endothelial cells of the said 
blood vessel to loosen their junctions, thereby allowing increased blood flow through the vessel 
as a consequence of vessel dilation. VEGF also enhances the permeability of the endothelial cell 
layer previously covered by the now liberated pericytes. This increased permeability enables 
plasma proteins from the endothelial cell layer to extravasate and form an extracellular matrix 
scaffold that can eventually house endothelial cells migrating as a result of integrin signaling. 
This is a stepping-stone in the crucial process of migration of endothelial cells to from a well-
developed vascular network that can abet the malicious interests of tumor cells.  
The molecular members of the VEGF family include the angiogenesis stimulators VEGF A, 
VEGF B, VEGF C and PlGF (Placental Growth Factor); the growth factor receptors VEGFR-1 
,VEGFR-2 and, and co-receptors NRP1 and NRP2. Table 1 summarizes their roles in the 
intricate angiogenesis mechanism.   
 
Molecule Class Function References 
VEGF A Stimulator (a) Predominates activation of angiogenesis in 
abnormal/diseased cases as well as during 
regular vascularization in the event of injury  
(b) Maintains vascular homeostasis if secreted 
by endothelial cells 
(c) Increases vessel branching and promotes 
[63-65] 
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abnormal vessel formation if secreted by 
tumor, myeloid and stromal cells 
VEGF B Stimulator (a) Promotes growth of cardiac vessels 
(b) Supports neuronal survival 
(c) Induces metabolic effects 
[66, 67] 
VEGF C Stimulator Stimulates “blood-vessel tip cells” that precede the 
endothelial cells forming new blood vessels 
[68] 
PlGF  Stimulator (a) Cytokine that activates tumor cells in disease 
but remains inactive during regular vascular 
functioning 
(b) Creates favorable microenvironment for 
replication and migration of tumor cells by 
activating the bone-marrow-based EPC, 
myeloid cells, stromal cells 
(c) Decreases population of tumor-associated 
macrophages and opposes benefits offered 
by chemotherapy 
[66, 69, 
70] 
VEGFR-1 Receptor (a) Regulates amount of VEGF A available to 
stimulate angiogenesis 
(b) Angiogenesis caused if signaled from 
intracellular components in angiogenic 
endothelial, stromal and myeloid cells 
[66, 71-
74] 
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(c) Signaling promotes growth of VEGFR-1+ 
tumor cells in response to VEGF A produced 
by endothelial cells 
VEGFR-2 Receptor (a) Receptor for VEGF A and C 
(b) Arterial morphogenesis caused if signaled 
from intracellular components 
(c) Causes vascular tumors, genetic 
polymorphisms leading to angiogenesis if 
VEGFR-2 mutation is activated 
[75-77] 
VEGFR-3 Receptor (d) Receptor for VEGF C 
(e)  aids formation of blood vasculature 
formation during early embryogenesis 
(f) Forms new lymphatic vessels from pre-
existing ones 
[78] 
NRP1 Co-receptor Enhance activity of VEGFR-2 [79] 
NRP2 Co-receptor Enhance activity of VEGFR-2 [79] 
     Table 1. Molecular members of the VEGF family and their role in the angiogenesis 
mechanism. 
5.5.1.1.2 Platelet-Derived Growth Factor 
While VEGF takes the lead in forming new blood capillaries, PDGF comes to the fore in order to 
help these neophytes become mature. The small blood vessels comprising of endothelial cells 
lack pericytic membrane coverage resulting in vessel leakage, tortuosity of blood flow, 
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microaneurysm formation and bleeding. Endothelial cell release PDGF-B which “chemoattracts” 
PDGF receptor-β (PDGFR- β)+ pericytes as well perivascular pericyte progenitor cells from the 
bone marrow, thereby, fortifying these frail, tumor-supporting vessels [mol. Mech jain]. PDGF-B 
released by tumor cells indirectly assists increasing the endothelial cell coverage of pericytes by 
upregulating stromal-cell-derived factor-1α. Preliminary studies with PDGF-B based pericyte 
recruitment certainly point towards PDGFR- β as a promising candidate for receptor inhibition 
[80]. It is important to note that blocking the PDGF-B angiogenic mechanism is effective only if 
the pericytes covering the endothelial cells are themselves releasing VEGF for further growth; 
implying a combination therapy of anti-VEGF and anti-PDGF drugs will achieve the same goal 
of arresting stabilization of newly formed tumor vessels by depleting their pericyte cell coverage. 
Apart from no additional advantages bestowed by the inhibition PDGF receptors over anti-VEGF 
therapy, there is also a sizeable amount of contradictory opinions in the literature regarding the 
efficacy of such a blockade in preventing tumor metastasis. It is a well-known fact that tumor 
vessels are leaky in nature. It is this leaky, tortuous nature that renders anti-cancer drugs 
ineffective in advanced tumors owing to poor drug delivery conditions. In fact, presence of 
extremely leaky blood vessels due to lack of perciytes due to PDGF-receptor inhibition can cause 
exacerbate tumor metastasis instead of preventing it. While stabilization and maturation of tumor 
vessels by other PDGF family members like PDGF-CC is known to diminish the effectiveness of 
anti-VEGF drugs, overexpression of PDGF-DD results in improved delivery of anti-VEGF drugs 
by normalizing tumor blood vessels.   
5.5.1.1.3 Fibroblast Growth Factor 
Both the acidic and the basic Fibroblast Growth Factors (aFGF and bFGF) play influential roles 
in the entire breadth of angiogenic activities: from the proliferation and migration of endothelial 
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cells to the upregulation of other growth factors that endorse the same angiogenic cause. These 
multi-faceted growth factors (especially FGFs 1,2 and 4) successfully execute the operation of 
endothelial cell proliferation by acting as mitogens, strongly binding to tyrosine kinase receptors 
(FGFRs 1 and 2) on the endothelial cell surface, thereby, stimulating the MAPK signaling 
pathway [81, 82]. To achieve the same end, VEGF and VEGFR-2 expression is upregulated by 
FGF2 [75]. 
In addition to proliferation of endothelial cells, FGF 1,2 and 4 also help accomplish the vital task 
of enabling the migration of endothelial cells by way of degradation of extracellular matrix 
proteins such as fibrin, which hinder the movement of endothelial cells. Urokinase-type 
plasminogen activator (uPA), a protein that has been identified for being instrumental in 
degradation of the ECM along with matrix metalloproteinases, is upregulated in endothelial cells 
by the activity of FGFs along with the upregulation of MMPs and uPA receptors [83]. Moreover, 
the existing blood vessels that sprouted during angiogenesis are further reinforced by FGFs, 
preventing vessel disintegration [43].  
5.5.1.1.4 Angiopoietins 
Unlike the FGFs, angiopoietins are more involved in the upkeep of blood vessels spawned by the 
proangiogenic effect of other growth factors rather than inducing endothelial cell proliferation 
itself. The ANG-TIE angiogenic system comprises of mural and tumor-cell secreted proteins 
ANG 1,2 and 4, which act as ligands for the TIE-2 tyrosine kinase receptors on endothelial cells. 
ANG 1, in the presence of reactive oxygen species, cements integrity of angiogenically sprouted 
blood vessels by inducing TIE-2 clustering at endothelial cell-cell junctions. The result is a more 
stable, mature, normalized and tight vascular network capable of ensuring endothelial cell 
survival and tumor nourishment. Contradictory to the proangiogenic role of ANG 1, ANG 2 and 
 82 
Tie-2 signalling is purported to make the vasculature leaky by enhancing vessel permeability and 
detachment of pericytes, which may be more detrimental to the delivery of drugs to solid tumors 
than it is advantageous for tumor undernourishment [43]. Moreover, despite countering the 
vessel stabilization effects of ANG 1, ANG 2 released from blood-vessel tip cells, stimulates 
endothelial cell growth and sprouting of new blood vessels, while eliciting decay of the existing 
ones. In tumors, ANG 2 secures the future growth of the newly sprouting vessels by recruiting 
pro-angiogenic TIE-2 expressing monocytes from the bone marrow. Tumor angiogenesis 
employs a favorable balance of ANG 1 and ANG 2 to obtain the desired effect, which is 
hypothesized to be disrupted by inhibiting ANG 2 or TIE-2 receptors, for more favorable anti-
angiogenic outcomes.  
5.5.1.1.5 Transforming Growth Factor-β 
Transforming growth factor-βs (TGF-β) such as TGF- β1 are cytokines which recruit other cells 
to fulfill the communal objective of stimulating angiogenesis. It is believed that receptors like 
activin receptor-like kinase (ALK) and endoglin (ENG) play a key part in the angiogenic ways of 
TGF-β1 [80]. As in the case of angiopoietins, there is a balance of the pro- and anti-effects TGF-
βs depending upon the extent of TGF-β1 production. The effect exerted by TGF-β1 is 
proangiogenic at low concentrations by attracting cells like macrophages which then release 
angiogenic factors. On the other hand, at higher concentrations TGF-β1 undertakes the task of 
vessel maturation instead of vessel sprouting or endothelial cell proliferation. This results in the 
production of mural cells, differentiation and recruitment of smooth muscle cells. Thus, the use 
of drugs that can inhibit ENG and ALK receptors stand to be encouraging candidates for anti-
angiogenic therapy. 
5.5.1.1.6 Epidermal Growth Factor-related receptors     
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The diversity of the epidermal growth factor-like peptides such as TGF-α, amphiregulin, 
heparin-binding EGF, epiregulin, heregulins, neuregulins, and betacellulin and their equally 
manifold receptors, only add to the complexity of the pathways that can potentially be inhibited. 
In the event of an epidermal growth factor binding to a tyrosine kinase receptor presenting itself 
on the extracellular side of the cell, the EGF receptor undergoes dimerization with itself or any 
of its homologous ErbB receptor family members [80]. This dimerization guides 
autophosphorylation from ATP, which in turn, culminates into upregulation of cellular 
proliferation, survival in addition to angiogenesis, invasion and metastasis. 
The concept of using EGFR inhibitors that bind to the ErbB receptor family is fundamentally 
similar to that of a particular antibody binding to a specific antigen on a cell surface. 
Appreciation of the ramifications of introducing EGFR inhibitors to compete with ATP 
molecules for intracellular catalytic sites of the EGF receptor led to the development of these 
tyrosine kinase inhibitors. The binding of tyrosine kinase inhibitors to EGF receptors blocks the 
catalytic site required for the autophosphorylation-motivated intracellular signal stimulation, 
thereby precluding the possibility of exacerbating tumor growth and development. The efficacy 
of such drugs has been theorized to be bolstered on the molecular scale by utilizing an 
irreversible tyrosine kinase inhibitor over a reversible inhibitor or an inhibitor that binds tightly 
to the target receptor [84].  
5.5.1.1.7 Other soluble and membrane-bound factors 
A broader perspective of the role of growth factors in other neoplasia promoting processes such 
as inflammation indicates a link between inflammation and tumor growth that has been 
epidemiologically verified. This idea germinated further study into the mechanism of action of 
some soluble factors found in the ECM which eventually led to the recognition of their 
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angiogenic faculties. Tumor Necrosis Factor-α (TNF- α), secreted by macrophages that may have 
been activated by other proangiogenic factors, has been implicated for bringing new blood 
capillary formation. While TNF- α may not be directly culpable for tumor growth and metastasis, 
it is certainly responsible for the intensification of the initial angiogenic effect produced by other 
growth factors [80]. Similarly, cellular adhesion regulating entities E-selectin and vascular 
cellular adhesion molecule – 1 are also deemed to be indirectly contributory to the cause of 
angiogenesis. E-selectin and VCAM-1 produced in activated endothelial cells, pass the torch of 
propagating angiogenesis to other endothelial cells by binding to the receptors for sialyl Lewis-X 
and VLA-4 ligands; thereby, wielding their angiogenic capabilities. Apart from directly actuating 
the proliferation and migration of endothelial cells, the aforementioned inflammatory cytokines 
can also activate nuclear factor-KB (NF-KB) in cancel cells, boosting their invasive tendencies. 
Nuclear factor-KB, which is also stimulated in necrotic cancer cells soliciting angiogenesis for 
survival, upregulates expression of genes coding for interleukin-8, matrix metalloproteinase-9, 
TNF-α and VEGF and promotes tumor development and advancement..     
5.5.1.2.  Extracellular Matrix Component related proangiogenic factors 
The extracellular matrix (ECM) is a network of macromolecules that includes the interstitial 
matrix, made by stromal cells, and the basement membrane, made by epithelial, endothelium and 
stromal cells, to separate epithelium and endothelium from the interstitial matrix [85]. The 
extracellular matrix is mostly composed of proteoglycans, hyaluronic acid, collagen, elastin, 
laminins, fibronectin, and other proteins that contribute to the biochemical, physical and 
mechanical properties of the ECM [86]. For instance, some of the physical and mechanical 
properties are rigidity, porosity, insolubility, topography, elasticity, barrier, anchorage site, and 
movement track that regulate cell behavior and play an essential role in differentiation and  in 
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cell migration [87, 88]. The biochemical properties encompass the ability of the ECM to regulate 
intercellular communication by controlling the diffusion rate and accessibility of ligands and 
other molecules to its receptors or target sites and by directly initiating signaling events. ECM is 
a highly dynamic structure, constantly under transformation, where cell interaction is a reciprocal 
and an essential constituent to the development of the ECM interconnected properties. 
Components of the ECM such as fragments of collagens type IV and XVIII are involved in 
regulation of angiogenesis, in collaboration with other factors such as VEGF. Stiffening of the 
ECM due to hypoxia causes blood vessels to branch resulting in sprouting angiogenesis. ECM 
components are also involved in vessel lumen formation and tubulogenesis through cellular 
morphogenesis [89, 90].  
Two important components that can modify the ECM and are highly involved in angiogenesis 
are matrix metalloproteases (MMPs) and Integrins.  
5.5.1.2.1 Matrix Metalloproteases 
Matrix metalloproteases (MMPs) are zinc-dependent endoproteinases that can break peptide 
bonds of specific non terminal aminoacids. The overexpression of MMPs can change the 
dynamics of the ECM and compromise the integrity of the basement membrane, which loses its 
function as a barrier. This loss of functionality affects permeability through the basement 
membrane, allowing migration and infiltration of cells. This increases the risks of penetration of 
cancer cells to the blood vessels to undergo metastasis. It also allows endothelial leading tip cells 
from the blood vessels to infiltrate the interstitial matrix and initiate the formation of new blood 
vessels [91]. 
5.5.1.2.2  Integrins 
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Integrins are adhesion receptors known to regulate the angiogenic process (Hocivala-Dilke 
2008). Integrins are transmembrane glycoproteins composed of one alpha (α) and one beta (β) 
chain that, upon ligand activation, start a signaling cascade that can either occur  intra or 
extracellularly [92]. There are several known mammalian integrins and their expression is cell 
type specific. Endothelial cells, which more cancers arose from, express αvβ3, αvβ5, α4β1, α5β1, 
α1β1, α2β1, α3β1, α6β1, α6β4, and α9β1 integrins. Integrin receptors can be classified depending 
on its ligand. For example, Vitronectin binds to αvβ3 and αvβ5, while fibronectin binds to α4β1 
and α5β1 [93]. Integrins provide mechanical traction for cell motility, migration and invasion. 
They are involved in the modification of the ECM. They contribute to cell proliferation in a 
ligand dependent and ligand independent manner. Overall, integrins may increase the 
malignancy of the tumor. Integrins are often overexpressed in many endothelial originated tumor 
cells, being αvβ3 one of the most studied integrin. Integrins are also expressed in angiogenic 
endothelial cells. The role of integrins in angiogenesis seems to differ depending on its type. For 
example, αvβ3 is involved in downstream activation of epidermal growth factor (EGFR) after 
fibroblast growth factor (FGF) binding. Meanwhile, αvβ5 promotes VEGF-induced angiogenesis 
upon interaction with VEGFR2. The integrin αvβ1, overexpressed in the endothelial vascular 
cells of angiogenic vessels interacts with vascular cell adhesion molecule 1 (VCAM1) present on 
pericytes for vessel stabilization [94]. 
5.5.2. Antiangiogenic therapy for cancer treatment 
There are several molecular entities and signaling pathways, both in cancer cells and endothelial 
cells, involved with the complex process of angiogenesis. Antiangiogenic therapy is mostly 
based on the fact that the inhibition of pro-angiogenics factors reduces angiogenesis. Due to the 
variety of entities involved in angiogenesis, there is a wide variety of antiangiogenesis strategies.  
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For example, the use of gene and antisense therapy to modulate the activation or inhibition of 
proteins involved in angiogenesis translates in a decrease in angiogenesis and hence, tumor 
growth. Specific signaling pathways can be obstructed by using anti-angiogenic drugs that can 
prevent, inhibit or decrease activation of tyrosine kinases on tumor cells/endothelial cells 
stemming out of primary tumor vasculature; thus, safeguarding judicious destruction of tumor 
cells over healthy cells. Tyrosine kinases are enzymes that can either be transmembrane (receptor 
tyrosine kinases, such as VEGFR) or cytosolic (non-receptor tyrosine kinases). Binding of a 
ligand to the extracellular end of the receptor tyrosine kinase commences a cascade of reactions 
through its carboxyl-terminated cytosolic end, catalyzing transfer of a γ phosphate group from 
adenosine triphosphate to target proteins within the cytoplasm. Realization of the kinase activity 
subsequently activates intracellular signaling cascades like Ras/Raf MAPK pathway, P3k/Akt 
pathway, STAT3 pathway, and the protein kinase C pathway [95, 96]. Not only does activation 
of these signaling pathways alter the proliferative tendencies of the particular tumor cell, but they 
also induce genetic alterations so as to propagate aggressive growth and angiogenic predilections 
across generations. Inhibition of the tyrosine kinase enzyme either by bloking the extracellular 
domain using antibodies or blocking the intracellular domain using tyrosine kinase inhibitor 
(TKI), have shown to be effective in antiangiogenesis therapy. 
5.5.2.1  Monoclonal Antibodies  
Antibodies belong to an important class of compounds that can specifically target cells and 
molecules revealed to play crucial roles in angiogenesis. A superior understanding of the series 
of events leading up to angiogenesis, and the cellular and extracellular components involved in 
the proceedings, have created a niche that therapeutic antibody agents can target.  Thus far, 
antibodies have been engineered to specifically target a cell surface receptors or extracellular 
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molecules implicated for their involvement in angiogenesis. These miscreant molecular targets 
are typically over-expressed in a vast majority of cancers that are metastasizing or have 
metastasized, and present an opportunity for the antibodies to latch on to. As a result of the 
potential of such a therapy, substantial research has been directed towards developing antibodies 
that can attach to receptors on endothelial cells or soluble molecules that interact with endothelial 
cells [97]. The ultimate goal of research in this area has been to thwart the mitogen-based 
signaling cascade that instigates endothelial cell multiplication, migration and proliferation, 
which is now known to be an intrinsic step in tumor angiogenesis. Further, developments in 
comprehending new biological mechanisms that could possibly underpin the development of 
blood vessels supplying nutrition to starving tumor cells continue to drive research in this area.  
Antibodies having the potential to perturb intracellular signaling pathways can either target 
endothelial cell growth directly or can aim to halt endothelial cell adhesion and migration. 
Endothelial cell surface receptors that bind to growth factors stimulating enhanced cell 
multiplication include the vascular endothelial growth factors VEGFR-1, VEGFR-2, and 
VEGFR-3, and the epidermal growth factor receptors HER-1 and HER-2, as previously 
discussed [98, 99]. Antibodies developed to target these receptors exclusively, evidenced to have 
been over-expressed in a number of tumors, can foil the signaling cascade resulting from growth 
factor binding. Anti-VEGFR and Anti-EGFR antibodies had demonstrated their ability to 
successfully compete with VEGF ligands and EGF or TGF-α, for binding to the extracellular 
domains of such tyrosine kinase receptors. Inhibition of this growth factor attachment averts 
dimerization of the receptor, a key step occurring prior to intracellular signal transduction in 
endothelial cells. Eventually, this results in receptor internalization and proteosomal degradation, 
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thereby preventing any further possibility of ligand-receptor binding for the rapid replication of 
endothelial cells. Similarly, FGFR activity can also be inhibited in similar fashion [100]. 
Endothelial cell migration pathways can be targeted by use of antibodies that inhibit the 
activity of integrins, VE-cadherins and angiogenins (DDT). Anti-integrin antibodies have 
demonstrated great efficacy in hindering the integrin receptor sites on endothelial cells that are 
essential for adhering to extracellular matrix components for the purpose of migration [101, 
102]. Similarly, VE-cadherins and angiogenins participate in cell-cell interactions and cell-
matrix interactions during endothelial cell adhesion and migration. Their action can be inhibited 
by use of antibodies that bind to the respective receptors instead of the cadherins and 
angiogenins, thus, eradicating their presence in the angiogenic mechanism [103].  
Some shortcomings that may impair the therapeutic efficacy of antibodies developed for 
cancer therapy include rapid renal clearance, lack of stability against proteolysis in the serum, 
possible threat of immunogenicity (especially for chimeric antibodies) or even interaction with 
healthy tissues, and most importantly, effective entry into tumor masses and high specificity and 
efficacy of binding to cell surface receptors or soluble cytokines [104]. Delivery mechanisms 
utilizing the wide array of carriers offered by progress made in the field of nanotechnology could 
perhaps help circumvent some if not most of the aforementioned shortcomings.    
5.5.2.2  Aptamers and proteins  
A vast body of research indicating the influential role of the Arg-Gly-Asp (RGD) peptide 
sequence, has been instrumental in helping midwife another class of molecules with anti-
angiogenic potential. It is known that the RGD sequence can exquisitely antagonize the αVβ3  
integrin; proving to be a hindrance to angiogenic cell-extracellular matrix interactions [105]. 
RGD motifs capable of homing molecules to tumors, can be incorporated into human/chimeric 
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protein based therapeutics such as bacteriophage peptides and immunoglobulin antibodies, by 
covalent coupling with side chain amino acids on the protein [106]. This conjugation ability of 
RGD sequences opens up new avenues not just for therapeutics, but also for diagnostic tools.  
Notably, in this regard, cyclic RGD peptides have demonstrated their superior antagonistic 
ability to deter angiogenesis, tumor growth and metastasis in melanoma-afflicted animal models 
[107]. Another conjugate, which echoes the success that can be achieved by use of cyclic RGD 
peptides, is the cyclic RGD-heparin bile acid derivative. The RGD sequence is believed to target 
the quickly dividing endothelial cells, while the heparin exerts its adverse effects on blood vessel 
development and angiogenesis. 
Initial success with RGD sequences that inhibit integrins spawned the search for other such 
potent peptidic domains, which could presumably bind to cell surface receptors culpable for 
tumor angiogenesis. Utilization of peptide libraries led to the discovery of peptides such as Gly-
Asn-Gln-Trp-Phe-Ile (GNQWF1 or anti-Flt1) capable of selectively inhibiting VEGFR1. On 
similar lines, single/double stranded short DNA/RNA molecules called aptamers, are capable of 
binding to specific molecules such as enzymes/receptors [108, 109]. They are typically 
segregated with peptides owing to comparable molecular weights (8-25 kDa). Aptamers enjoy 
the same advantages as small peptide sequences such as increased solubility and tissue 
penetrability, and steer clear of the drawbacks characteristic of antibodies like reduced 
immunogenicity and blood circulation times [110]. The short length of aptamers make them 
suitable for targeting purposes in therapeutic and diagnostic applications alike. 
5.5.2.3  Antisense and gene therapy 
Gene therapy encompasses the introduction of DNA into the cell nucleolus in an attempt 
to restore the loss of a gene. Cancer cells present mutations and alterations in their genes that 
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translate into the loss of proteins that are involved in the normal cell cycle. The loss of these 
proteins leads to an increase in proliferation, inability to properly regulate the cell cycle, and 
gained ability to metastases. Healthy cells can also present aberrant behavior due to paracrine 
manipulation from cancer cells. This is the case for endothelial cells, located near tumors, which 
respond to pro-angiogenic signals from the cancer cells within the tumor. By restoring the ability 
to synthesize anti-apoptotic proteins in both endothelial cells and cancer cells, the angiogenesis 
process can be considerably minimized. The most common genes delivered and transfected for 
anti-angiogenesis therapy are those encoding the endogenous anti-angiogenic proteins 
interferons, angiostatin,endostatin, and vasostatin [111].  
Interferon alpha (IFN-α) is a glycoprotein that has been used in anti-angiogenic cancer 
therapy because it down-regulates bFGF and VEGF (Singh 95). Preclinical studies using IFN- α 
have shown inhibition of angiogenesis in Kaposis’ sarcoma, glioma, renal, and ovarian cancer, 
among others. Angiostatin is a plasminogen fragment that inhibits endothelial cell proliferation 
and migration and suppresses tumor growth and metastases. Angiogenesis gene therapy showed 
delay in tumor growth in melanoma xenografted mice after intratumoral injection. Similar results 
were found in lymphoma tumors in mice livers after portal vein injection and in human glioma in 
mice after intramuscular injection. Endostatin is a collagen fragment that inhibits endothelial 
cells functions by binding to the α5β1 integrin receptor [112]. Endostatin also inhibits cyclin D1 
and attenuate[112-114]s VEGFR signaling [114]. It has been used for anti-angiogenesis therapy 
but it appears to be tumor specific, as reported by heteregenous results in tumor growth. 
Vasostatin is a peptide that showed inhibition of endothelial cell proliferation in vitro and tumor 
growth in vivo [113]. Gene therapy involving vasostatin showed both inhibition and 
enhancement of tumor growth. 
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Antisense therapy comprises the use of oligonucleotides to prevent messenger RNA 
(mRNA) transcribed from a specific gene to be translated into proteins. Small interference RNA 
(siRNA) has been widely used in antisense therapy to disrupt cellular pathways by knocking 
down genes, opening the door for new treatments of diseases caused by aberrant gene expression 
[115, 116].  A great variety of siRNA to knockdown different genes encoding for proteins 
involved in angiogenesis have been used to reveal the function of cellular signaling factors, 
cytokines, receptors, matrix proteins, and adhesion molecules involved in the formation of new 
blood vessels. The use of siRNA for antiangiogenic purposed has been widely used to elucidate 
the mechanisms of angiogenesis. In recent years, there has been an increasing interest in using 
siRNA as a therapeutic agent for antiangiogenesis therapy.   
For instance, Hanze et al. (Hnze 2003, Biochem. Biophys.research commu.) used siRNA 
against the hypoxia induction factor (siHIF-1) which inhibited its downstream signaling . This 
correlated with a decrease in VEGF expression that affected cellular proliferation. It has been 
demonstrated that an increase in Progesteron B (PR-B) in breast cancer cells correlates with an 
increase in VEGF. By treating human breast cancer with siPR-B, Wu et al. (Wu 2004, cancer 
research) observed a significant decrease in expression levels of VEGF. The intratumoral 
injection of siVEGF in MCF-7 breast tumor models xenografted in mice, reduced significantly 
tumor gowth (Kurenova 2009). The same observations were found in PC-3 prostate cancer 
xenografts in mice. The in vitro studies with PC-3 prostate cells showed almost a complete 
inhibition of VEGF (Takei 2004 Cancer research). The use of siVEGF in a neuroblastoma 
synergic tumor model also reduced significantly tumor growth (Schiffelers 2004, Nucleaic acid 
research). It has been reported that VEGF inhibits the protein Thrombospondin-1 (TSP1), which 
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regulated vascularization and tumor growth. The use of siVEGF in a fibrosarcoma tumor model 
in mice, restore the ability of TSP1 to reduce vascularization and tumor growth. 
The use of siRNA as an antisense antiangiogenic therapy for cancer treatment, has shown 
very promising results in vitro and in vivo. However, poor cellular uptake, low selectivity for the 
desired tissue, and rapid systemic clearance of siRNA through the renal system have been 
reported for intravenous injection of siRNA.  Moreover, when injected intravenously, siRNA 
chains exhibit a short half-life due to intravascular degradation by the catalytic activity of 
Ribonuclease (RNase) enzymes present in the bloodstream (Chen 11 from co-delivery).  The use 
of nanocarriers as siRNA delivery systems can prevent both renal clearance and RNase 
degradation, effectively increasing the siRNA half-life in blood (aliabadi 2011, Singha 2011).  
5.5.3  Delivery systems  
The overall survival rate of cancer patients depends largely on the extent of dissemination 
of tumorous cells in the body. One way of improving the chances of patient survival is the use of 
antiangiogenic therapy. Several entities for antiangiogenic therapy, such as small drugs, siRNA, 
peptides, etc. aspire to inhibit the spread of cancer by reducing oxygen supply to the tumor mass. 
Poor solubitlity of small drugs, degradation, poor tumor uptake, and low selectivity towards 
cancer cells are some of the challenges that antiangiogenic agents present.  The existence of a 
variety of antiangogienic agents requires the development of an equal variety of delivery systems 
to overcome the limitations of the aforementioned agents. 
5.5.3.1 Small drug delivery systems 
The matrix metalloproteinase is another target for antiangiogenic therapy as it degrades 
the ECM paving the way for migration of tumor cells to distant parts of the body. TNP-470 is a 
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small molecule angiogenic inhibitor that binds to and incapacitates the MMP in addition to 
halting replication of vascular endothelial cells. However, TNP-470 is a highly hydrophobic 
molecule making intravenous administration an issue. Moreover, TNP-470 has been shown to be 
degraded due to a hydrophilic environment when delivered intravenously. This warrants the need 
to develop novel drug delivery systems that can circumvent the problems facing delivery of an 
antiangiogenic inhibitor alone.  
PLA (Poly-lactic acid) based biodegradable systems offer great promise when it comes to 
enhancing intravenous delivery of drugs. However, the hydrophobic nature of TNP-470 requires 
the presence of a hydrophobic moiety within the conventional PLA system that can associate 
preferentially with hydrophobic drugs. Kakinoki et al. [preparation of poly-lactic acid micro] 
have used medium chain tri-glyceride to form oily domains within PLA microparticles that can 
enhance encapsulation of TNP-470 by the microparticles. The TNP-470 released from such a 
composite microparticle drug delivery system was observed to be more stable in vitro, thereby 
suggesting an influential role could be played by PLA microparticles in improving the 
therapeutic effect of TNP-470. 
5.5.3.2 Monoclonal Antibody-based delivery systems 
More popular in targeting studies, is the use of monoclonal antibodies to home on to 
VEGFR2, and release a cytotoxic drug such as docetaxel or paclitaxel. Lecithin based lipid 
nanoparticles targeted to VEGFR2 used by Liu et al. have demonstrated increased accumulation 
in tumor vasculature owing to antiangiogenic targeting [117]. 
Sequential delivery of antiangiogenic drugs followed by an anticancer drug is supposed to reduce 
tumor vasculature and further enhance the delivery of chemotherapeutics to the diseased area.  
Sengupta et al. formulated a nanocapsule made up of inner coating (containing an anticancer 
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drug) and an outer coating (containing an antiangiogenic drug combretastatin A4) to allow for 
temporal release of drugs and to increase the efficacy of the therapeutic treatment [118]. 
Pegylated-phospholipid block copolymers containing PLGA. On the other hand, Wang et al. 
conjugated paclitaxel to PLA in order to permit timely release of paclitaxel only within the tumor 
vasculature.  
Instead of releasing drugs or therapeutic agents of any kind, Kalishwaralal et al. have 
researched the potential of silver nanoparticles in the size range of 100-500 nm alone, in 
blocking the binding of VEGF to receptors and calling off the mitogen-based progression of 
angiogenesis [119]. Silver nanoparticles are hypothesized to prevent the phosphorylation of Akt, 
a crucial step of the Protein kinase B/Akt pathway. 
5.5.3.3  Aptamers and proteins delivery systems  
Peptides synthesized from polyamino acidic groups are rapidly being developed mainly 
due to their abilities to cater to specific biological targets. These peptides are believed to interfere 
with the proliferative abilities of VEGF and bFGF, thereby proving to be an impediment to 
microvessel formation. However, their specificity makes them extremely susceptible to loss of 
activity through degradation and require vehicles that can transport and release them with great 
efficacy.  PLGA (Poly(lactic-co-glycolic acid)), a highly researched biodegradable carrier, 
seemed like a suitable candidate for this job. However, degradation of PLGA causes formation of 
acidic oligomers that decrease the pH of the environment around the peptide, resulting in 
degradation. Loss of functionality of these peptides implies loss of antiangiogenic action. I 
d’Angelo et al. blended PLGA with poloxamers to minimize accumulation of PLGA aligomers 
in the presence of proteins, thereby preserving the biodegradable nature of the carriers as well the 
specificity of the peptides. Poloxamers are triblock copolymers consisting of a hydrophobic 
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(polyoxypropylene) chain in the middle, flanked by two hydrophilic (polyoxyethylene) chains at 
the end. PLGA-poloxamer blended nanocarriers and microcarriers showed great efficacy in vitro 
in the loading and release of JS-2892b, a polyaminoacid based peptide. 
Use of polysaccharide molecules, such as chitosan and dextran sulfate blends, has also 
shown to produce positive results for delivering peptides. Chen et al. demonstrated 75% 
entrapment efficiency of ARH protein in chitosan-dextran sulfate nanoparticles formed by 
coacervation. However, any in vivo/cell based studies illustrating the ability of this system to 
inhibit growth of VEGF in metastasizing vascular endothelial cells was lacking.   
Integrins such as αVβ3, αVβ3, and α5β1 play a crucial role in the dissemination and growth 
of tumor cells by modulating cell-cell adhesion and cell-ECM adhesion.  As a result, molecules 
that inhibit the action of these integrins offer great potential for anti-angiogenic therapy. Cyclic 
RGD peptides developed by Kessler et al. [In vitro and in vivo evaluation paper] have 
demonstrated their antiangiogenic efficacy in preclinical tumor models. However, their 
therapeutic potential has been severely limited by shortcomings such as poor bioavailability, 
shorter half-life, and most importantly inherently weak lethal effect on endothelial cells. RGD 
peptides have always been known for their ability to bind to integrins and this makes them a 
suitable candidate for targeting purposes. Ryppa et al. have conjugated paclitaxel to RGD 
peptides in order to compliment/boost the antiangiogenic potential of RGD peptides alone. 
Paclitaxel albumin-cyclopeptide conjugates were developed using EDC-NHS chemistry. RGD 
peptides act as antagonists to the integrins central to angiogenesis homing the conjugate to the 
area of interest. Upon attaching to integrins, the ester bond connecting paclitaxel to the RGD 
peptide can be cleaved to release paclitaxel and bring about endothelial cell death. This method 
was shown to inhibit endothelial cell migration and proliferation in xenograft models in vitro as 
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well as mice in vivo. Instead of using Paclitaxel conjugated cyclopeptide alone, Eldar-Boock et 
al. used PGA-Paclitaxel conjugated cyclopeptide to deliver paclitaxel by targeting integrins. 
PGA being biocompatible, non-immunogenic, and biodegradable by cathepsin B expressed 
strongly in tumor cells is believed to provide a safer route for paclitaxel delivery.  
5.5.3.4 Antisense and gene delivery systems 
Antiangiogenic gene and antisense therapy involve transfection of DNA and siRNA 
respectively, into human cells tailoring the cellular interaction and replication at a genetic level. 
Transfection of specific DNA or siRNA can be used to restore natural antiangiogenic or 
knockdown proangiogenic gene expression of cancer cells. DNA and siRNA are highly 
degradable if injected systemically due to nucleases and other enzimes present in the blood 
stream. It is primordial to keep the integrity of both DNA and siRNA to increase treatment 
efficiency.   Nucleotides delivery can be achieved in two ways- using viral vectors and non-viral 
vectors. Viral vectors are extremely efficacious in transfecting nucleotides into cells but are 
limited by shortcomings such as low loading capacity, chances of infection and increased risk to 
cancer due to viral infection. Non-viral vectors have recently been looked into to bypass some of 
these shortcomings. Nanoparticles offer desirable properties to deliver nucleotides: high 
solubility, easy to modify, and with a great surface/volume ratio that provides large 
complexation surface. However, non-viral vehicles present lower transfection efficiency and cell 
toxicity. This is mostly due to the positive charge present in the nanoparticle surface that allows 
negatively charged nucleotides to complex on the surface and also improves transfection 
efficiency. Different strategies have been used to achieve high transfection efficiency and low 
toxicity nanoparticles formed by lipids, dendrimers, silica, and a variety of polymers.    
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The use of lipidic nanoparticles for different biomedical and pharmaceutical applications 
has been widely spread among the scientific community, (Garcia Fuentes 05) specially for 
transfection efficiencies since the liposome Lipofectamine ® became the commercial standard 
for nucleotide transfection.  Other liposomes and lipid bases nanoparticles are being investigated 
as transfection vehicles. For example Saad et al. (Saad 08) synthesized a liposome using 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP) and complexed siRNA through electrostatic 
interactions. Chen et al. (Chen 2010) synthesized cationic liposome-DNA (LPD) using the 
guanidine containing cationic lipid N,N-distearyl-N-methyl-N-2-(N-arginyl) aminoethyl 
ammonium chloride (DSAA)(Chen 2010). siVEGF was complexed onto the liposome surface. 
Yu et al. (Yu 11) synthesized high transfection cationic nanoparticles using 1,2-Dioleoyl-sn-
glycero-3-ethylphosphocholine (EDOPC) and then complexed siRNA on the surface. Li et al. (Li 
2012) tested different formulations and concluded that the use of the stable nucleic acid lipid 
particle (SNALP), a distearylphosphatidylcholine (DSPC) based liposome, performed the best in 
transfection efficiency in vitro, but it was effective only in highly vascularized in vivo tumor 
models (Li 12).  
Dendrimers, such as polyamidoamine dendrimer (PAMA) , can be use to confer a 
positive charge to silica nanoparticles, to complex siRNA and serve as delivery vehicles. (Chen 
2009). Dendritic polyamines conjugated to β-cyclodextrin and complexed to siRNA against 
EGFR offered also a vehicle system for nucleotide delivery. (Kim 11) 
 Green et al. have recently studied the use of poly(β-amino esters) to deliver DNA to HUVECs, a 
genetically stable and prominently refractory class of endothelial cells. Key findings have 
suggested that poly(β-amino esters) nanoparticles may be efficacious in delivering DNA to 
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HUVECs due to their ability to condense DNA into the nanoparticles. Poly(β-amino esters) are 
able to buffer endosome and they are biodegradable.  
While polymeric and biopolymeric particles constitute the majority of this kind of 
vectors, they are far from being applied in a clinical setting owing to their lack of 
biocompatibility or even biodegradability. Great effort is being made to synthesize polymeric 
nanoparticles with high complexation, high transfection, lox toxicity, and high degradability. For 
example, Zhu et al. (Zhu 2010) modified the toxic and highly transfection efficiency polymer 
poly (2-(N,N-dimethyl aminoethyl) methacrylate) P((DMAEMA) with poly(ε-caprolactone) 
(PCL) a biodegradable and biocompatible polymer. The resulting block co-polymer  2-(N,N-
dimethyl aminoethyl) methacrylate-b- poly(ε-caprolactone)-b 2-(N,N-dimethyl aminoethyl) 
methacrylate (PDMAEMA–PCL–PDMAEMA) was assembled in  biodegradable cationic 
micelles that had great transfection efficiency and biocompatibility.  
5.6  DELIVERY TO MULTIDRUG-RESISTANT CANCERS 
 Multidrug resistance in cancer cells, a condition which accompanies metastatic cancer, is 
also responsible for a majority of cancer-related deaths and lack of potent treatment options [50]. 
Sequence-specific gene silencing has been explored extensively in this regard to favorably 
sensitize refractory cancer cells to conventional chemotherapy [120, 121]. A wide range of 
strategies have been developed for improving biodistribution of nanoparticles at the tumor site, 
however, recently, schemes to increase intracellular concentration of chemotherapeutics within 
multidrug resistant cancer cells is gaining importance. The advent of RNAi based therapeutics 
has led the charge in this area, by opening up otherwise insensitive cancer cells to the cytotoxic 
effects of chemotherapeutics. Especially because, multidrug resistance is manifested by 
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genetically engineering cancer cells to rapidly expel anti-cancer drugs that are subsequently 
recycled back into the bloodstream.  
 From a material design perspective, hyaluronan (HA), a major ligand of CD44 is a 
suitable active targeting ligand for most types of cancerous cells, as HA receptors are largely 
upregulated in these cells. As previously mentioned, HA also promotes long circulation owing to 
its non-immunogenicity and hydrophilicity. Cohen et al. have used HA-coated phospholipid 
nanoparticles to encapsulate DOX and PTX, both of which are substrates for P-gp receptors 
overexpressed in cancer cells [53]. They demonstrated increased cytotoxicity and reduced IC50 
values in an NCI/ADR-Res ovarian cancer cell model that was derived by continuous exposure 
to increasing DOX concentrations in cell culture. Internalization of the ~500 nm drug loaded 
particles led to evasion of the drug efflux mechanism, and subsequent surge in intracellular DOX 
concentration in otherwise DOX-resistant cells.   
 In a recent study, Kim et al. surmounted two key challenges with one nanomedicine 
platform, by gaining access across the blood-brain barrier and sensitizing refractory glioblastoma 
cells to temozolomide (TMZ), which acts a substrate for the O
6 –methylguanine-DNA 
methyltransferase (MGMT) enzyme [54]. Incorporation of a wild-type p53 plasmid DNA within 
a cationic liposome, and separate administration of TMZ was shown to have appreciable 
cytotoxic effect in both in vitro and in vivo models. 
 Researchers seek to utilize the considerable surface area of carbon nanotubes (up to 
~2600 m
2
/g) and strong optical absorption leading to compatibility with photodynamic therapy, 
for the development of potent nanoformulations [122]
,
[123]. It is evident that liposomes continue 
to be the nanomedicine of choice for cases requiring cellular uptake or gene therapy. To tackle 
this problem from another perspective, Bhirde et al. engineered a semiconducting single-walled 
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carbon nanotube (sSWCNT) drug delivery system that showed it is possible to achieve more 
effectiveness in killing cancer cells by wrapping nanoparticles with hyaluronic acid rather than 
PEG [57]. Cholanic acid-derivatized hyaluronic acid (CAHA) biopolymer is coated on sSWCNT 
to leverage the substantial affinity of hyaluronic acid to CD44 receptors that are over-expressed 
in metastatic cancer cells. The combined π- π stacking resulted in greater DOX encapsulation; 
while, rapid intracellular trafficking of CAHA-sSWCNTs occurs with ease owing to their small 
size (2-4 nm), especially in drug-resistant OVCAR8/ADR cells that overexpress CD44 receptors 
and tumor bearing mice xenograft models. Additionally, viscoelastic response of drug-resistant 
cancer cells was also analyzed to show that higher uptake with CAHA-sSWCNT caused an 
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 Choi and others investigated the role of Zn(II)-DPA and a Calcium Phosphate coating to 
load RNAi-based therapeutics to accompany small molecule drugs for sensitizing 
OVCAR8/ADR tumor cells in vitro and in vivo [58]. These dual-responsive nanoparticles were 
also coated with hyaluronic acid to establish tumor-specific biodistribution subsequent to 
intravenous administration. Their “nanoformula” is described as a versatile platform that can 
simultaneously deliver a wide range of therapeutics in one formulation.   
 Developing nanoformulations that can release multiple therapeutics holds tremendous 
potential for combination cancer therapy. One such approach, established by Liao and 
colleagues, orchestrated the loading and release of small molecule drugs encapsulated within the 
same nanoparticle in a precise, controlled manner. Although multidrug delivery approaches are 
typically limited by overlapping toxicity profile, these hurdles can be overcome by a judicious 
choice of drug solutes and their molar ratios within the same particle. Ensuring rational design of 
synthesis and encapsulation techniques is another challenge that needs to be addressed here. To 
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enable differential release of multiple drugs encapsulated within the same nanoparticles, Liao et 
al. prepared nanoscopic brush-arm star polymers (BASPs) using a ring-opening metathesis 
polymerization method (ROMP) [124]. Drug-macromonomer conjugates were developed to 
allow for improved solubility and responsiveness to environmental stimuli. To enable controlled 
release for each of the three drugs, drug conjugates were synthesized to respond to three different 
stimuli. DOX and CPT were conjugated to a PEGylated-norbornene macromonomer using a 
graft-through ROMP synthesis [125]. DOX conjugate were shown to respond to a photo-trigger 
such as long-wavelenght UV (UVA). Cisplatin was conjugated to Pt(IV) diester derivative that 
released the cytotoxic ingredient Pt(II) upon reduction in the presence of intracellular 
glutathione. Another method of linking camptothecin involved covalently conjugation to 
zwitterionic polyMPC (poly(methacryloyloxyethyl phosphorylcholine)) using an ATRP-“click” 
bioconjugation strategy. Herein, conjugation was achieved through an esteric linker that 
underwent hydrolysis in a manner dependent upon the length and steric hindrance around the 
linkage. The triple drug combination therapy demonstrated effectiveness against an otherwise 
camptothecin-resistant OVCAR3 (human ovarian carcinoma cell line).    
 Targeting the lysosomal cell death pathway is another premise that holds immense 
promise for nanomedicine-mediated treatment of multidrug resistant cancers and especially 
apoptosis-resistant cancers. In refractory cancers that resist apoptosis by conventional 
chemotherapy, lysosomal membrane permeabilization can stimulate release of cathepsins and 
proteolases, engendering cytosolic protein digestion and induction of apoptosis [61]. The 
obvious challenge is to specifically deliver to the subcellular target – lysosomes. In a recent 
investigation, Sanchez et al. accomplish induction of apoptosis and cell death by activation of the 
lysosomal death pathway by means of iron oxide nanoparticles grafted with peptidic ligands for 
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targeted delivery to cancer cells [62]. Functionalization of an iron oxide nanocrystal with gastrin, 
a peptidic ligand for the cholecystokinin-2 receptor (a G-protein couple receptor) resulted in 
strong binding and internalization of the composite nanoparticles. Unlike other magnetic stimuli-
based approaches, cell death was incurred through lysosomal internalization subsequent to 
endocytosis instead of hyperthermia. The method demonstrated that particles accumulated within 
the lysosome induced cell death in HEK293 and CCKR2 over-expressing endocrine tumor cells 
upon application of an alternating magnetic field that possibly, triggered lysosomal membrane 
permeabilization and production of reactive oxygen species, leading to highly selective tumor 
cell demise. 
5.7 CONCLUSION 
 Nanoscale therapeutics for cancer therapy represent a promising strategy to enhance 
therapeutic outcomes by reducing off-target side effects compared to intravenously administered 
chemotherapeutics. Polymer based nanotherapeutics have received the most attention from 
researchers, but there is a wealth of promising research on inorganic nanomaterials which is 
primarily focused upon photothermal therapy and co-delivery. With respect to the design of these 
systems, nanomaterials with a size on the order of 100nm of various morphologies have become 
the most prominent.  The desired charge of the system depends largely on the application.  
Recently, increased attention has been focused on the development of cationic nanotherapetuics 
for the purpose of co-delivery of chemotherapeutics and interfering RNA.  Surface 
functionalizations for many nanotherpaetuics has been primarily focused upon using PEG to 
enhance circulation time and thereby the localization of the nanomaterials to the tumor by the 
EPR effect.  However, recent literature has shown that reliance solely on the EPR effect is 
insufficient for many nanotherapeutic to penetrate the tumor intersitium, and as a result the use 
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of active targeting agents has become increasingly compulsory.  Finally, with the prominence of 
drug-resistant cancers, there is an increasing need to design therapeutic agents with the ability to 
sensitize or synergistically target cancerous cells over healthy cells to effectively reduce off-
target effects.  
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Chapter 6:  Synthesis and Characterization of pH-Responsive Nanoscale 
Hydrogels for Oral Delivery of Hydrophobic Therapeutics  
 
 
 
 
 Nanoscale hydrogels were synthesized for oral delivery of hydrophobic therapeutics 
 Interplay exists between factors such as selection of hydrophobic monomer component of 
and physicochemical and biological characteristics providing a basis for optimization 
 Physicochemical characterization of hydrogels was conducted to analyze and compare 
swelling properties and cellular cytotoxicity, alongside validation of composition using 
FTIR and NMR.   
 Other relevant properties such as mucoadhesion and uptake by macrophages were also 
considered 
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6.1  INTRODUCTION 
 
Oral delivery of hydrophobic therapeutics using polymer-based nanomaterials relies on 
the rational design of carriers with respect to size, charge, and surface properties so that they can 
effectively mediate diverse physicochemical and physiological barriers encountered in the 
gastrointestinal (GI) tract [1]. An expansive review of current technologies and drug delivery 
carriers used to orally deliver hydrophobic drugs, as described in Chapter 4, connotes several 
desirable particle-design features, including the presence of a lipophilic element that associates 
preferentially with the payload. Other performance criteria expected involve releasing the drug at 
the location of the small intestine, improved mucoadhesiveness to allow more time for the drug 
to cross over from the gastrointestinal lumen into the small intestine and finally, the ability to 
inhibit efflux pumps on intestinal enterocytes that recycle such drugs back into the lumen. 
Making carriers that meet these touchstones will improve bioavailability of hydrophobic drugs 
by increasing their solubility and permeability subsequent to oral intake.  
We have proposed the development of nanoscale, polyanionic, pH responsive hydrogel 
system to overcome the physicochemical and physiological challenges of delivering hydrophobic 
drugs orally so as to ensure release at the site of the small intestine and facilitate transport of the 
hydrophobic drug across the intestinal epithelium. Stimuli-responsive hydrogels that can respond 
to pH changes in order to realize controlled drug release in the GI tract have been reviewed by 
Sharpe et al. [2]. Such pH responsive polymeric networks are designed with the aim of retaining 
the drug during passage through the stomach, and releasing the drug only at the site of the small 
intestine. Because these hydrogels contain acidic pendant groups that ionize at pH values higher 
than the pKa of the acid, and the subsequent ionic repulsion between the negatively charged 
groups leads results in swelling of the hydrogel. The polyanionic hydrogel system, shown in 
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Figure 3, will consist of a backbone comprised of a copolymer of methacrylic acid (MAA) and a 
hydrophobic monomer.  
Modifying the copolymer composition to tailor polymer properties has been widely 
examined for a variety of biomedical applications [3-6]. In the present study, a set of four 
different formulations was developed using a diverse hydrophobic monomer each time. The four 
hydrophobic monomers selected are tert-butyl methacrylate (t-BMA), n-butyl methacrylate 
(nBMA), n-butyl acrylate (nBA) and methyl methacrylate (MMA). The hydrophobic monomer 
will form a lipophilic core that can associate preferentially with hydrophobic drugs. The 
copolymer backbone will be grafted with poly(ethylene glycol) tethers that confer colloidal 
stability to the nanoparticles in solution and also facilitate hydrogen bonding in the collapsed 
state in the stomach. Similarly, the presence of PEG tethers on the nanoparticle surface is 
believed to modulate biocompatibility and even promote mucoadhesion [7]. More importantly, 
PEG tethers of different molecular weights have been reported to play a role in the inhibition of 
efflux pumps that regulate the transport of hydrophobic drugs on the apical side of the small 
intestine [8]. The use of nano-sized hydrogels instead of micro-sized is believed to enhance the 
dissolution rate of the non-covalently linked drug owing to a higher surface area-to-volume ratio. 
Moreover, it has been suggested that, in order to diffuse “against” a mucus layer that is 
continuously being secreted or cleared, and accumulate at the intestinal epithelium in large 
proportions to release drugs, the size of the particles should be less than 500 nm [9].  
The emulsion polymerization technique used to synthesize the nanoscale hydrogels 
allowed for a panel of formulations to be developed with different hydrophobic monomer 
components (t-BMA, n-BMA, n-BA, and MMA) in the feed. Photoemulsion polymerization 
conditions and relative feed monomer ratios were kept constant across the set of four formulation 
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variants containing different hydrophobic monomers. Formulations were evaluated for criteria 
commonly identified as metrics for effective oral delivery of hydrophobic drugs, such as in vitro 
cytocompatibility to intestinal epithelium model and other physicochemical characteristics, 
capacity for drug loading and release at in vitro conditions mimicking site of the intestinal 
epithelium within timelines relevant to the GI tract emptying and absorption (described in 
Chapter 7), and finally apical-to-basal transport of the drug across an in vitro intestinal cell 
model (described in Chapter 8).  
The method of synthesis and purification employed in the production of nanoscale drug 
delivery system for controlled release is directly influenced by the nature and size of the drug to 
be encapsulated, the nature of comprising monomers and final polymer to be produced, mode of 
administration, and expected duration of drug release typically dictated by desired therapeutic 
range. Within each facile synthesis method, numerous parameters can be varied to yield 
nanoparticles that satisfy pharmacological requirements. Design parameters that affect polymeric 
nanoparticle physicochemical and biological properties, drug encapsulation efficiency, and drug 
release rate include polymer type and molecular weight, composition of copolymers, cross 
linking density, drug loading concentrations, type of solvent, types of surfactants, and other 
reaction conditions such as pH, temperature, concentration [10]. Finally, the response of 
polymeric nanoparticles to environmental stimuli can also be modulated to achieve favorable 
responses for the specific drug delivery application by tuning material properties. Material 
properties affecting the in vitro, in vivo, and clinical response of the nanoparticles broadly 
encompass physicochemical properties such as the particle size and size distribution, particle 
shape and surface morphology, surface chemistry and biological interactions, colloidal stability, 
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drug encapsulation efficiency, surface/bulk erosion/degradation, cell cytocompatibility, 
hemodynamic properties, and diffusion/permeability/kinetics of drug release.  
 Here, we present the synthesis of polymeric nanoparticles for the oral delivery of 
hydrophobic therapeutics. Interplay between hydrophilic monomer-hydrophobic monomer 
composition, and the resultant particle properties provides a basis for optimization of these 
nanoparticles, with the overarching goal of obtaining a favorable response to the environment 
these particles may be exposed to upon oral administration. For the specific application of oral 
delivery, it is required that the polymer nanoparticle retain the encapsulated drug as it traverses 
through the stomach, and that the drug be released only at the site of oral absorption i.e. the small 
intestine. The chief environmental condition that changes as a drug carrier travels through the 
stomach into the small intestine is the pH of the surrounding milieu, as it changes from a pH of ~ 
2 (fasted stomach) to a pH 6.1 (small intestine). Consequently, it is expected that a cross linked 
hydrogel nanoparticle remain collapsed within the stomach (thereby retaining the drug) and swell 
only in the intestine (thus, releasing the drug at the site of absorption), as shown schematically in 
Figure 6.1. Another response that can be tuned is the rate at which entrapped drug diffuses out of 
the cross linked hydrogel. Keeping this function in mind, interplay between parameters such as 
polymer hydrophobic composition and cross linking density, and the resulting particle swelling 
response and drug encapsulation/release efficiency provides a strong basis to optimize our 
formulation. 
6.2  PHYSICOCHEMICAL CHARACTERIZATION: MATERIALS AND METHODS 
 
 Blanchette and Peppas [11] previously investigated P(MAA-g-EG) hydrogel 
nanoparticles for their ability to deliver the cancer therapeutic bleomycin, which is a relatively 
hydrophilic drug freely soluble in water. However, the P(MAA-g-EG) nanoscale hydrogels did 
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not have a hydrophobic component that could associate well with hydrophobic drugs. As a result, 
P(MAA-g-EG) nanoparticles may be unsuitable for the purpose of delivering extremely 
lipophilic drugs such as doxorubicin. In this thesis, we propose the development of nanoscale 
hydrogel with a hydrophobic component that can preferentially associate with hydrophobic 
drugs. We have chosen methacrylate based hydrophobic monomers that have previously 
demonstrated success at forming non-covalent associations with lipophilic molecules. Inclusion 
of hydrophobic monomer components or hydrophobic moieties is believed to favorably impact 
drug loading and release by preferentially associating with the hydrophobic drug, and there are 
increasing reports of such a strategy for improving efficacy of intravenously administered 
nanoscale approaches for anticancer drug delivery [12-14]. Modulating polymer composition and 
the resulting polymer-solvent interactions can also affect critical phenomena involving polymer 
phase transitions; various reports provide examples of changes in temperature/pH at which phase 
transitions occur in response to varying polymer composition [15-17].   In this chapter, we 
describe the synthesis of these formulations using a photoemulsion polymerization method and 
examine the impact of changing the hydrophobic monomer component on the physicochemical 
and biological properties of the nanoscale formulations.    
6.2.1 Synthesis of Polyanionic Nanoscale Hydrogel Systems  
To synthesize the nanoscale hydrogels, we have adapted a UV-initiated free radical 
polymerization method developed in our lab [11]. Nanoscale polyanionic hydrogels were 
synthesized by UV-initiated free radical polymerization of a pre-polymer solution mixture. The 
pre-polymer mixture was comprised of monomers - methacrylic acid (MAA), tert-butyl 
methacrylate (t-BMA) or other hydrophobic monomer, poly(ethylene glycol) monomethyl ether 
methacrylate (PEGMMA) (molecular weight ~ 2080),  and cross linking agent tetraethylene 
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glycol dimethacrylate (TEGDMA) at 1% mole fraction of total monomer amount. The 
surfactants sodium dodecyl sulfate and Brij-30
®
 were then added to the system followed by 
Irgacure 2959 at 0.5 wt% of total monomer. For the formulation including methyl methacrylate 
as the hydrophobic monomer, sodium dodecyl sulfate was the only surfactant used as the use of 
Brij-30
®
 led to destabilization of the emulsion. The mixture was mixed and emulsified using a 
Misonix sonicator for 10 minutes. Nitrogen was bubbled into the mixture for 20 minutes to 
eliminate any oxygen that may scavenge free radicals participating in the polymerization. 
Finally, polymerization was initiated with a Dymax BlueWave
®
 200 UV (Dymax, Torrington, 
CT) point source for 2.5 hours at 100 mW/cm
2 
, with emulsion constantly stirring.  
After polymerization, the polymeric nanoparticles were first completely swollen by 
addition of 1N NaOH, followed by precipitation and extraction using acetone. Purification to 
eliminate any residual monomers was carried out by alternate washes with 0.5 N NaOH and 
acetone, followed by centrifugation. The polymeric nanoparticles were then dialyzed against 
water for 14 days to elute any more surfactants or monomers that may be present from the 
polymerization process. Finally, the nanoscale hydrogels were freeze-dried/lyophilized and 
stored in a desiccator until further use.  
Using this method, four different formulations were developed. The four formulations are 
as follows (with unique hydrophobic monomer component emboldened):  
1. Poly (Methacrylic acid-g-poly(ethylene glycol)-co-tert-butyl methacrylate) or 
P(MAA-g-PEG-co-tBMA) 
2. Poly (Methacrylic acid-g-poly(ethylene glycol)-co-n-butyl methacrylate) or 
P(MAA-g-PEG-co-nBMA) 
3. Poly (Methacrylic acid-g-poly(ethylene glycol)-co-n-butyl acrylate) or 
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P(MAA-g-PEG-co-nBA) 
4. Poly (Methacrylic acid-g-poly(ethylene glycol)-co-methyl methacrylate) or 
P(MAA-g-PEG-co-MMA) 
Structures of the monomers used in the emulsion polymerization procedure and the four 
hydrophobic monomers are shown in Figure 6.2 and Figure 6.3 respectively.  
After synthesis of P(MAA-co-tBMA-g-PEG), the cross linking density of the hydrogel 
was increased to 2% and 5% of the total monomer mole fraction. Increased cross linking density 
of the hydrogel offers greater resistance to swelling forces, causing an increase in the pH at 
which the formulation swells. This may be advantageous for ensuring that the hydrogel 
nanoparticles swell at a later stage (small intestine) of their GI tract transit. Similarly, changing 
the hydrophobic monomer content may also play a role in shifting the critical swelling pH. 
However, preliminary studies conducted with these increased cross linking densities suggested 
that increasing cross linking density of these nanoparticle formulations does not have a 
significant impact on physicochemical properties. For instance, it was observed that the variation 
in swelling behavior was not significant for increase in cross linking density from 1% to 2% of 
total monomer mole fraction, as shown in appendix A. Hence, for the present study, cross linking 
density was maintained at 1% of total monomer and focus is on observing trends across 
formulations containing a different hydrophobic monomer.   
6.2.2   Dynamic Light Scattering Studies  
The swelling behavior of P(MAA-co-tBMA-gPEG) nanoparticles is a key aspect that 
would characteristic of their success in responding to the contrasting pH conditions found in the 
stomach as opposed to the small intestine. Dynamic swelling responses exhibited by these 
nanoscale hydrogel formulations were studied using dynamic light scattering (DLS) at different 
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pH conditions. Dynamic light scattering (DLS) measurements were taken using a Malvern 
Zetasizer Nano ZS to determine the size and zeta potential of the nanoparticles as the pH of the 
solution changed.  
Dynamic light scattering was used to measure the size of the nanoscale hydrogels and 
evaluate their swelling response to changes in pH. An aqueous suspension of the nanoparticles 
was prepared by resuspending lyophilized nanoparticles in 1X PBS at a concentration of 0.5 
mg/ml. The DLS measurements and z-average particle diameters were collected using a Malvern 
Zetasizer NanoZS (Malvern Instruments, Malvern, UK). The measurements were obtained at 
25
o
C using a 633 nm laser source. The swelling response to dynamic pH was observed by 
varying the pH from 4.0 to 7.0 at intervals of 0.5 through the facility of a MPT-2 Autotitrator.   
Samples were prepared by suspending freeze-dried nanoscale particles at a concentration of 0.5 
mg/ml in 1X Phosphate Buffered Saline (PBS). Dynamic light scattering measurements were 
taken at increments of 0.5 pH units over the range of pH 4 (acidic, characteristic of conditions in 
the stomach) to pH 7 (neutral, characteristic of conditions in the small instestine). Each sample 
was measured with n=3 and the procedure repeated for three formulations, each possessing a 
different hydrophobic monomer in the polymer. Size measurements at different pH points shed 
light onto the swelling behavior of particles and the influence of the hydrophobic monomer on 
the overall swelling ability of the particles.  
6.2.3 Zeta Potential Measurements 
Zeta potential is an indicator of the magnitude of the polymer surface charge and is also 
representative of their colloidal stability. Surface zeta potential values were measured using the 
Malvern Zetasizer NanoZS (Malvern Instruments, Malvern, UK). Lyophilized samples were 
resuspended in 1X PBS (pH 7.4) and transferred into a disposable capillary cell (DTS1070) to be 
used with the Malvern Zetasizer NanoZS for zeta potential measurement. Electrophoretic light 
scattering measurements of the surface ζ-potential were collected at 25°C with nanoscale 
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hydrogels. Changes to the surface zeta potential were determined by varying the pH from 4.0 to 
7.0 at intervals of 0.5 using a MPT-2 autotitrator.  
6.2.4 Scanning Electron Microscopy 
Nanoscale hydrogels were imaged using a FEI Quanta 650 FEG scanning electron 
microscope. Prior to imaging, freeze dried nanoparticles were suspended in ultrapure DI water 
and dropped onto carbon-tape covered aluminum stubs. A 12 nm Pt/Pd coating was applied to 
the prepared stub samples using a Cressington 208 Benchtop sputter coater. Scanning electron 
microscopy images were obtained using an FEI Quanta 650 FEG scanning electron microscope.   
6.2.5 Fourier Transform Infrared Spectroscopy 
Fourier Transform Infrared Spectroscopy was used to elucidate subtle differences in 
copolymer composition by comparing characteristic infrared bands of the four nanoparticle 
formulations. All nanoparticles were investigated using a Thermo Mattson Infinity Gold
® 
spectrometer (Thermo Fisher Scientific, Waltham, MA). The characteristic infrared spectra were 
acquired by pressing freeze dried nanoparticle powder (~ 5 mg) into 195 mg KBr (Sigma-
Aldrich) disks. In all cases, sample spectra were analyzed subsequent to subtracting background 
KBr (~ 200 mg) spectra.  
6.2.6 
1
H-NMR Spectroscopy 
1
H-NMR spectra were obtained to examine the composition of uncrosslinked polymer 
formulations using a Varian (Palo Alto, CA) DirectDrive 400 MHz nuclear magnetic resonance 
spectrometer fitted with an automatic sampler. Deuterium oxide (D2O, 99.9%) was purchased 
from Cambridge Isotope Laboratories (Andover, MA). Prior to using the spectrometer, all 
relevant glassware, including NMR tubes (Wilmad Lab Glass, Vineland, NJ), Pasteur pipettes, 
and 3 mL sample vials were dried overnight in a vacuum oven. Freeze-dried polymer 
nanoparticle samples of approximately 25 mg were first weighed out directly in sample vials and 
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1 mL D2O was added to achieve a final concentration of 25mg mL
-1
. To ensure uniform 
dispersion of the sample in D2O, sample solutions were sonicated in an ultrasound bath, and then 
transferred to NMR tubes for spectrometry. SpinWorks 3
 TM
 software was used to analyze the 
1
H-NMR spectra. 
6.2.6 Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) is often performed on polymeric materials to 
uncover information regarding the thermal properties of the polymer by subjecting samples to a 
thermal cycle of heating and cooling, and gain further insight into the molecular make of the 
polymer. We obtained DSC thermograms for the set of four nanoparticle formulations that we 
have synthesized with the same hydrophilic monomers, but different hydrophobic monomers. 
We investigate the thermal transition temperatures across the set of nanoparticle formulations 
using a differential scanning calorimeter (Mettler-Toledo DSC1). For calorimetry, about 10 mg 
of sample of each polymer formulation was loaded tightly into an aluminum DSC pan equipped 
with a lid comprising a 0.1 mm hole. Prior to thermal cycling, we thoroughly dry the sample in a 
vacuum oven at a temperature of about 60
o
C. Then, any reminiscent thermal history associated 
with the sample is removed by annealing the sample at 130
o
C. Subsequent to annealing, we cool 
the samples from 130
o
C to -65
o
C before heating the samples to 150
o
C. A heating rate of 
10
o
C/min and a 5
o
C/min cooling rate were employed to operate the thermal cycles under a 
nitrogen gas atmosphere.  
For obtaining the second set of DSC thermograms, we used about 5 mg of sample of each 
polymer nanoparticle formulation that was first loaded into an aluminum pan and dried by 
ramping up the temperature at 20
o
C/min to 120
o
C in a Thermogravimetric Analysis (TGA) 
equipment (TGA Q500, TA Instruments, Delaware, US), followed by isothermal heating at 
120
o
C to allow for removal of any moisture content. Once dried, the sample was subjected to a 
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heat-cool-heat cycle in a differential scanning calorimeter (DSC Q2000, TA Instruments, 
Delaware, US). For the first heating cycle, temperature was ramped up to 200
o
C at a heating rate 
of 10
o
C/min, followed by a cooling cycle at the rate of 10
o
C/min to 10
o
C. For the final heating 
cycle, temperature was raised once again from 10
o
C to 200
o
C at a rate of 10
o
C/min. All the 
cycles were operated under a nitrogen gas atmosphere.    
6.3 BIOLOGICAL CHARACTERIZATION: MATERIALS AND METHODS 
In addition to evaluating physicochemical properties, it is crucial to understand the 
behavior of these nanoscale hydrogels in the presence of cells that may be encountered during 
the course of their drug delivery function in the GI tract. Importantly, the cytocompatibility of 
the polymer formulations in the presence of an intestinal cell layer model was determined in 
vitro using two different, commercially available assays. The [3-[4,5-dimethylthiazol-2-yl]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay evaluates cellular 
proliferation of the intestinal cell model, while the lactate dehydrogenase (LDH) assay 
investigates the plasma membrane integrity of the intestinal cell model.     
6.3.1 Cellular Cytocompatibility using MTS Assay 
Cytocompatibility of the nanoscale hydrogel systems was evaluated by incubation with 
the Caco-2 human colon adenocarcinoma cells. The Caco-2 cells are popular as a model 
intestinal epithelial cell line.  
To conduct the cytotoxicity studies, aforementioned cells were incubated with the 
particles for periods of two hours, in order to better simulate the time spent by the nanoparticles 
within the small intestine. A CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
(Promega Corp., Madison, WI) will be used to measure cell proliferation. Cell proliferation 
greater than 80% is indicative of better tolerance of the cells to the polymeric nanoparticles.  
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Cytotoxicity studies were carried out for the four formulations with different hydrophobic 
monomer components, namely, P(MAA-g-PEG-co-tBMA), P(MAA-g-PEG-co-nBMA), 
P(MAA-g-PEG-co-nBA),  and P(MAA-g-PEG-co-MMA). Each formulation was incubated with 
the Caco-2 monolayer at concentrations ranging from 4 mg/ml to 0.008 mg/ml.  Nanoscale 
hydrogel formulations were added at 10 different concentrations ranging from 4 mg/mL to 0.008 
mg/ml in culture medium. The negative control was a 3% (v/v) bleach solution in culture 
medium and the positive control was culture medium. After incubation with particles for 2 hours, 
the particle solution was vacuum aspirated and the cells were rinsed with culture medium once to 
ensure removal of particles. The cells were then incubated with the MTS assay solution for 2 
hours. Subsequent to incubation with the assay solution, the absorbance of the supernatant was 
measured at 490 nm using a Bio-Tek Synergy™ HT multi-mode plate reader (Winooski, VT). 
Background absorbance measured at 690 nm was subtracted from the values to account influence 
from bubbles, cell debris or other anomalies.  
6.3.2 Cellular Cytocompatibility using LDH Assay 
A CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Promega Corp., Madison, 
WI) was used to determine release of lactate dehydrogenase (LDH) from cells that underwent 
membrane damage subsequent to nanoparticle exposure. Caco-2 cells were seeded into 96-well 
black, fluorescence-measurement compatible plates, and polymer solutions added in 
aforementioned fashion. Polymer formulations were incubated with the cells for a 2 hour time 
period at 37
o
C in congruence with the incubation time for the MTS assay, and roughly time 
potentially spent by the particles in the small intestine prior to mucocilliary clearance. The 
CytoTox™ Reagent solution was then added and fluorescent measurements at 530 ex/590 em 
taken after 10 mins of incubation with reagent solution.       
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6.3.2 Mucoadhesion and Macrophage Uptake 
6.3.2.1 Mucoadhesion  
Biological response and interaction of newly developed biomaterials with components of 
the GI tract can play a role in determining their fate as oral delivery agents [18]. Enterocytes and 
the mucus layer covering these intestinal cells can play a role in governing outcomes related to 
oral drug delivery system, in addition to regulating absorption and distribution of drugs. 
Cytotoxicity studies with Caco-2 cells are a measure of the interactions of the particles with the 
intestinal epithelial layer, while mucoadhesive studies help ascertain how the polymeric system 
interacts with the mucosal layer covering the epithelial cells. Bioavailability of hydrophobic 
drugs may be improved by fortifying interactions of nanoparticles with the intestinal mucosa and 
this interaction depends on a number of factors such as electrostatic interactions, hydrogen 
bonding, van der Waals interactions and even polymer chain penetration [19]. A strong 
interaction with the mucosa permits the nanoparticle to reside for longer times in the GI tract, 
thereby allowing most of the loaded drug to release and cross the intestinal epithelial layer [7].  
 Mucoadhesive studies with nanoparticles were completed using a Q-Sense E4 system 
(BiolinScientific/Q Sense, Sweden) that characterizes surfaces by quantifying mass and 
structural changes to molecules and films at the interface. Firstly, mucin was deposited on an 
oscillating quartz plate, whose frequency and energy dissipation is monitored by a quartz crystal 
microbalance (QCM-D). 1X PBS solution (without any polymeric nanoparticles) was then 
pumped through the system for 20 min as a control to reference the frequency and energy 
dissipation of the oscillating plate. A solution of hydrogel nanoparticles was then pumped 
through the same system for another 20 min. This solution was prepared by suspending freeze 
dried nanoparticles in 1X PBS.  
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6.3.2.1 Uptake by Macrophages 
Another parameter that could potentially be of relevance in oral delivery considerations is 
the uptake of nanoparticles by intestinal M cells. M cells comprise 1% of the 200 m
2 
intestinal 
surface area orally delivered nanoparticles may potentially encounter. As a result, the probability 
of uptake by M cells is quite low, but cannot be ruled out owing to the size of the nanoparticles. 
Uptake by M cells can lead the nanoparticles into the Peyer’s patches, allowing for contact with 
antigen-sampling cells/macrophages [20]. As a result, it is relevant to observe the uptake of 
nanoparticles by macrophages to note if there is a strong chance of losing nanoparticles to the 
intestinal lymph nodes. From a molecular design perspective, it is reasonable to assume that 
polyanionic nanoparticles may be excluded from most cells owing to their negative charge. 
However, it has been noted that addition of hydrophobic moieties can lead to some cellular 
uptake.  
To assess if our polyanionic nanoparticles are uptaken by macrophages, we use confocal 
microscopy to provide insight regarding internalization, and compare it against polycationic 
nanoparticles designed for cellular uptake. For the study, 1 mg/ml fluorescently tagged 
nanoparticles were incubated with RAW264.7 cells for 2 h. Experimental conditions and image 
acquisition and processing settings for both polyanionic and polycationic nanoparticle uptake 
study were kept consistent to compare internalization by RAW 264.7 cells. Minimal uptake by 
macrophages can also imply lower uptake by most other cells, since macrophages are typically 
more prone to uptake of nanoparticles [21].  
6.4  PHYSICOCHEMICAL CHARACTERIZATION: RESULTS AND DISCUSSION 
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6.4.1 Synthesis of Polyanionic Nanoscale Hydrogel Systems  
We use an emulsion polymerization method to prepare the nanoscale hydrogels for oral 
delivery of hydrophobic therapeutics. Preparation of the nanoparticles by a UV-initiated free 
radical polymerization is presented by a schematic diagram in Figure. The surfactant plays an 
important role by stabilizing and solubilizing the hydrophobic monomer through interactions 
with the nonpolar ends formed within the interior of the surfactant micelles. Water-soluble 
initiators stimulate chain growth at the polar, hydrophilic surface of the micelle confronting the 
solvent i.e. water. The polymerization reaction propagates and continues inside the micelle as 
more and more monomer droplets from the exterior aqueous solution enter the interior of the 
micelle upon depletion of monomer droplets already present inside. As with any free radical 
reaction, the polymerization process continues until it is terminated by other free radicals. In the 
case of a UV-initiated free radical oil-in-water emulsion polymerization technique, the 
nanoparticle formation and physicochemical properties is affected by the monomer 
concentration, stirring speed/sonication intensity for emulsification, surfactant/stabilizer type and 
concentration and duration/conversion of reaction. All other parameters remaining constant, 
changing the monomer concentration will directly influence the nanoparticle properties such as 
size, molecular mass, and degree of cross linking/rigidity. In this chapter, we synthesize a panel 
of nanoparticles containing four different hydrophobic monomers and investigate the effect on 
the physicochemical properties that deserve priority for oral application – namely, size and 
swelling response with variation of the surrounding pH, and cell cytocompatibility in the 
presence of an intestinal epithelial cell model. Another important property that is investigated is 
the hydrophobic therapeutic loading and release, and is covered in chapter 7 [22]. A combination 
of FTIR and NMR was used to validate the presence of functional groups and monomers in the 
four polymer formulations. 
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One way to modify core hydrophobicity of the nanoscale hydrogels is by changing the 
hydrophobic monomer itself. N-butyl acrylate (n-BA) and n-butyl methacrylate (n-BMA) have 
been studied extensively for their ability to demonstrate preferential association with lipophilic 
drugs as hydrophobic core components of block copolymer micelles and even hydrogels [23-25]. 
N-butyl acrylate is highly hydrophobic but has a lower reactivity ratio for methacrylic acid 
copolymers, implying greater presence of methacrylic acid in the random copolymer formed. An 
indirect implication of increasing the hydrophobicity of polymeric systems can be increased 
cytotoxicity [26]. In fact, n-butyl acrylate and n-butyl methacrylate have demonstrated 
significant hemolytic activity and cytotoxicity in biological membranes owing to their ability to 
induce injurious changes in the lipid bilayers of living cells and disrupting functionality of 
membrane-bound proteins [27]. Intuitively, n-butyl acrylate has even been used to coat coronary 
stents and induce death among smooth muscle cells with the aim of preventing restenosis [28].  
As a result, an optimization of factors such as cytotoxicity (which gets top priority) and drug 
loading and release kinetics will eventually provide the rationale for our choice of the 
hydrophobic monomer in the oral delivery of lipophilic agents. Cytotoxicity of these 
formulations has been evaluated in Section 6.3.  
An extensively employed method to theoretically predict and speculate the composition 
of the final polymer nanoparticle is the use of reactivity ratios, which requires Q and e values for 
the different monomers [29, 30]. Q and e values for the different monomers employed in 
synthesis, and the corresponding reactivity ratios are shown in Table 6.1 and Table 6.2 
respectively. Reactivity ratio for each monomer in the copolymer was calculated assuming 
negligible PEG concentration since PEG is present at < 3 mol %, and thereby assuming the final 
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formulation to be a copolymer of hydrophilic monomer and hydrophobic monomer, instead of a 
terpolymer.  
Reactivity ratios are given by the following equations: 
 𝑟1 =
𝑄1
𝑄2
 exp [−𝑒1(𝑒1 − 𝑒2)]              (1) 
  𝑟2 =
𝑄2
𝑄1
 exp [−𝑒2(𝑒2 − 𝑒1)]                                      (2) 
6.4.2   Dynamic Light Scattering Studies  
The pH responsive behavior of the particles is as shown in figure . All four formulations 
exhibited a critical swelling pH around pH 4.9, and underwent a size and volume phase transition 
to a swollen state. For the P(MAA-co-tBMA-g-PEG) nanoparticles with 1% crosslinker, the size 
of the particles, represented by the z-average diameter in the measurements, increased from 80 
nm to around 120 nm, as the pH of the buffer increased from 4 to 8 (Figure 6.4). We next 
investigated the P(MAA-g-PEG-co-nBMA) nanoparticle formulation for their swelling response 
to changing pH, and observed a size change from about 85 nm in the collapsed state to 115 nm in 
the fully swollen state (Figure 6.5). The P(MAA-g-PEG-co-nBA) formulation possessed a 
diameter of size approximately 125 nm at the lower pHs as shown in Figure 6.6, and a diameter 
of 171 nm at pH 7.5 representative of the small intestinal pH. Interestingly, the P(MAA-g-PEG-
co-MMA) nanoparticle formulation underwent the largest size change from a mean z-average 
diameter of 277.3 nm to 472.3 nm at pH 7.5 (Figure 6.7). Incorporating MMA into the polymer 
network resulted in a dramatic size change of the formulation, in addition to having a marked 
effect on the pH-responsive size change as can be seen when swelling behavior of all 
formulations is shown together in Figure 6.8. All samples also demonstrated increased 
aggregation at pH values lower than the 4, perhaps due to the lack of ionic repulsion (since the 
carboxylic acid anionic groups are protonated below the pKa of 4.8-4.9) to counter the forces 
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driving the nanoparticles out of an aqueous solution (since the nanoparticles have a hydrophobic 
core).   
6.4.2  Zeta Potential Measurements  
Zeta potential measurements for all four formulations are shown in table. The zeta 
potential measurement values for all the formulations lie in the range of -17.5 to 20 mV at pH 7.5 
(Figure 6.9). As the pH was lowered, the zeta potential values increased with decreasing pH as 
can be expected due to protonation of the anionic charges on the carboxylic acid groups of the 
polymer network. All formulations except the P(MAA-g-PEG-co-MMA) collapsed out of 
solution before the zeta potential reached a perfectly neutral value, as can be anticipated based on 
the aggregation of these particles previously observed at a pH lower than the pKa of methacrylic 
acid.  
The negative surface charge on the polymer nanoparticles can be attributed to the 
carboxylic acid groups on the polymer core surface/polymer backbone. One way of reducing 
particle size is to increase concentration of surfactant/stabilizing agent such as Pluronic F68 [31]. 
Similarly, PEG chains grafted to the core polymer surface allow for steric stabilization leading to 
the formation a stable, aqueous dispersion. Interestingly, surfactants/stabilizing agents used 
during the emulsion polymerization process can remain associated with the surface of the 
nanoparticles even after repeated washing. Residual surfactants affect the zeta potential of the 
resulting nanoparticles in a manner that is related to the charge of the surfactants themselves. For 
instance, neutral PVA based surfactants mask the negative charge associated with carboxylic 
acid groups on the polymer core, while anionic surfactants can reinforce the charge leading to a 
higher zeta potential [32]. Similarly, neutrally-charged, grafted PEG can mask negative charge 
associated with carboxylic acid groups giving a net neutral charge to the particles, which is 
desirable for intravenously administered particles that might otherwise by uptaken by 
macrophages. Increasing PEG density and length can also increase the zeta potential from 
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negative to zero [33] however in this case, for the application of oral delivery, a negative surface 
charge at pH 7 is ideal for desirable pH-responsive behavior.  
6.4.3  Scanning Electron Microscopy  
The micrographs in Figure 6.10 help us visualize the nanoparticles. One caveat of using 
SEM is that the polymeric nanoparticles are subjected to vacuum and considerable electronic 
charging, leading to poorer resolution and conditions dissimilar to the pH 4-7 aqueous solutions 
used for sizing by DLS. As a result, the SEM images may be more of a suggestive measure of 
consistency in morphology than particle size itself. Particle size and swelling behavior are more 
crucial to the determination of optimal characteristics for use in oral delivery of hydrophobic 
therapeutics, and we primarily use dynamic light scattering and zeta potential measurements to 
substantiate these crucial properties.   
6.4.4  Fourier Transform Infrared Spectroscopy  
The infrared spectrum of all formulations is shown in Figure 6.15. As can be expected, 
the infrared spectra are not on a single nanoparticle level owing to resolution limitations of 
infrared radiation. However, the IR spectra can reveal information of the formulation on a 
broader, microscopic scale representative of a group or collection of nanoscopic elements, and 
we qualitatively look at trends in information regarding bond formation across the panel of 
formulations. A recent report by Tress et al. experimentally illustrates using broadband dielectric 
spectroscopy that properties arising from glassy dynamics of polymer chains are bulk-like to the 
extent of 0.5 nm, a size characteristic of near isolated polymer chains [34]. Since the carbonyl 
groups are present in each formulation, broad spectral bands at about 1760 cm
-1
 suggesting the 
presence of carboxylic acid groups can be observed in the carbonyl stretching region (Figures 
6.11- 6.14). Similarly, spectral bands that were common to all nanoparticle formulations also 
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include the ester linkage belonging to the acrylate groups in the 1760 – 1665 cm-1. In this case, 
peaks at 1714.4 and 1658.5 show absorption of about 86-88% (or transmittance of 12-14%). The 
concurrence of bands in the 1760-1690 regions and the 3500-3200 cm
-1
 confirm the presence of 
carboxylic acid groups and esters. Similarly, the O-H stretch band can be seen in the 3500-3200 
cm
-1
 is representative of hydrogen bonding. PEG has characteristic strong absorption peaks 
arising from the C-H and C-O stretching vibrations detected in all the polymer formulations. 
Given the presence of alkane groups (nBMA, nBA, tBMA, and MMA) we can also observe –C-
H stretching vibrations in the range of 3000 and 2800 cm
-1
. Interesting to note is the presence of 
–C-H- bending vibrations in the 1500-1300 cm-1 range that can be seen for MMA and tBMA 
owing to the absence of a long hydrocarbon side chain and the umbrella deformation peak from 
the tert-butyl group at 1370 cm
-1 
[35]. 
6.4.5  
1
H-NMR Spectroscopy 
Inclusion of monomers in the polymerization was also verified using NMR. Investigation 
of NMR spectra was conducted using linear polymer chains of each formulations synthesized 
using the same UV-initiated photopolymerization method, however, broadening of some peaks 
suggest the presence of physical crosslinks that may have formed between the linear chains. The 
most prominent peak (δ=3.55 ppm) can be attributed to the incorporation of PEG grafts into the 
all the polymer chains (Figures 6.16 to 6.19). Inclusion of grafted PEG as demonstrated by the 
PEG oxyethylene protons indicates the presence of a surface brush of solvated PEG chains in 
D2O. As previously stated, PEG grafted to the polymer surface, is an important constituent of our 
formulations owing to its role played in favorable biocompatibility, colloidal stability, possible 
inhibition of P-glycoprotein efflux pumps, and improved mucoadhesion; and is most solvated by 
the D2O and prominently detected by the solution-state NMR spectroscope. In the case of 
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P(MAA-g-PEG-co-tBMA), inclusion of tert-butyl methacrylate is ascribed to the presence of the 
tert-butyl group (-C-(CH3)3-, δ=1.305 ppm), i.e. the alkyl side group of the alkoxy moiety of the 
methacrylate. The methyl/methylene group (-CH2- or –CH2-CH2-) that dominates the polymer 
chain backbone of all nanoscopic formulations is ubiquitous across all spectra from Fig. at 
δ=0.8-0.9 ppm. In the spectra for P(MAA-g-PEG-co-nBMA), downfield proton peaks at δ=1.37 
ppm and δ=1.67 ppm are indicative of the presence of hydrogens belonging to the n-butyl group 
of the alkoxy moiety. Broadening of these peaks in the P(MAA-g-PEG-co-nBMA) can be the 
artifact of poor incorporation of n-butyl acrylate in the polymer chain owing to the affinity of 
methacrylic acid to react with itself in an ideal free radical copolymerization reaction between 
MAA and nBA. Inclusion of the protons belonging to the group closest to the electronegative 
oxygen of the alkoxy moiety consistently present in all formulations can be seen further 
downfield at δ~3.2 ppm, especially in the case of the P(MAA-g-PEG-co-MMA) spectrum which 
lacks other notable peak assignments and corresponding protons in its molecular structure. 
Approximate experimental quantification of the constituent monomers in the actual crosslinked 
polymer formulations is possible can be further pursued by means of solid state NMR 
spectroscopy.     
6.4.6  Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) was performed on polymeric materials to 
uncover information regarding the thermal properties of the polymer by subjecting samples to a 
thermal cycle of heating and cooling. This method can help gain further insight into the 
molecular make of the polymer. The DSC thermograms are shown in Figure with transition 
temperatures annotated on the charts. In the thermograms, the most important transition we see is 
the glass transition temperature. The UV-initiated photopolymerization method employed is a 
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random, free radical polymerization method and is consistent with the blunter glass transition 
observed. The P(MAA-g-PEG-co-tBMA) formulation has the highest glass transition 
temperature and sharpest decline, a characteristic that has previously been observed with 
polymer networks containing tBMA (Figure 6.20) [36].  
In the second set of DSC thermograms (Figures 6.21 to 6.24), melting endotherms in all 
formulations are observed at a temperature of and can be attributed to the melting of crystallites 
formed by segregation of PEG chains or grafts present in the copolymer. These PEG crystallites 
may especially be an artifact of the random copolymerization method used to synthesize the 
nanoparticle formulations leading to a more heterogeneous distribution of PEG chains, or result 
from crystal growth introduced during the drying method employed to eliminate the presence of 
moisture in the sample. Introduction of crystallinity can reduce the extent of enthalpic relaxation 
and restrict chain mobility leading to lower glass transition temperatures [37]. It is worthwhile to 
note that the melting endotherm for PEG-crystallites is at a temperature lower than that of the 
PEGMA polymer observed at 58
o
C, since this is a copolymer rather than a PEG homopolymer 
[36, 38].  The broad endotherm at a temperature of  is the melting point (Tm), subsequent to 
which, the  sample possibly solidifies from the melt to a glassy amorphous state upon cooling, 
given that the melting point endotherm peak is absent in the second heating cycle. Both the lower 
glass transition temperature and the melting point are consistent with those observed for PEG-
based copolymers [39]. 
To obtain an estimate of the degree of crystallinity, Xc, for the copolymer as the ratio of 
PEG crystallites to the total amount of PEG in the copolymer, we use the following equation, 
with heat of melting for PEG homopolymer, ∆𝐻𝑚,𝑃𝐸𝐺
0 = 200 𝐽/𝑔 , and are summarized in Table 
6.3. 
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𝑋𝑐 =  
∆𝐻𝑚,𝑐𝑜𝑝𝑜𝑙𝑦𝑚𝑒𝑟
∆𝐻𝑚,𝑃𝐸𝐺
0 ×
1
𝑚𝑃𝐸𝐺
𝑚𝑐𝑜𝑝𝑜𝑙𝑦𝑚𝑒𝑟
                                                                                 (3) 
The TGA curves (Figures 6.25 to 6.28) enable observation of the degradation rate of the 
polymer formulations upon exposure to high temperatures in air and nitrogen. This stability may 
be relevant if the polymer nanoparticle formulations are undergo processing strategies 
occasionally used in the pharmaceutical industry such as hot melt extrusion or even sterilization 
procedures.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
6.5  BIOLOGICAL CHARACTERIZATION: RESULTS AND DISCUSSION 
6.5.1 Cellular Cytocompatibility using MTS assay 
 To ensure that interaction of the polymer formulations with epithelial cells is not 
unfavorable, we ascertain a couple of key indicators of good cell health- cell proliferation and 
cytotoxicity. The MTS assay was used to measure and quantify the percentage of cells 
undergoing proliferation subsequent to incubation with the synthesized formulations. In our case, 
the assay was performed with Caco-2 cells, an intestinal epithelial cell monolayer model, which 
was incubated with each of the four nanoparticle formulations for a period of two hours.  
 Methods commonly used to assess cell health include determination of cellular 
proliferation and cell viability. Overall cell viability can be governed by the integrity of cell 
membranes, redox potential of the cell population or the functionality/ activity of crucial cell 
enzymes [40-42]. Quantitative assays representing viability of whole cell populations are 
generally conducted using microplate assays. Cell viability is closely associated with cell 
metabolic activity, and hence, high cellular reduction potential owing to mitochondrial 
hydrogenases that utilize NADH for reduction, is a key metric that is symptomatic of healthy, 
viable and proliferating cells. The MTS assay (Promega Corp., Madison, WI) probes the 
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reducing power of a live cell population, generating a signal that is proportionate to the amount 
of colored reporter and redox reaction product- formazan. Alternatively, the redox indicator 
resazurin signals presence of metabolic activity when it gets converted to the fluorescent and 
colorimetric molecule resorufin (alamarBlue®). Relative cellular proliferation based on 
absorbance values is calculated and normalized using the equation, 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛
=  
(𝐴𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
(𝐴𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
⁄  
 Results (Figures 6.29 to 6.32) demonstrate that cellular incubation with the formulation 
resulted in no adverse cytotoxic events, and in almost all conditions mean cellular proliferation 
of the live cell population was above the threshold of 80%, implying 80% of the cells continued 
undergoing cellular proliferation with no residual effects from nanoparticle incubation. There are 
no significant trends across the formulations suggesting that changing the hydrophobic monomer 
incorporated within a polyanionic network may not greatly impact its cytotoxic effects on in 
vitro intestinal cell models for the duration of the study.    
6.5.2 Cellular Cytocompatibility using LDH assay 
Appraisal of cell viability independent of metabolic activity can be achieved by determining cell 
membrane permeability. Loss of membrane permeability is compelling evidence of cell death, 
additionally acting as an indicator of cytotoxicity. Lactate dehydrogenase (LDH) release is a 
common indicator of cell membrane damage and can be detected using an enzymatic assay that 
converts resazurin into resorufin subsequent to LDH release [43]. To quantify LDH release in 
our in vitro intestinal cell model upon nanoparticle incubation, the CytoTox-ONE™ assay 
(Promega Corp., Madison, WI) was employed to measure LDH release from damaged cells by 
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detecting resorufin fluorescence. Relative cellular viability based on fluorescence values is 
calculated and normalized using the equation,    
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
(𝐴𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑎𝑐𝑘𝑔𝑟𝑑)
(𝐴max 𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝐴𝑏𝑎𝑐𝑘𝑔𝑟𝑑)
⁄  
 
Results (Figures 6.33 to 6.36) demonstrate that cellular incubation with the formulations 
resulted in no adverse cytotoxic events, and in almost all conditions membrane integrity and 
thus, cellular viability of the live cell population was above the threshold of 80%, implying 80% 
of the cells underwent no damage or residual effects from nanoparticle incubation. There are no 
significant trends across the formulations suggesting that changing the hydrophobic monomer 
incorporated within a polyanionic network may not greatly impact its cytotoxic effects on in 
vitro intestinal cell models for the duration of the study.    
Other methods exist to determine if membrane integrity has been compromised involves 
staining cell DNA with DNA-binding fluorescent dyes that are cell-impermeant (enter only lysed 
cells) and fluoresce only upon binding to the nucleus. A step further, would be to compare 
viability levels in different cells within a population, by measuring reduction potential and 
esterase activity of live cells and complementing it with DNA binding data. This can be done by 
using two probes- for instance, one cell-impermeant probe that will undergo fluorescence 
excitation in dead cells, and another metabolic activity/reduction potential indicator that will 
clearly differentiate dead cells from live cells in a given population. However, the LDH assay is 
superior for applications involving quantification of cytocompatibility of polyanionic 
nanoparticles, while others may be more relevant for polycationinc nanoparticles intended for 
endosomal escape.  
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Since the combination of cellular proliferation and cell viability did not reveal any major 
cytocompatibility-related adverse effects of polymer nanoparticles on in vitro cell models, we 
conclude that the nanoparticle formulations are suitable for further in vitro studies with intestinal 
cell models. 
6.5.3 Mucoadhesion Studies and Uptake of Nanoparticles by Macrophages 
6.5.3.1 Mucoadhesion Studies 
 
Hanes and group have previously demonstrated and extensively reviewed that 
PEGylation of nanoparticles in the size range of 100-500 nm can lead to a dramatic increase in 
their transport through intestinal mucus [44]. Transport through mucus trends linearly with an 
increase in PEGylation density. In this study, we tested our PEGylated formulation for its 
mucoadhesiveness. Similarly, another in vivo study demonstrated that nanoparticle engineered 
with low molecular weight PEG display good mucoadhesion. Nanoparticles with a hydrophobic 
core were also shown to exhibit mucoadhesiveness [45]. Formulations synthesized in this work, 
sport a number of properties that have previously been shown to promote mucoadhesion, 
including but not limited to appropriate size range, surface charge, PEGylation, and presence of a 
hydrophobic core. Here, we perform a proof-of-concept study to validate mucoadhesion.   
 Mucoadhesive interactions with the immobilized mucin were found to be substantial for a 
nanoparticle concentration of 0.5 mg/ml, whereas a concentration of 0.001 mg/ml showed no 
conclusive mucoadhesive response (Figure 6.37 (a)). At a concentration of 0.5 mg/ml, the 
nanoparticles adhered to the mucin on the oscillating quartz plate. As a result of this increase in 
mass adhering to the oscillating plate, there was a decrease in the frequency with which the plate 
was oscillating (Figure 6.37 (b)). Consequently, an increase in the mass and thickness of 
viscoelastic material on the plate surface (Figures 6.38 (a) and 6.38 (b)), led to an increase in the 
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energy dissipation of the oscillating plate. This can be explained by the fact that polymeric 
nanoparticles, being viscoelastic, are able to absorb (and thus, dissipate) the vibrational 
mechanical energy of the oscillating quartz plate, thereby displaying a considerable increase in 
the net energy dissipated.  
6.5.3.2 Uptake of Nanoparticles by Macrophages 
M cells account for a very small amount of total surface area of the GI tract (1% of total 
intestinal surface, and 5% of human follicle-associated epithelium), and nanoparticle transport by 
M cells for various applications such as vaccine and therapeutic delivery into Peyer’s patches has 
remained elusive. In our case, transcytosis/phagocytosis by intestinal M cells is undesirable, 
since we have designed our nanoparticles to release drug at the site of the intestinal lumen, and 
subsequently be cleared through the GI tract. Nanoparticle uptake by M cells is largely unlikely 
owing to the lower amount of M cells present in the small intestine, and M cell targeting agents 
have been studied  [46]. The approach we described for our uptake study, investigated in vitro 
uptake of our nanoparticles by macrophages to assess potential M-cell phaogyctotic uptake of the 
nanoparticle formulation.  The optimum size prescribed for particle uptake by M cells is about 
100 nm [20].  
 Confocal microscopy was used to observe internalization of the polyanionic nanoparticle 
formulation. Representative images are shown in Figures 6.39 to 6.42. We observe 
internalization of fluorescently tagged polyanionic nanoparticles in RAW 264.7 cells. Diffuse 
stain seen closer to the cell periphery indicates minimal uptake if any, and non-homogeneous 
distribution of the particles as compared with to the polycationic nanoparticle uptake study 
conducted separately as a reference.  
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6.6 CONCLUSIONS 
 
 pH-responsive, nanoscale hydrogels were developed and characterized to screen for 
optimal physicochemical properties for the goal of delivering hydrophobic therapeutics. 
Composition of the copolymer was varied by incorporating four different hydrophobic 
monomers, namely, tBMA, nBMA, nBA, and MMA. A combination of 
1
H-NMR and FTIR was 
used to verify the copolymer composition. All four nanoparticle formulations underwent a 
transition in size in response to an increase in pH from 4 to 7.5 as measured by dynamic light 
scattering measurements. While the commencement of swelling begins at a pH of around 4.9 for 
all formulations, the formulations undergo size transitions that are diverse in magnitude, with the 
formulaiton containing MMA undergoing the largest size and volume phase transition. 
Depending upon the hydrophobic monomer incorporated within the polymer network, the size of 
the formulations ranged from about 100-500 nm at pH 7. Despite considerable changes in 
swelling properties with a change in the hydrophobic monomer, all formulations displayed 
appreciable cytocompatibility in the presence of an in vitro intestinal cell model. By displaying 
amenable physicochemical properties and agreeable cytocompatibility, the pH-responsive 
nanocarriers thus, exhibited the key characteristics expected from a potential oral drug delivery 
system.  
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Table 6.1 – Q, e values of monomer components 
Monomer e Q 
methacrylic acid (MAA) 0.65 2.34 
tert-butyl methacrylate -0.35 1.18 
n-butyl acrylate 1.06 0.5 
n-butyl methacrylate -0.23 0.72 
methyl methacrylate 0.40 0.74 
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Table 6.2 – Reactivity ratios for Methacrylic acid (designated as 1) and comonomers used in 
polymerization 
Copolymer 
(1/2) 
r1 r2 r1 r2 
MAA/tBMA 1.035 0.355 0.3674 
MAA/n-BA 6.109 0.1384 0.8454 
MAA/n-BMA 1.834 0.2513 0.4609 
MAA/MMA 2.6877 0.3495 0.9394 
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Table 6.3 – Ratio of crystalline PEG to total PEG in the nanoparticle formulations. 
No. Formulation Xc 
1 P(MAA-co-tBMA-g-PEG) 0.0097 
2 P(MAA-co-nBMA-g-PEG) 0.0023 
3 P(MAA-co-nBA-g-PEG) 0.0072 
4 P(MAA-co-MMA-g-PEG) 0.0098 
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Figure 6.1 – Schematic of the swelling behavior and drug release from a pH-responsive hydrogel 
for the oral delivery of doxorubicin, a hydrophobic therapeutic. 
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Figure 6.2 – Structures of monomers used in the emulsion polymerization procedure. MAA is the 
hydrophilic monomer, PEGMMA is used to form PEG grafts, and tetraethylene glycol 
dimethacrylate is the cross-linker. These monomers were maintained consistent for all four 
formulation syntheses. 
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Figure 6.3 – Structures of the four hydrophobic monomers used. Formulation containing, (a) tert-
butyl methacrylate is denoted as P(MAA-g-PEG-co-tBMA), (b)  n-butyl methacrylate is denoted 
as P(MAA-g-PEG-co-nBMA), (c) n-butyl acrylate is denoted as P(MAA-g-PEG-co-nBA), and 
(d) methyl methacrylate is denoted as P(MAA-g-PEG-co-MMA) 
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Figure 6.4 – Dynamic swelling data for P(MAA-g-PEG-co-tBMA). Data points shown are mean 
of measurements ± SD.  
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Figure 6.5 – Dynamic swelling data for P(MAA-g-PEG-co-nBMA). Data points shown are mean 
of measurements ± SD. 
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Figure 6.6 – Dynamic swelling data for P(MAA-g-PEG-co-nBMA). Data points shown are mean 
of measurements ± SD. 
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Figure 6.7 – Dynamic swelling data for P(MAA-g-PEG-co-MMA). Data points shown are mean 
of measurements ± SD. 
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Figure 6.8 – Dynamic Swelling behavior of all formulations as measured by dynamic light 
scattering. P(MAA-g-PEG-co-MMA) underwent the largest size increase upon 
increasing pH, while P(MAA-g-PEG-co-tBMA) underwent the smallest size 
increase. Data points shown are mean of measurements ± SD. 
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Figure 6.9 - Zeta potential measurements for all formulations. Nanoparticle surface charge 
typically increases from -17.5 to -20 mV at pH 7.5, to slightly less negative at lower 
pH. Data points shown are mean of measurements ± SD. 
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           (a)                                                          (b)  
 
                      (c)                                                           (d)                                                           
Figure 6.10 - Representative scanning electron micrograph images. Scale bars: (a) 300 nm, (b) 
10 µm, (c) 100 nm, and (d) 500 nm 
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Figure 6.11 - Fourier Transform-Infrared (FTIR) spectra for P(MAA-g-PEG-co-tBMA).  
Y-axis: Relative Fraction Transmittance or (1-absorbance)  
X-axis: Wavenumbers (cm
-1
), wavenumber = 1/λ 
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Figure 6.12: Fourier Transform-Infrared (FTIR) spectra for P(MAA-g-PEG-co-nBMA).  
Y-axis: Relative Fraction Transmittance or (1-absorbance)  
X-axis: Wavenumbers (cm
-1
), wavenumber = 1/λ 
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Figure 6.13: Fourier Transform-Infrared (FTIR) spectra for P(MAA-g-PEG-co-nBA).  
Y-axis: Relative Fraction Transmittance or (1-absorbance)  
X-axis: Wavenumbers (cm
-1
), wavenumber = 1/λ 
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Figure 6.14: Fourier Transform-Infrared (FTIR) spectra for P(MAA-g-PEG-co-MMA).  
Y-axis: Relative Fraction Transmittance or (1-absorbance)  
X-axis: Wavenumbers (cm
-1
), wavenumber = 1/λ 
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Figure 6.15 - FTIR spectra of all formulations. Light blue: P(MAA-g-PEG-co-tBMA); Red: P(MAA-g-PEG-co-MMA);  Green: P(MAA-g-
PEG-co-nBA); Blue:P(MAA-g-PEG-co-nBMA) ; Y axis: Fraction Transmittance
0500100015002000250030003500
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Wavenumbers [1/cm]
T
ra
n
sm
itt
a
n
ce
 167 
 
tBMA 
 
Figure 6.16 - 
1
H-NMR spectrum of P(MAA-g-PEG-co-tBMA) 
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Figure 6.17 - 
1
H-NMR spectrum of P(MAA-g-PEG-co-nBMA) 
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Figure 6.18 - 
1
H-NMR spectrum of P(MAA-g-PEG-co-nBA) 
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Figure 6.19 - 
1
H-NMR spectrum of P(MAA-g-PEG-co-MMA) 
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Figure 6.20 - Differential scanning calorimetry thermograms of P(MAA-co-tBMA-g-PEG) 
nanoparticle formulation (red), P(MAA-co-nBMA-g-PEG) nanoparticle formulation (green), 
P(MAA-co-nBA-g-PEG) nanoparticle formulation (red). 
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Figure 6.21 - DSC thermogram of P(MAA-co-tBMA-g-PEG) nanoparticle formulation as seen when subjected to a heat-cool-heat 
cycle.   
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Figure 6.22 - DSC thermogram of P(MAA-co-MMA-g-PEG) nanoparticle formulation as seen when subjected to a heat-cool-heat 
cycle.   
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Figure 6.23 - DSC thermogram of P(MAA-co-nBMA-g-PEG) nanoparticle formulation as seen when subjected to a heat-cool-heat 
cycle.   
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Figure 6.24 - DSC thermogram of P(MAA-co-nBA-g-PEG) nanoparticle formulation as seen when subjected to a heat-cool-heat cycle.   
 
 176 
 
Figure 6.25 - TGA thermogram of the P(MAA-co-tBMA-g-PEG) polyanionic nanoparticles with nitrogen atmosphere. Weight Change 
% (green line) and derivative of Weight Change % with respect to time (blue line) are shown with increasing temperature. 
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Figure 6.26 - TGA thermogram of the P(MAA-co-MMA-g-PEG) polyanionic nanoparticles with nitrogen atmosphere. Weight Change 
% (green line) and derivative of Weight Change % with respect to time (blue line) are shown with increasing temperature. 
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Figure 6.27 - TGA thermogram of the P(MAA-co-nBMA-g-PEG) polyanionic nanoparticles with nitrogen atmosphere. Weight 
Change % (green line) and derivative of Weight Change % with respect to time (blue line) are shown with increasing temperature. 
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Figure 6.28 - TGA thermogram of the P(MAA-co-nBA-g-PEG) polyanionic nanoparticles with nitrogen atmosphere. Weight Change 
% (green line) and derivative of Weight Change % with respect to time (blue line) are shown with increasing temperature. 
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Figure 6.29 - in vitro cell proliferation % of evaluated by MTS assay for P(MAA-g-PEG-
co-tBMA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.30 - in vitro cell proliferation % of evaluated by MTS assay for P(MAA-g-PEG-
co-nBMA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.31 - in vitro cell proliferation % of evaluated by MTS assay for P(MAA-g-PEG-
co-nBA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.32 - in vitro cell proliferation % of evaluated by MTS assay for P(MAA-g-PEG-
co-MMA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.33 - in vitro cell viability % of evaluated by LDH assay for P(MAA-g-PEG-co-
tBMA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.34 - in vitro cell viability % of evaluated by LDH assay for P(MAA-g-PEG-co-
nBMA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.35 - in vitro cell viability % of evaluated by LDH assay for P(MAA-g-PEG-co-
nBA); n=4. Data are expressed as mean of measurements ± SD. 
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Figure 6.36 - in vitro cell viability % evaluated by LDH assay for P(MAA-g-PEG-co-
MMA); n=4. Data are expressed as mean of measurements ± SD. 
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    (a) 
    (b) 
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Figure 6.37 - Mucoadhesion studies performed with a quartz crystal microbalance with 
(a) 0.001 mg/ml polymeric nanoparticles, (b) 0.5 mg/ml polymeric 
nanoparticles. 
 
 
(a) 
 
      (b) 
Figure 6.38 - Change in (a) mass and, (b) thickness of immobilized mucin owing 
adhesion of polymeric nanoparticles. 
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(A) 
   
(B) 
 
 
 
            (C) 
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Figure 6.39 - Confocal microscopy images of fluorescently tagged polyanionic 
nanoparticles incubated with RAW 264.7 for 2 hr. Red: Alexa Fluor
®
 594 
wheat-germ agglutinin (WGA); Blue: DAPI; Green: AlexaFluor
® 
488 
tagged nanoparticles. 
 
      
                         (a)                                                                                      (b) 
  
                                (c) 
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Figure 6.40 - Composite confocal microscopy images with merged color channels of 
fluorescently tagged polyanionic nanoparticles incubated with RAW 264.7 
for 2 hr. Red: Alexa Fluor
®
 594 wheat-germ agglutinin (WGA); Blue: 
DAPI; Green: AlexaFluor
® 
488 tagged nanoparticles. 
 
Figure 6.41 - Montage of Z-stack orthogonal view, with XZ –planes and YZ planes to 
visualize internalization of polyanionic nanoparticles. 
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Figure 6.42 - Montage of Z-stack orthogonal view, with XZ –planes and YZ planes to 
visualize internalization of polycationic nanoparticles. 
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Chapter 7:  Modulation of Hydrophobic Solute Permeation through 
Anionic Crosslinked Hydrogels for Cancer Drug Delivery Applications 
 
 
 
 Formulations were evaluated for their ability to load and release doxorubicin, a 
hydrophobic chemotherapeutic 
 Studies were conducted to determine the diffusivity and permeability of 
doxorubicin through membranes in drug diffusion cells that were synthesized with 
similar feed composition 
 Powder X-ray diffraction was also used to substantiate amorphous nature of 
doxorubicin-loaded nanoscale hydrogels 
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2.1  INTRODUCTION 
Loading and release experiments were performed using doxorubicin as a model 
hydrophobic drug. Doxorubicin is an anthracycline antibiotic that acts by intercalating 
between DNA, or by generation of free radical species through redox cycling, eventually 
causing cell death by inhibition of DNA topoisomerase II [52]. The molecular structure 
of doxorubicin contains an anthraquinone fragment which is the planar chromophore 
component responsible for its bright red color. Presence of Beta-hydroxycarbonyl groups 
in the molecular structure allows for strong chelation between doxorubicin and the 
phosphate groups of cell DNA. Formation of harmful radicals is also singularly 
responsible for the notorious cardiotoxicity of doxorubicin, the most prominent side-
effect upon intravenous administration. Doxorubicin, despite its side effects, is the most 
extensively used chemotherapeutic and is essential in treating breast cancer, oesophageal 
carcinomas, Kaposi’s sarcoma, and Hodgkin and non-Hodgkin lymphomas.  
Based on the BDDCS system, doxorubicin is classified as a class IV drug (low 
solubility, low permeability) and has an oral bioavailability of 5%. Doxorubicin is the 
most commonly used chemotherapeutic as it is effective against a number of cancer 
malignancies such as breast, lung, lymphomas, bone and colon cancers. Doxorubicin has 
a molecular weight of about 543 g/mol and a solubility of less than 1 mg/ml in water.   
2.2  MATERIALS AND METHODS  
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2.2.1 Synthesis of polymer formulations 
Nanoparticle polymer formulations were synthesized as described in Section 
6.2.1. Briefly, Nanoscale polyanionic hydrogels were synthesized by UV-initiated free 
radical polymerization of a pre-polymer solution mixture. The pre-polymer mixture was 
comprised of monomers - methacrylic acid (MAA), tert-butyl methacrylate (t-BMA), 
poly(ethylene glycol) monomethyl ether methacrylate (PEGMMA) (molecular weight ~ 
2080),  and cross linking agent tetraethylene glycol dimethacrylate (TEGDMA) at 1% 
mole fraction of total monomer amount. The surfactants sodium dodecyl sulfate and Brij-
30
®
 were then added to the system followed by Irgacure 2959 at 0.5 wt% of total 
monomer. The hydrophobic monomer was varied in each case to yield a different core 
hydrophobicity for each formulation.  
 Membrane formulations for the drug diffusion and partitioning studies were 
synthesized using a film polymerization technique. In similar fashion to the nanoparticle 
synthesis, the pre-polymer mixture was comprised of monomers - methacrylic acid 
(MAA), tert-butyl methacrylate (t-BMA) or other hydrophobic monomer, poly(ethylene 
glycol) monomethyl ether methacrylate (PEGMMA) (molecular weight ~ 2080),  and 
cross linking agent tetraethylene glycol dimethacrylate (TEGDMA) at 1% mole fraction 
of total monomer amount. No surfactants were added and the solvent was ethanol instead 
of water. The mixture was placed in a sonic bath and sonicated for 10 mins, before being 
transferred the gap between two plates, and placed under a UV flood source for 30 mins. 
The resultant film was washed in water for 7 days and then punched into appropriates 
sized disks for the membrane drug diffusion and partitioning studies. 
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2.2.2 Doxorubicin loading studies  
Doxorubicin was loaded into the P(MAA-co-tBMA-g-PEG) nanoscale hydrogels 
by imbibition or equilibrium partitioning. In this method, a 0.15mg/ml stock solution of 
doxorubicin was prepared in 1X PBS solution, using 2 vol% Dimethyl sulfoxide (DMSO) 
to solubilize the hydrophobic drug. Adriamycin (doxorubicin hydrochloride, purchased 
from Biotang Inc., MA) was first solubilized in DMSO, followed by addition of 1X PBS 
(pH 7.4). The stock solution was kept stirring for 24 hours to ensure mixing. Nanoscale 
hydrogel particles were then added to the stock solution at a concentration of 1.2 mg/ml 
and were allowed to stir for a period of 6 hours. During the 24 hour period, 200 ul 
samples were taken in triplicate at distinct time intervals to analyze the doxorubicin 
concentration of the stock solution with time. Samples were taken at regular time 
intervals and nanoparticles were filtered off using Amicon
®
 Ultracel
®
-0.5 centrifugal 
filter devices (MWCO: 30,000) (Millipore, MA) centrifuged at 14,000g for 20 min, and 
filtrate doxorubicin analyzed using HPLC. Doxorubicin in the samples was detected 
using Waters HPLC, and 45:55 Acetonitrile:Water solvent ratio was run for 10 mins, and 
displayed an elution peak for doxorubicin (maximum absorbance wavelength = 485 nm) 
at ~ 3.7 mins. The doxorubicin concentration in the membrane and its partition 
coefficient was calculated by performing a mass balance for doxorubicin. 
After 24 hours, 1 N HCl was added to collapse the polyanionic hydrogel 
nanoparticles and entrap the drug molecules that may have diffused into the nanoparticles 
over the 6 hour period. The drug-loaded nanoparticles were then isolated from the 
doxorubicin stock solution using Amicon
®
 Ultra
®
-15 centrifugal filter devices (Millipore, 
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MA) with molecular weight cut-off 30,000. The drug loaded nanoparticles thus obtained 
as retentate as a result of the centrifugal filtration process, were rinsed with water to 
remove any surface adsorbed doxorubicin.  
Doxorubicin Loading Efficiency =
𝐶𝑜−𝐶𝑓
𝐶0
∗ 100           (7.1)                                                           
Where, Co is the initial doxorubicin concentration and Cf is the final doxorubicin 
concentration remaining in the solution.  
2.2.3 Doxorubicin release studies  
Release experiments were performed in beakers with constant stirring and at 37 
°C. To perform the release studies, 5 mg of doxorubicin-loaded nanoparticles were added 
to a beaker containing 1X PBS. To simulate the gastric pH conditions, first the drug-
loaded nanoparticles were released at a pH 2.0 for a period of 2 hours (representative of 
the gastric emptying time). The pH was then raised to 7.4 for the remaining duration of 
the experiment to mimic the neutral conditions of the small intestine. Samples were taken 
at regular time intervals and nanoparticles were filtered off using centrifugal filter devices 
(Amicon
®
 Ultracel
®
-0.5 centrifugal filter devices, MWCO: 30,000, Millipore, MA), and 
filtrate doxorubicin analyzed using HPLC. Doxorubicin in the samples was detected 
using Waters HPLC, and 45:55 Acetonitrile:Water solvent ratio was run for 10 mins, and 
displayed an elution peak for doxorubicin (maximum absorbance wavelength = 485 nm) 
at ~ 3.7 mins. The doxorubicin concentration in the membrane and its partition 
coefficient was calculated by performing a mass balance for doxorubicin. 
 205 
2.2.4 Powder X-ray diffraction studies  
We tested the amorphous nature of our DOX-loaded nanoparticle drug 
formulations using powder X-ray diffraction (P-XRD). P-XRD experiments were 
conducted using drug-loaded powder samples of the formulations and pure DOX powder 
as obtained from the manufacturer. The P-XRD patterns were obtained using a R-AXIS 
SPIDER (Rigaku Corporation, Tokyo, Japan) instrument using a 3 kW sealed Cu (1.54Å) 
filament radiation. Measurements were conducted at a voltage of 40kV and a current of 
40mA.    
2.2.5 Solute diffusion studies  
To better understand solute-polymer interactions, we studied diffusion of 
doxorubicin through a microscale membrane containing the same monomer components 
as their nanoscale counterparts. To perform doxorubicin diffusion studies, we used a 
Valia-Chen diffusion cell (Crown Glass Co., Inc., Somerville, NJ), which consists of 
side-by-side donor and receptor reservoirs. These diffusion cells have been used 
extensively in the past to study solute diffusion and permeation through ionic hydrogels. 
Previously, however, studies were conducted with hydrophilic solutes, and this is the first 
instance of the evaluation of drug diffusion studies performed in Valia-Chen diffusion 
with hydrophobic solutes diffusing through hydrogels with a hydrophobic component.  
To simulate physiological conditions of drug diffusion, the temperature was 
maintained at 37
0
C, and a physiologically relevant buffer (1X PBS) was used. The 
apparatus comprised of two half-cells- a donor cell and a receptor cell. Each half cell has 
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a volume of 3 mL and a side opening with a diameter of 9mm to place the hydrogel 
membrane. Before securing the membrane in the side opening, the membrane was pre-
swollen and equilibrated under the same pH conditions and buffer as the actual diffusion 
experiment. The membrane was then secured firmly between the half-cells to avoid any 
loss of solvent by evaporation. It is crucial that the membrane remain swollen during the 
course of the diffusion experiment to ensure proper diffusion of the solute through the 
hydrogel. The hydrogel membranes used in the experiment were membrane versions of 
the four formulations synthesized using the film polymerization method mentioned 
above, namely, P(MAA-g-PEG-co-tBMA), P(MAA-g-PEG-co-nBA), P(MAA-g-PEG-
co-nBMA), and P(MAA-g-PEG-co-MMA). Doxorubicin was the model solute used to 
evaluate and compare the ability of these hydrogels to permeate hydrophobic solutes.  
The donor cell was filled with a 0.15 mg/ml solution of doxorubicin, consistent 
with the solute concentration we have used throughout our drug loading experiments. The 
doxorubicin solution was prepared by dissolving doxorubicin (Adriamycin, Selleck 
Chemicals) in 1X PBS solution containing 2% v/v DMSO. The receptor cell contained 
1X PBS to emulate physiological conditions of drug release. Samples (50 ul) were taken 
from the donor and receptor cells every day and replaced with appropriate solutions to 
compensate for mass lost when taking samples. The doxorubicin concentrations in donor 
and receptor cells were thus analyzed as a function of time. Doxorubicin in the samples 
was detected using HPLC. The HPLC equipment comprised of a Waters 2695 Separation 
Module (Waters Corporation, Milford, MA) attached to a Waters 2487 Dual λ 
Absorbance Detector (Waters Corporation, Milford, MA). Analysis was performed using 
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a reverse-phase analytical HPLC method that used water with 0.1% volume 
trifluoroacetic acid (TFA) as solvent A, and acetonitrile with 0.1% volume trifluoroacetic 
acid (TFA) as solvent B. During the process, the mobile phase consisted of 45% 
Acetonitrile (solvent B) and 55% Water (solvent B) ratio; it was run for 10 mins and 
displayed an elution peak for doxorubicin (maximum absorbance wavelength = 485 nm) 
at ~ 3.7 mins.     
2.2.6 Membrane partitioning 
Next, we determined the solute partition coefficients in the four P(MAA-g-PEG-
co-hydrophobic monomer) membranes. Before conducting the partitioning experiments, 
the membranes were pre-swollen and equilibrated in the same pH conditions and buffer 
as the actual permeation experiment (pH 7.4, 1X PBS). The membranes were then placed 
in 30 mL of doxorubicin stock solution (Adriamycin in 2%v/v 1X PBS) with a 
concentration of 0.15 mg/mL. Samples were taken every day and analyzed using the 
HPLC method previously described. Doxorubicin in the samples was detected using 
Waters HPLC, and 45:55 Acetonitrile:Water solvent ratio was run for 10 mins, and 
displayed an elution peak for doxorubicin (maximum absorbance wavelength = 485 nm) 
at ~ 3.7 mins. The doxorubicin concentration in the membrane and its partition 
coefficient was calculated by performing a mass balance for doxorubicin. 
2.3  RESULTS AND DISCUSSION 
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2.3.1 Synthesis of polymer formulations 
To assess the capacity of our proposed nanoscale hydrogel system to load a 
hydrophobic therapeutic, and arrive at an optimal formulation, we quantify the loading of 
the hydrophobic drug doxorubicin into the panel of formulations we have synthesized. 
These formulations are summarized in Figure 7.1. 
Basically, we synthesized nanoscale and microscale versions of each formulation 
obtained by changing the hydrophobic monomer component. We then studied the 
differences in doxorubicin loading, permeability, and partitioning observed upon varying 
the hydrophobic monomer. Given the marked difference in the scale of the formulations 
and the kinetics of the polymerization synthesis process, it is plausible that any trends 
anticipated may be skewed despite the use of a UV initiated free radical polymerization 
owing to adaptations that had to be made to synthesize the entire panel of nanoparticles 
using the same emulsion process, and all microparticles using the same film 
polymerization technique. 
Upon synthesis, numerous differences between the nanoscale and membrane 
version of formulations became apparent. For instance, P(MAA-g-PEG-co-tBMA) films 
were relatively more hydrophilic and prone to breaking, as opposed to the P(MAA-g-
PEG-co-tBMA) nanoparticles that are relatively more hydrophobic. On the other hand, 
P(MAA-g-PEG-co-nBMA)  and P(MAA-g-PEG-co-nBA) were extremely tough and 
opaque to visible light suggesting a higher degree of hydrophobicity. Given the marked 
difference in the scale of the formulations and the kinetics of an emulsion polymerization 
synthesis process and film polymerization technique, it is plausible that any trends 
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anticipated between nanoparticles and their membrane counterparts, may be skewed 
despite the use of similar monomers and feed compositions because different proportions 
of the monomer actually got incorporated within the polymer network in the reaction 
time. 
2.3.2 Doxorubicin loading studies  
To systematically study and obtain a nanoparticle formulation that can efficiently 
load doxorubicin, loading of doxorubicin into the P(MAA-g-PEG-co-hydrophobic 
monomer) nanoscale hydrogels were performed by incubating each formulation with a 
doxorubicin stock solution of 0.15 mg/ml. Samples were taken at intervals of 2, 4, 6, and 
24 h and amount of free doxorubicin in the solution was evaluated. Equation 7.1 was 
used to calculate loading efficiency. Partitioning or the partition coefficient was 
calculated using equation 7.2. 
𝐾𝑑 =
𝐶𝑛𝑝
𝐶𝑜
=  
𝐶𝑜−𝐶𝑒
𝐶𝑜
     
 (7.2) 
Where, Kd = partition coefficient, Cnp = Concentration of doxorubicin in nanoparticles, 
Co= initial solution concentration of DOX, and Ce= equilibrium solution concentration of 
DOX (measured at 24 hr time point). The results for loading efficiencies and partition 
coefficients are shown in Table 7.2.  
 Loading of hydrophobic therapeutics into nanoscale hydrogels containing a 
hydrophobic core per se, is expected to be influenced by the hydrophobic interactions 
between the drug and the hydrogel, and the ability of the hydrogel to swell and permit 
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diffusion of the drug. The loading efficiencies are shown in Figure 7.2. P(MAA-g-PEG-
co-MMA) showed the highest loading efficiency and partitioning. The high degree of 
swelling and size and volume phase transition undergone by the P(MAA-g-PEG-co-
MMA) nanoscale hydrogels at the loading pH 7, it is possible that these hydrogels are 
able to afford an increased mesh size that can permit ready diffusion of doxorubicin into 
the polymer network despite being relatively hydrophilic as compared to other polymer 
networks we synthesized, in addition to having an optimal distribution of hydrophobic 
groups that can retain the doxorubicin once it has diffused into the network. On the 
contrary, the more hydrophobic P(MAA-g-PEG-co-tBMA) nanoscale hydrogels load 
most of their equilibrium amount of doxorubicin in the first 4-6 hrs of loading itself, 
indicating a faster but loading that may not be overall as efficient. P(MAA-g-PEG-co-
nBA) nanoscale hydrogels which showed appreciable swelling and size transition, 
demonstrated the lowest loading efficiencies which could be attributed to a poorer 
distribution of hydrophobic groups that allow for more swelling but less doxorubicin 
entrapment and retention.  
2.3.3 Doxorubicin release studies  
To investigate the ability of our nanoscale hydrogels to release doxorubicin 
specifically at the site of the small intestine, and examine retention at a pH that mimics 
the stomach, release studies were conducted with doxorubicin-loaded nanoparticles, and 
are shown in Table 7.3. In the first stage of the release study, the pH of the 1X PBS 
solutions was maintained at pH 2 to emulate the pH of the stomach, and the release of 
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DOX was evaluated. In the low pH phase of the study, we assess if the nanoscale 
hydrogels are capable of retaining the drug at pH conditions similar to that of the 
stomach. In this study, the P(MAA-g-PEG-co-tBMA) nanoparticles showed the most 
release, with 14.47% of drug released at the 2h mark. The P(MAA-g-PEG-co-nBMA) 
hydrogels released the released the least amount around 6%. After 2 hours, the pH was 
raised to a pH 7 to simulate the pH of the small intestine and the release of DOX was 
evaluated. The release at the 24 hour time point was denoted as M∞ and the release 
percent results are presented as Mt/ M∞ where Mt is the mass of the DOX that was 
released at time t. P(MAA-g-PEG-co-nBMA) nanoscale hydrogels showed the lowest 
efficiency of release suggesting that a more prominent hydrophobic presence can actually 
impede substantial release of the drug, promoting and inducing association and 
partitioning of the drug within the polymer network instead of release. P(MAA-g-PEG-
co-tBMA)  released most of the loaded drug, about 95.55% of the loaded drug after about 
6h at pH 7 (total 8h). P(MAA-g-PEG-co-MMA) released about 74.71% of the drug in 6h 
at pH 7. The almost linear release response of P(MAA-g-PEG-co-tBMA) may suggest 
surface or close to surface loading of doxorubicin in these nanoscale hydrogels despite 
considerable surface washing. It could also mean that small size of these hydrogels imply 
minimal diffusion path length for doxorubicin to diffuse out assuming similar tortuosity 
in all nanoscale hydrogel formulation pores.   
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2.3.4 Powder X-ray diffraction studies  
A general theory for inducing an improvement in apparent drug solubility 
prescribes that an increase in solubility comes with a concomitant decrease in 
permeability, as a part of the defining decree of the thermodynamic solubility-
permeability trade-off [1]. This is a prominent feature in reformulations of lipophilic 
drugs using cyclodextrin-complexation and micellization, where affinity of the lipophilic 
drug with the solubilizing moiety reduces free fraction of the drug available for intestinal 
membrane permeability. Reduced free drug concentration in the unstirred water layer in 
contact with the intestinal membrane, leads to smaller concentration gradients and 
consequently, lower thermodynamic driving force for intestinal permeation/partitioning 
[2]. Controlled release formulations such as the ones used by us are an improvement 
because they rely on sustained release of the drug over time to maintain sufficient 
concentration gradients across the intestinal wall.    
To further amplify the advantages of using controlled release formulations, one 
widely employed method for improving solubility of hydrophobic therapeutics is the 
encapsulation of lipophilic drugs in amorphous solid dispersions, followed by using 
techniques such as spray drying [3]. This spray-drying technique requires the use of an 
amorphous solid dispersion of a lipophilic drug in a polymer formulation, and produces a 
considerable advancement in apparent drug solubility via supersaturation.    
Arguments in favor of amorphous formulations over crystalline ones are grounded 
in thermodynamic predictions as well as experimental testing [4]. Hancock and Parks 
found that the theoretical solubility advantage of amorphous formulations is anywhere 
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between 10 to 1600 fold, based on predictive calculations assuming the amorphous form 
to be equilibrium supercooled liquid or pseudo-equilibrium glass [5]. While in vitro and 
in vivo dissolution of amorphous formulations is difficult to measure in non-equilibrium 
conditions, the solubility advantage is significantly higher than their crystalline 
counterparts.  
Powder X-ray diffraction is a powerful, non-destructive solid-state technique 
routinely exploited by the pharmaceutical industry for determining the amorphous or 
crystalline nature of powder pharmaceutical formulations, identifying and monitoring 
batch differences and uniformities, excipient compatibility, and detection of impurities 
[6]. X-ray diffraction has also been applied to resolve if drug-loaded particles are 
amorphous which can be correlated to formation of a homogeneous, single phase with a 
higher apparent solubility than crystalline/partially crystalline drug alone [7]. 
We tested the amorphous nature of our drug formulations using powder X-ray 
diffraction (P-XRD). Presence of crystalline lattices in drug loaded particles display 
relatively sharper peaks in congruence with one-dimensional crystal diffraction patterns, 
as opposed to purely amorphous formulations that reveal a broad scattering profile with 
no sharp peaks [8]. Angle of diffraction (θ), or in this case measured angle of diffraction 
(2θ) for the various drug-loaded formulations in reported in Table 7.1, along with crystal 
lattice d-spacing values as calculated through use of Bragg’s law. Further polymorphic 
determination was enabled by executing elemental scans that compared sample peak 
positioning to crystal patterns of similar molecules from single-crystal X-ray diffraction 
studies. For comparison, the P-XRD pattern for free doxorubicin powder is provided in 
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Figure 7.4. Our analysis revealed that all DOX-loaded polymer nanoparticle formulations 
(except P(MAA-g-PEG-co-nBMA)) display broad featureless diffraction patterns and are 
purely amorphous within resolution of our powder X-ray diffraction detection (Figures 
7.5 to 7.8).  
We compared the P-XRD patterns of DOX-loaded nanoparticles to that of DOX 
alone. Visually the DOX-loaded nanoparticles appear slightly red owing to the red color 
imparted by DOX, but for P-XRD patterns, we ran an elemental scan which displayed 
good comparison with peaks for compounds similar to DOX and containing Nitrogen 
(present in DOX, but absent in our polymer nanoparticles), substantiating the presence of 
DOX in the amorphous formulations via P-XRD. All analysis for simultaneous elemental 
information scanning and complementary peak comparison were performed using 
DIFFRAC.EVA (Bruker Corp., Billerica, MA) XRD data analysis software (Bruker 
Corp., Billerica, MA). Figures 7.9 to 7.14 compare, match and visually indicate P-XRD 
pattern for DOX-loaded polymer nanoparticles with crystal structure peaks of known 
compounds.  
2.3.5 Solute diffusion studies  
Hydrogel permeability of various small molecules and large molecules has 
previously been studied to gain a nuanced understanding of the size of solutes which can 
diffuse through the polymer [9-13], using an experimental set-up comprising of diffusion 
cells or Valia-Chen cells. Diffusion cells were used for experimental elucidation of solute 
diffusion and permeability, owing to a lack of experimental methods for evaluation of 
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solute diffusion and permeability through polymeric nanoparticles, although methods 
involving simulation of diffusion have been explored [14].  Solute diffusion and 
permeation through the membrane hydrogel networks were investigated for doxorubicin 
for all four formulations of the P(MAA-g-PEG-co-hydrophobic monomer) using 
diffusion cells/Valia-Chen cells. A schematic showing the Valia-Chen cell is shown in 
Figure 7.15. Plots of recipient cell concentration (mg/ml) which can be correlated with 
mass permeated with time can be seen in Figure 7.16. P(MAA-g-PEG-co-MMA) gels 
witnessed an almost linear rate of permeation indicating steady state permeation. 
P(MAA-g-PEG-co-tBMA) which we observed to soft and gel-like underwent a collapse 
and rupture, possibly due to swelling stress over a two day period, at the end of 2 days, 
and hence permeation rate and subsequent calculations are based on their behavior for the 
two days. P(MAA-g-PEG-co-nBMA)  and P(MAA-g-PEG-co-nBA) were extremely 
hard, opaque, seemingly hydrophobic and allowed minimal permeation at the end of 3 
days, possibly due to small mesh sizes and hydrophobic interactions that permitted size 
exclusion of doxorubicin. Permeability coefficients were calculated using the slopes of 
linear regression fits based on and presented in Table 7.3.  
2.3.6 Membrane partitioning 
Partitioning of the solute in the membranes increased over time. Permeation is 
believed to proceed with a lag phase that can be attributed to size exclusion phenomena 
as is previously suggested. As the membranes equilibrate in the doxorubicin solution for 
a longer period of time and become fully ionized, more free space is available for 
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doxorubicin to diffuse into the gel and undergo partitioning. This partitioning is likely to 
be driven by hydrophobic interactions between doxorubicin and the hydrophobicity of the 
membrane. The mesh size of membranes prepared in this manner typically ranges 100 
Angstrom to 320 Angstrom, while doxorubicin has a diameter of about 10 Angstrom. 
Hence, it can be anticipated that partitioning of doxorubicin increases linearly if the 
experiment is performed over a long enough time period. The difference in permeation 
across the membranes that differ only in hydrophobic monomer as such indicate, that 
diffusion and partitioning of doxorubicin within the membranes indicate that any changes 
in swelling phenomena and mesh size changes may dominate the results in diffusion that 
occur as a result of increasing hydrophobicity of the membranes, and is tabulated in 
Table 7.4, and shown in Figure 7.17.  
A careful calculation of the mesh size can help us understand how the drug 
diffusion changes with changes in mesh size resulting from changing the hydrophobic 
monomer. However, there appears to be little or no correlation between the nanoscale 
hydrogels and membrane hydrogels that are synthesized with the same feed composition. 
This is essentially the effect of a compositional drift that occurs differently in the 
synthesis of nanoscale hydrogels via emulsion polymerization, as compared to the 
compositional drift that occurs in the synthesis of the membrane hydrogels. While there 
may be some thermodynamic correlation between partitioning within membrane versions 
of the hydrogel and nanoscale version with same final composition, it is understood that 
there will be a fundamental difference in kinetics of diffusion on the nanoscale and 
microscale per se. Given the lack of correlation between the two forms of the hydrogel 
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system and the minimal diffusion observed in the case of membrane hydrogels, we did 
not pursue any further evaluation of the membrane hydrogels, as we no longer consider it 
to be within the scope of assessing the merit of nanoscale hydrogels for oral delivery of 
doxorubicin.    
2.4  NANO FORMULATION DOSAGE FEASIBILITY 
In this section, we estimate the dosage feasibility of our nanoscale hydrogel formulation 
by calculating the amount of orally deliverable formulation required to administer the 
equivalent of a typical intravenous dosage of doxorubicin. Now, typical intravenous 
dosage of doxorubicin given to patients is about 50 mg/m
2 
per week (typically given over 
a period of 48 hrs via IV infusion per week). Usually this regimen is divided into three 
48-hour treatments over the course of three weeks, with subsequent treatment depending 
on off-target side-effects/toxicity and response to treatment. Boyd’s formula is used to 
calculate body surface area in determining the total mass of doxorubicin to be 
administered. 
For this estimate, we use the following Boyd’s formula to calculate the body surface 
substituting H and W of a patient with average height and weight of 180 cm and 80 kg, 
= 0.0003207 x (W)
(0.7285-0.0188log(W) 
x (H)
0.3
= 2.0107 m
2
 
Thus, total DOX dosage required = 100.53473 mg. We used a drug concentration of 0.15 
mg/ml, in combination with a 1 mg/ml concentration of nanoparticles. Assuming a 
conservative estimate of 60% loading efficiency, we find the amount of nanoparticles 
loaded into 1 mg of nanoparticle formulation to be 0.09 mg. Bioavailability of free 
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doxorubicin drug has been estimated to be 5% in some intestinal absorption models [15]. 
If we assume a lower conservative estimate of 10% bioavailability (intestinal absorption) 
and a release of 90% of loaded drug, we obtain the mass of doxorubicin absorbed into the 
blood stream per mg of nanoparticles used. This value is equal to: 0.09 mg x 0.1 x 0.9 =  
0.0081 mg DOX/mg nanoparticle delivered. Hence, to ensure delivery of 100 mg of 
doxorubicin that is equivalent to a weekly total, we will need 12.345 g of nanoparticles 
per week. This is the amount to be given orally over a week, and can be accomplished via 
two tablets Capsule size 000 (each approximately with a mass ~ 6g) or four tables per 
week of capsule size 12 (each approximately with a mass ~ 3g), or a tablet of capsule size 
11 taken once daily over the entire week of treatment (each approximately with a mass ~ 
1.6g). Thus, based on this estimate the use of aforementioned nanoscale formulations is 
feasible from a practical, pharmacological standpoint.  
2.5  CONCLUSIONS  
We examined and compared the capacity of the nanoparticle formulations to load 
and release the hydrophobic therapeutic, doxorubicin. Loading studies were performed at 
pH 7.4 when the hydrogel networks are fully swollen. The capacity of loading 
hydrophobic therapeutics into the nanoscale hydrogel formulation is expected to be 
influenced by the hydrophobic interactions between the drug and the hydrogel, and the 
ability of the hydrogel to swell and permit diffusion of the drug during the loading 
procedure. By changing the hydrophobic comonomer in the nanoparticle formulations, 
we were able to successfully load doxorubicin, with loading efficiencies ranging from 40-
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70%, with the P(MAA-g-PEG-co-MMA) formulation showing the highest loading 
efficiency. Further, we investigated the ability of these formulations to perform favorably 
under pH conditions similar to those encountered during transit through the GI tract. 
Specifically, we examined their ability to retain doxorubicin at an acidic pH expected to 
be found at the site of the stomach, and release the drug in response to alkaline conditions 
of the small intestine. P(MAA-g-PEG-co-tBMA)  released most of the loaded drug, about 
95.55% of the loaded drug after about 6 hours at pH 7 (total 8h). P(MAA-g-PEG-co-
MMA) released about 74.71% of the drug in 6 hours at pH 7. The almost linear release 
response of P(MAA-g-PEG-co-tBMA) may suggest surface or close to surface loading of 
doxorubicin in these nanoscale hydrogels despite considerable surface washing. It could 
also mean that small size of these hydrogels imply minimal diffusion path length for 
doxorubicin to diffuse out assuming similar tortuosity in all nanoscale hydrogel 
formulation pores.  Powder X-ray diffraction analysis revealed the amorphous nature of 
the drug formulations suggesting an increase in the solubility of doxorubicin under 
conditions mimicking the site of drug release. Solute diffusion and permeation were 
explored indirectly through the use of membrane hydrogel networks with the same 
monomer feed composition as the nanoscale hydrogel formulations, although little or no 
correlation exists between the behavior of the nanoscale and macroscale networks. It is, 
however, worthwhile to note that partitioning of the solute in the membranes increased 
over time, while permeation is believed to proceed with a lag phase that can be attributed 
to size exclusion phenomena. Nanoscale hydrogel formulations exhibited the capacity to 
load and release the hydrophobic therapeutic doxorubicin, and varying the hydrophobic 
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comonomer keeping the same nominal feed composition can play a role in modulating 
drug loading/release efficiencies. 
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Table 7.1: Powder X-ray diffraction peak values for doxorubicin-loaded formulations 
    
 
DOX-loaded 
nanoparticle 
formulation     
 
            2θ value         d-spacing 
 
P(MAA-g-PEG-co-
MMA) 17.189 5.154 
 
      
 
 P(MAA-g-PEG-co-
nBMA) 17.135 5.17 
 
  31.599 2.829 
 
  45.322 1.999 
 
  56.36 1.631 
 
  27.246 3.27 
 
  56.934 1.616 
 
      
 
P(MAA-g-PEG-co-
nBA)     
 
  17.728 4.999 
 
      
 
P(MAA-g-PEG-co-
tBMA)  17.587  5.039 
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Table 7.2: Doxorubicin loading efficiencies and partition coefficients with nanoscale 
hydrogel formulations at the end of the study. Calculated as % efficiency = 
Co-Ct/Co ; n= 3, Reported as mean +/- SD. Kd= cm/ce = (c0 – ce)/ce; 
Nanoscale Hydrogel 
Formulation 
Equilibrium Loading 
Efficiency 
(%) 
Partitioning 
Coefficient 
Kd  
P(MAA-g-PEG-co-
tBMA) 
56.63 ± 0.1 1.306 
P(MAA-g-PEG-co-
nBMA) 
58.88 ± 0.4 1.432 
P(MAA-g-PEG-co-
nBA) 
40.59 ± 2.2 0.6832 
P(MAA-g-PEG-co-
MMA) 
70.13 ± 2.9 2.348 
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Table 7.3: Permeability coefficients/slopes for the diffusion of doxorubicin through the 
membrane formulations.  
 
Membrane Formulation Slope/Permeability Coefficient (cm
2
/s) 
(in 10
-6
 cm
2
/s) 
P(MAA-g-PEG-co-tBMA) 1.444 
P(MAA-g-PEG-co-nBMA) 0.9722 
P(MAA-g-PEG-co-nBA) 0.9722 
P(MAA-g-PEG-co-MMA) 4.75 
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Table 7.4: Membrane formulation and their permeability coefficients, partitioning 
coefficients, and diffusion coefficients 
 
Membrane 
Formulation 
Slope/Permeability 
Coefficient (cm
2
/s) 
(in 10
-6
 cm
2
/s) 
Partitioning 
Coefficient 
Kd = cm/ce = (c0 – 
ce)/ce 
Diffusion Coefficient 
= P/Kd 
(cm
2
/s) 
P(MAA-g-PEG-co-
tBMA) 
1.444 1.465 9.8570 x 10
-7
 
P(MAA-g-PEG-co-
nBMA) 
0.9722 0.3360 2.8931 x 10
-6
 
P(MAA-g-PEG-co-
nBA) 
0.9722 0.1726 5.633 x 10
-6
 
P(MAA-g-PEG-co-
MMA) 
4.75 0.8485 5.5979 x 10
-6
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Figure 7.1: Molecular structure of doxorubicin. 
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Figure 7.2: Formulation map showing nanoscale formulations for drug loading and relase 
studies, and powder X-ray diffraction. Micro or membrane formulations of 
the same component monomers had to be synthesized for compatibility with 
drug diffusion studies/cells and membrane partitioning. 
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Figure 7.3: Doxorubicin loading efficiencies with nanoscale hydrogel formulations. 
Calculated as % efficiency = Co-Ct/Co ; n= 3, data points shown are mean of 
measurements +/- SD. Loading efficiency among treatment groups is 
statistically significant with p<0.05. 
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Figure 7.4: Doxorubicin release efficiencies with nanoscale hydrogel formulations. 
Calculated as % efficiency = Co-Ct/Co ; n= 3, data points shown are mean of 
measurements +/- SD. Loading efficiency among treatment groups is 
statistically significant with p<0.05. 
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Figure 7.5: Powder X-ray diffraction pattern for free doxorubicin powder as obtained 
from manufacturer. Sharp peaks (indicated by red lines) imply a partially 
crystalline powder.  
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Figure 7.6: Powder X-ray diffraction pattern for doxorubicin loaded P(MAA-g-PEG-co-
tBMA). Absence of any peaks implies an amorphous powder. 
 233 
 
Figure 7.7: Powder X-ray diffraction pattern for doxorubicin loaded P(MAA-g-PEG-co-
nBMA). Presence of peaks at 2θ=31.599, 45.322, 56.36 suggests powder is not fully 
amorphous and has a crystalline character to it. 
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Figure 7.8: Powder X-ray diffraction pattern for doxorubicin loaded P(MAA-g-PEG-co-
nBA). Absence of any peaks implies an amorphous powder. 
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Figure 7.9: Powder X-ray diffraction pattern for doxorubicin loaded P(MAA-g-PEG-co-
MMA). Absence of any peaks implies an amorphous powder 
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Figure 7.10: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale 
hydrogels (blue) and compared with peaks of 5-beta-dihydrotestosterone 
standard, which has a structure similar to doxorubicin, implying presence of 
doxorubicin in amorphous powder. 
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Figure 7.11: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale hydrogels (blue) and 
compared with peaks of L-lactide-poly(ethyleneglycol) 
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Figure 7.12: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale hydrogels (blue) and 
compared with peaks of Succinic acid-2-urea 
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Figure 7.13: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale hydrogels (blue) and 
compared with peaks of 3-(3-Methyltoluyl)-1,2,2-trimethylcyclopentanecarboxylic acid. 
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Figure 7.14: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale hydrogels (blue) and 
compared with peaks of Indole-2-carboxylic acid 2,4-dinitrobenzoic acid. 
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Figure 7.15: Elemental data scanning and Peak comparison. Powder X-ray diffraction 
pattern of Doxorubicin-loaded P(MAA-g-PEG-co-MMA) nanoscale 
hydrogels (blue) and compared with peaks of 3-Aminobenzoic acid 5-
nitroquinoline. 
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Figure 7.16: Schematic of solute diffusion cells or Valia-chen cells for drug diffusion 
studies. 
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Figure 7.17: Recipient cell concentration of doxorubicin in solute diffusion studies 
performed using diffusion cells and membrane formulations. Data points 
shown are expressed as mean +/- SD. 
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Figure 7.18: Calculation of slope for doxorubicin solute permeability studies conducted 
in Valia-Chen diffusion cells.  
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Chapter 8:  Evaluation of the Effect of Nanoscale Hydrogels on the 
Permeability of Hydrophobic Therapeutics across in vitro Cell Models  
 
 
 
 Increased permeability of hydrophobic therapeutics across the GI tract is an 
important aim for oral drug delivery systems   
 Permeability of doxorubicin is greatly reduced due to the drug efflux transporter 
P-glycoprotein 
 To evaluate transport of doxorubicin across intestinal epithelial monolayer, 
transport studies were conducted in vitro for all formulations 
 Elucidation of the impact of nanoscale hydrogels on P-glycoprotein was achieved 
using a P-gp overexpressing multidrug resistant cell line and compared with non-
overexpressing cell lines 
 Two assays were used to evaluate this interaction – Calcein AM retention in the 
presence of hydrogels, and cellular proliferation of multidrug resistant cancer 
cells in the presence of doxorubicin-loaded nanoparticles 
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8.1  INTRODUCTION 
This chapter is part of the integrative approach towards understanding the in vivo 
and clinical behavior of the orally deliverable platform we have developed. Recently, 
owing to high costs associated with in vivo and clinical development of drug 
formulations, there is a growing emphasis on development of in vitro screening 
techniques that can better predict and evaluate the efficacy of formulations at the early 
product development stage itself. Here, we present the in vitro investigation of the 
potential influence of our nanoscale hydrogel platform on the permeability of 
hydrophobic therapeutic doxorubicin subsequent to oral administration.     
In this Chapter, we first evaluate and compare the transport of doxorubicin 
across an in vitro intestinal epithelium model. To investigate the potential of the 
nanoscale hydrogels to inhibit P-glycoprotein related drug efflux, we assess the ability of 
our nanoscale formulations to inhibit the overly expressed drug efflux proteins that 
impede transport across intestinal epithelium and also confer drug resistance to cancer 
cells. By surface functionalizing pH responsive polymer nanoparticles with 
polyoxyethylene chains, we hypothesize that the nanoscale delivery vehicle can 
potentially sensitize drug resistant cancer cells and empower an improved treatment 
modality against multidrug resistant cancer. By implementing a tailorable polymer 
nanotechnology-based oral delivery platform, we can provide chemotherapeutics 
unprecedented access to otherwise “inaccessible” cytoplamsic regions of multidrug 
resistant tumor cells without eliciting any adverse effects. Such a multifunctional system 
that responds to changes in the pH and intelligently inhibits only cancerous cells 
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precludes the usage of other pharmacological agents and complex, cost prohibitive 
treatment strategies that are currently implemented to combat multidrug resistant cancer.  
In this proposed work, we describe a promising new strategy that involves 
nanoscale system that can help evade barriers instituted by metastatic tumors to elude 
traditional cancer drugs and are designed to be orally delivered with the intention of 
improving patient quality of life. This work, thus, looks to develop a broadly applicable 
platform that can deliver a robust and actively targeted therapeutic package, by 
intelligently sensing and reacting to the gastrointestinal tract milieu and ensuring its 
delivery to the site of action by deactivating any drug efflux associated barriers that a 
drug may otherwise encounter. To address outstanding questions regarding the spread of 
tumor metastases through blood vessels, my work explores the potential of using a 
nanoscale platform that can deliver a wide range of therapeutics, in addition to releasing 
traditional chemotherapeutics in a controlled manner to destroy any other circulating 
tumor cells. It can help establish the structural framework for a nanotechnological 
toolbox that enables cancer drugs to infiltrate cancer’s evasive mechanisms and may be a 
promising new approach to non-invasively treat metastatic cancer, a disease condition 
which has now attained the “chronic” status.  
As previously mentioned, a promising approach to overcoming this drug 
resistance on the cellular scale would be to inhibit the drug efflux pump receptors and 
increase accumulation of chemotherapeutics within the cytoplasm, thereby empowering 
the cytotoxic drug to exert its therapeutic effect by localizing at the nucleus. Several 
pharmacological efforts have explored delivering a variety of appropriate ligands to 
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interdict the drug efflux pumps, but they have not been without unfavorable 
consequences due to local cytotoxicity to normal cells. In this work, we discuss the 
possibility of incorporating such an inhibitory functionality within the delivery system 
itself, thereby avoiding co-delivery of other pharmacological agents and thus, any 
additional unwanted side effects. By implementing a tailorable polymer nanotechnology-
based oral delivery platform, we can provide chemotherapeutics unprecedented access to 
the now “inaccessible” cytoplamsic regions of multidrug resistant tumor cells without 
eliciting any adverse effects.  
During the past few decades, significant efforts have been directed towards 
understanding and interdicting the basic cellular mechanisms by which tumor cells 
acquire resistance to traditional chemotherapeutics such as doxorubicin, tamoxifen, 
cisplatin, methotrexate etc. Owing to multidrug resistance exhibited by such cancerous 
cells, normal cells are more affected by the drug than cancerous cells, since the drug 
diffuses through tissues and cells indiscriminately but leads to death of normal cells while 
cancerous cells continue progression and evasion of apoptosis. Increasing evidence points 
to one major mechanism of multidrug resistance- an over-abundance of efflux pump 
proteins on tumor cell membranes. Proteins such as P-glycoprotein, MRP1, MRP2, and 
BCR, have been observed to be over-expressed in multiple cancer cell lines and are 
responsible for removing cancer drugs (which are substrates for such receptors) to the 
extracellular matrix and away from their site of therapeutic action [1]. This leads to a 
precipitous decrease in the intracellular concentration of the drug and drastically reduces 
the efficacy/ability of the drug to act against cancer cells. Interestingly, P-gp is also 
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amply expressed in many cancers (small and large intestine, liver, pancreas, kidney, 
ovary, and testicle) along with other metabolizing organs such as small and large 
intestine, and the liver [1]. Small intestine and the liver often metabolize orally 
administered anticancer drugs to reduce their bioavailability by coupling p-gp reception 
with CYP450 metabolizing enzyme action. A further application, any solution to 
overcome multidrug resistance could also help shed insight into ways that can broadly 
improve oral bioavailability of such cancer drugs as well.  
One strategy to resolve this issue would be to inhibit these cell membrane proteins 
responsible for the reduced efficacy of cancer drugs. While there may be small molecule 
inhibitors capable of thwarting the action of such efflux pumps, their advantage is not 
without deleterious pharmacological consequence. Several reports have identified 
excipients that can inhibit of P-gp proteins and can interdict the functioning of a wide 
variety of ABC transporter proteins. Much focus has been given to developing 
nanoparticles that can co-deliver small molecule inhibitors of P-gp such as verapamil 
along with chemotherapeutics. However, the results of using such co-delivery led to 
increase in vivo toxicity and were limited to reversing drug resistance only in a few 
cancers. One excipient that has shown striking promise has been polyethylene glycol. 
Presence of PEG (MW~300) in the vicinity of cancer drugs was found to inhibit rat 
jejunal membrane and over-expressing Colon adenocarcinoma cells [2]. In this project, 
we propose to examine the efficacy of PEG by grafting PEG to our nanoparticles. PEG 
grafted nanoparticles can interact with P-gp receptors expressed on cancer cells to reduce 
their function, while simultaneously releasing chemotherapeutics. Such a delivery system 
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that not only delivers but also guarantees one-way transport of drugs is crucial in the 
treatment of metastatic cancer.  
For this study, we plan on using Caco-2 cells which are known to over-express p-
gp proteins on their cell membrane as a model to study release of chemotherapeutics from 
the nanoscale, PEGylated hydrogel particles. We look to evaluate/demonstrate the ability 
of the nanoparticles to increase transport of drug across the cell line using a transport 
study. In addition, we intend to understand the mechanism of P-gp binding/inhibition, the 
mechanism that is used by these nanoparticles to evade p-gp barriers in metastatic cancer 
cells. A detailed understanding of how PEGylated nanoparticles can inhibit p-gp and can 
help further the vast/substantial body of research that can help create a structural 
framework of nanoscale particles that can help overcome multidrug resistance. 
The inhibitory effect of PEG is typically believed to be the consequence of either 
or both of the two mechanisms: (1) direct inhibition/modulation of ATP binding sites of 
drug efflux transport proteins, (2) alteration of cell membrane fluidity leading to 
conformational changes in transport proteins. Previous work suggests that PEG, being 
osmotically active causes local osmotically-driven water transfer across cell membranes, 
thereby altering membrane fluidity. Membrane fluidity changes lead to a modification in 
the structure of drug efflux transport proteins commonly over-expressed in tumor cells, 
indirectly reducing the binding ability of the proteins. Similarly, it is likely that the 
oxyethylene groups in PEG may cause nonspecific steric hindrance of drug binding sites 
or may embed themselves in cell membranes, impeding drug-protein interaction in the 
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binding sites. Both these mechanisms lead to an overall decrease of ATPase activity of 
the efflux proteins in multidrug resistance cells.  
Common methods of overcoming multidrug resistance usually rely on passive 
diffusion of nanoparticles into resistant cells, leading to higher apparent, intracellular 
drug concentrations. However, intravenous administration of nanoparticles is associated 
with challenges of their own such as immunogenicity, renal clearance, and endosomal 
sequestration leading prior to drug release. In addition to inhibition of drug efflux pumps, 
PEG also fulfills a number of other functions such as improved mucoadhesion in the 
small intestine and enhanced biocompatibility. Hence, it is not surprising that other 
approaches use polyethylene glycol alone as an excipient or a solubilizing agent that may 
or may not encapsulate the drug.  
8.2  MATERIALS AND METHODS 
8.2.1 Transport Studies with Nanoparticle Formulations 
8.2.1.1 Cell Culture: 
To provide a model for the intestinal epithelial layer, across which we expect 
doxorubicin to be transported, we used a Caco-2 cell culture, a widely implemented and 
most popular in vitro intestinal cell model [3-5], that was plated on 12-well Corning
®
 
Costar
®
 Transwell
® 
plates (Corning Inc., New York). The 12 well plates were equipped 
with 24mm Corning® Costar ® Transwell® cell culture inserts (Corning Inc., New York) 
with a 0.4 um polyester membrane for cell growth.  
Caco-2 cells were cultured in T-75 flasks until about 80% confluent. Cells were 
then subcultured, counted and plated onto Transwell
®
 inserts placed in 12 well plates at a 
 252 
seeding density of 1x10
5 
cells/cm
2
. Subsequent to plating, the cells were cultured for 21-
24 days with media replaced every other day. 
8.2.1.2 Transepithelial Electrical Resistance (TEER) Studies: 
In the 21-24 days leading up to the study, Caco-2 cells were monitored for the 
formation of tight junctions by performing TEER measurements. Measurement of TEER 
values was performed using a chopstick electrode and an EVOM epithelial volt-ohm 
meter (World Precision Instruments, Sarasota, FL). TEER measurements were performed 
every other day prior to media change to indirectly gauge development of tight junctions 
that are characteristic of Caco-2 cell monolayers.   
Tight junction formation was assessed by calculating resistance of cell layer, 
denoted by Rcell , and computed using the equation: 
Rcell  = Rt – R0  
Where, 
Rt= Resistance at any given time t,  
R0= Resistance related to membrane and media without any Caco-2 cells 
After 21-24 days of culturing Caco-2 cells in the Transwell
®
 plates and ensuring 
attainment of constant TEER values in all wells, the cells were considered to be ready for 
the actual transport study. The transport of doxorubicin in the presence of the library of 
nanoscale hydrogels synthesized as described in Chapter 6 was evaluated and compared, 
to judge the impact of each hydrophobic monomer incorporated on the transport of 
doxorubicin. Prior to conducting the transport study, cell media was removed from the 
apical and basolateral side, and washed thrice with pre-warmed Hank’s Balanced Salt 
Solutions (HBSS) on both sides. The washing was followed with replacing both apical 
and basolateral sides of the insert with the HBSS solution. HBSS was used as a buffering 
system to ensure maintenance of physiological pH and osmotic balance of the solutions 
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across the insert during the course of the transport study. The cells were then allowed to 
equilibrate in their new culture environment for a 2 hour time period, after which their 
TEER values were measured to ensure absence of any disruptions in tight junction 
formation.  
The transport study was started by replacing the HBSS solution on the apical side, 
with pre-dissolved, sterile solutions of nanoparticles in HBSS. Nanoparticle solutions of 
the four formulations were used at a concentration of 1 mg/ml as particle controls to 
assess the impact of pre-swollen polyanionic nanoparticles alone on the tight junctions. 
Another control used included free doxorubicin (0.15 mg/ml) in the presence of cells. 
Control cells were incubated with HBSS alone without any media or doxorubicin. For 
studying doxorubicin transport in the presence of nanoparticles, doxorubicin (250 µL of 
0.15 mg/ml) and nanoparticle formulations (250 µL of 1 mg/ml) were added separately in 
a 1:1 ratio to bring the total apical solution volume to 500 µL. TEER values were 
measured every 15 min for 3 hr. Samples from both apical and basolateral side of the 
inserts were taken every 30 min and analyzed for doxorubicin using UV-Vis 
spectroscopy.  
 
8.2.2 Transport Studies with PEGylated and non-PEGylated Formulations 
8.2.2.1 Cell Culture 
To provide a model for the intestinal epithelial layer, across which we expect 
doxorubicin to be transported, we used a Caco-2 cell culture that was plated on 12-well 
Corning
®
 Costar
®
 Transwell
® 
plates (Corning Inc., New York). The 12 well plates were 
equipped with 24mm Corning® Costar ® Transwell® cell culture inserts (Corning Inc., 
New York) with a 0.4 um polyester membrane for cell growth.  
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Caco-2 cells were cultured in T-75 flasks until about 80% confluent. Cells were 
then subcultured, counted and plated onto Transwell
®
 inserts placed in 12 well plates at a 
seeding density of 1x10
5 
cells/cm
2
. Subsequent to plating, the cells were cultured for 21-
24 days with media replaced every other day. 
8.2.2.2 Transepithelial Electrical Resistance (TEER) Studies: 
In the 21-24 days leading up to the study, Caco-2 cells were monitored for the 
formation of tight junctions by performing TEER measurements. Measurement of TEER 
values was performed using a chopstick electrode and an EVOM epithelial volt-ohm 
meter (World Precision Instruments, Sarasota, FL). TEER measurements were performed 
every other day prior to media change to indirectly gauge development of tight junctions 
that are characteristic of Caco-2 cell monolayers.   
Tight junction formation was assessed by calculating resistance of cell layer, 
denoted by Rcell , and computed using the equation: 
Rcell  = Rt – R0  
Where, 
Rt= Resistance at any given time t,  
R0= Resistance related to membrane and media without any Caco-2 cells 
After 21-24 days of culturing Caco-2 cells in the Transwell
®
 plates and ensuring 
attainment of constant TEER values in all wells, the cells were considered to be ready for 
the actual transport study. The transport of doxorubicin in the presence PEGylated and 
non-PEGylated microscale hydrogels were studied to study the impact of poly(ethylene 
glycol) on the transport of doxorubicin in an intestinal epithelial cell model. We used a 
microscale hydrogel system to test this particular hypothesis because non-PEGylated 
nanoparticles of the system used in other studies were unstable, and aggregated and 
collapsed out of solution. PEG provides additional colloidal stability to the emulsion and 
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facilitates formation of nanoparticles. Absence of PEG prevented the formation of PEG. 
For this transport study, we used P(MAA-co-NVP-g-PEG) microparticles as a substitute 
for our system. We use the non-PEGylated version, namely,  P(MAA-co-NVP) to 
investigate any differential gain in the increase of doxorubicin transport that may be 
arising from PEGylation. 
Similar to the previous transport study, prior to conducting the transport study, 
cell media was removed from the apical and basolateral side, and washed thrice with pre-
warmed Hank’s Balanced Salt Solutions (HBSS) on both sides. The washing was 
followed with replacing both apical and basolateral sides of the insert with the HBSS 
solution. HBSS was used as a buffering system to ensure maintenance of physiological 
pH and osmotic balance of the solutions across the insert during the course of the 
transport study. The cells were then allowed to equilibrate in their new culture 
environment for a 2 hour time period, after which their TEER values were measured to 
ensure absence of any disruptions in tight junction formation.  
The transport study was started by replacing the HBSS solution on the apical side, 
with pre-dissolved, sterile solutions of the particles in HBSS. Particle solutions of the 
four formulations were used at a concentration of 1 mg/ml as particle controls to assess 
the impact of pre-swollen polyanionic nanoparticles alone on the tight junctions. Another 
control used included free doxorubicin (0.15 mg/ml) in the presence of cells. Control 
cells were incubated with HBSS alone without any media or doxorubicin. For studying 
doxorubicin transport in the presence of nanoparticles, doxorubicin (250 µL of 0.15 
mg/ml) and particle formulations (250 µL of 1 mg/ml) were added separately in a 1:1 
ratio to bring the total apical solution volume to 500 µL. TEER values were measured 
every 15 min for 3 hr. Samples from both apical and basolateral side of the inserts were 
taken every 30 min and analyzed for doxorubicin.     
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8.2.3 Doxorubicin Uptake Studies using Image Flow Cytometry  
To prepare for the doxorubicin uptake study, colon adenocarcinoma cells (Caco-2 
cells) were seeded at 1 x 10
5 
cells/well in 6- well plates and grown to 80% confluence, 
and washed with PBS prior to incubation with DOX-loaded nanoparticles. Subsequent to 
attaining confluence, Caco-2 cells were incubated with 200 µL of doxorubicin loaded 
nanoparticles at a concentration of 1 mg/ml. Cells were exposed to nanoparticles for a 
period of 3 hours, after which the solution was aspirated and cells washed 3x with PBS. 
Following the rinses, cells were incubated in 2 mL DMEM and the Hoechst 33342 
nuclear stain was added to each well at a final concentration of 2.5 µg/ml. Cells were 
allowed to incubate with the stain for a period of 45 mins. To generate cell suspensions 
from the adherent Caco-2 cells, trypsin-EDTA was added and incubated at 37
o
C for 8 
min. To avoid deleterious effects to Caco-2 cells, DMEM was added to neutralize the 
trypsin and the collected cell suspension centrifuged for 4 min at 50xg. Post-
centrifugation supernatant was discarded and the cell pellet resuspended to obtain Caco-2 
cells tagged with a nuclear stain and ready to be imaged for doxorubicin uptake. 
Propidium iodide was added to the cell suspensions just prior to flow uptake and analysis 
with ImageStream. 
Cellular uptake of doxorubicin released from doxorubicin-loaded nanoparticles 
was observed in Caco-2 cells using image stream cytometry. The Amnis ImageStream
x
 
(Seattle, WA) imaging flow cytometer has lasers at 405 nm, 488 nm, 658 nm, and 785 
nm. For studies conducted for doxorubicin uptake, we used the following channels to 
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collect fluorescent emission data - Channel 1 (430 – 505 nm) for Hoescht (nuclear stain); 
Channel 2 (505 - 595 nm) for doxorubicin; Channel 4 (595 – 660 nm) for propidium 
iodide which offers distinguishability between live and dead cells, Channel 5 (brightfield 
images), and Channel 6 (745 – 800 nm) for side scatter. A 60x objective was used to 
image the cells. Flow velocity of the fluid was fixed at 40 mm/sec. 
8.2.4 Evaluation of P-glycoprotein Inhibition  
8.2.4.1 Evaluation of P-glycoprotein Inhibition using Multidrug Resistance Assay 
All previous studies and attempts at understanding transport and permeability 
with doxorubicin were conducted with Caco-2 cells, which while known to express P-
glycoprotein, their P-glycoprotein expression varies dramatically based on passage 
number and gene expression levels in vitro. To obtain a more robust understanding of the 
influence of the nanoparticle formulations and their influence on P-glycoprotein, we used 
a different set of cell lines with varied levels of P-gp expression.  
Three cell lines were used to conduct the Vybrant
®
 Multidrug Resistance Assay 
(Life Technologies) with the nanoparticles. P-gp overexpressing and doxorubicin 
resistant, lung carcinoma cell line - NCI H69/LX4 (Sigma Aldrich/European Collection 
of Cell Cultures) was obtained. This cell line (originated at MRC Clinical Oncology, 
Cambridge, UK) has been certified to overexpress P-gp and is resistant to doxorubicin by 
the P-gp efflux mechanism. The cell line was obtained at passage number 5, and cultured 
in RPMI 1640 media with 2mM L-glutamine & 10% FBS along with and 0.4 µg/mL 
doxorubicin (to maintain resistance) as recommended. As a control of normal Pgp 
expression, NCI H69 (Sigma Aldrich/European Collection of Cell Cultures) which is 
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verified to show normal expression of P-gp was also used. Raji B (B lymphpoma) cells 
were used as another control of P-gp underexpression. All cells were cultured until 
sufficient cells were available for assay. 
All nanoparticles formulations were studied with the assay, First, nanoparticle 
solutions ranging from 4 mg/ml to 8 µg/ml were prepared in PBS. As reference, 
cyclosporin A and verapamil hydrochloride, known inhibitors of Pgp were used as 
controls, in addition to blank PBS. Cells were added to 96-well microplates at a 
concentration of 5 x 10
5 
cells in RPMI 1640 media. 50 uL of nanoparticles, reference 
inhibitors were added to the cells and incubated for 15 mins at 37
o
C. After incubation for 
15 mins, microplates were washed 3x by centrifuing for 5 mins at 200g, and supernatant 
removed and resuspended in 200 ul cold RPMI 1640 media. Calcein retention was 
measured by fluorescence at 494 nm(ex)/525(em). 
8.2.4.1 Evaluation of P-glycoprotein Inhibition using Cellular Proliferation Assay 
Lastly, as a final in vitro measure of the nanoparticle formulations to exert a P-gp 
inhibitory/modulatory effect, we evaluated the ability of doxorubicin to induce an anti-
proliferative effect on P-gp overexpressing/doxorubicin-resistant cell line – H69/LX4. As 
controls – H69 and Raji cells were also used.  
For evaluating cellular proliferation, an MTS assay was used with all three cell 
lines. P-gp overexpressing and doxorubicin resistant, lung carcinoma cell line - NCI 
H69/LX4 (Sigma Aldrich/European Collection of Cell Cultures) was cultured in RPMI 
1640 media with 2mM L-glutamine & 10% FBS along with and 0.4 µg/mL doxorubicin 
(to maintain resistance) as recommended. As a control of normal Pgp expression, NCI 
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H69 (Sigma Aldrich/European Collection of Cell Cultures) which is verified to show 
normal expression of P-gp was also used. Raji B (B lymphpoma) cells were used as 
another control of P-gp underexpression. All cells were cultured until sufficient cells 
were available for assay. 
All nanoparticles formulations were studied in the presence of doxorubicin with 
the assay. Cells were added to 96-well microplates at a concentration of 50,000
 
cells/well 
in RPMI 1640 media. First, nanoparticle solutions ranging from 4 mg/ml to 8 µg/ml were 
prepared in RPMI 1640 medium, and added to cells. As reference, the anti-proliferative 
ability of doxorubicin alone was evaluated. The microplates were incubated at 37
o
C for 4 
hours. Subsequent to which the solutions were removed, and cells washed thrice with 
RPMI 1640 media by centrifugation 300g for 5 mins. 20 ul of MTS reagent was then 
added to each well and incubated for 2 hr. Microplates were then read for absorbance of 
formazan indicative of cellular proliferation.  
8.3  RESULTS AND DISCUSSION  
8.3.1 Transport Studies with Nanoparticle Formulations 
To assess permeation of doxorubicin in the presence and absence of nanoscale 
hydrogel formulation, we conducted transport studies using an in vitro intestinal cell 
model. Caco-2 cells were cultured on Transwell
®
 plates for a period of 21-24 days to 
allow for development of tight junctions. Tight junction development was monitored for 
the 21-24 day period by TEER measurements performed using a chopstick electrode and 
an EVOM epithelial volt-ohm meter. The TEER values typically increase from 100 ohm-
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cm
2
 (resembling blank HBSS control and undeveloped tight junctions) to 400-500 ohm-
cm
2
 at the end of the 21-24 day culture period. In contrast to human small intestinal 
epithelial cell monolayers that exhibit TEER values of 50-100 ohm-cm
2
, the in vitro 
intestinal cell model displayed TEER values of about 400-500 ohm-cm
2
 at the end of the 
21-24 day culture period. These tighter junctions obtained in an in vitro experimental 
setting are representative of colonic tight junctions and it is understood that the 
permeability values will be attenuated/underestimated as compared to actual in vivo 
permeability values.  
Permeation studies were performed under same conditions for all four 
nanoparticle formulations serving as vehicle controls for evaluating impact of each 
nanoparticle formulations on tight junction integrity, as well as free doxorubicin serving 
as the free drug control. To investigate the impact of each formulation on the in vitro 
intestinal transport of doxorubicin in the presence of the nanoparticles, the formulation 
was incubated with doxorubicin on the apical side of the Transwell
®
 for a 3 hr period, 
with doxorubicin concentration analyzed regularly on the basolateral side. TEER 
measurements were also taken to monitor tight junction integrity throughout the 
experiment. All formulations were used at a concentration of 1 mg/ml to allow for proper 
comparison between formulations. 
The particle control, or wells containing nanoparticle formulation alone 
contributed to about 20% decrease in TEER measurements which likely to be caused due 
to chelation of Ca
2+
 by the nanoparticle formulation on the apical side driving an influx 
of Ca
2+
 from the basolateral side to the apical side to maintain homeostasis. Chelation of 
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Ca
2+
 by P(MAA-g-EG) hydrogels and resulting flux has previously been reported by 
Ichikawa and Peppas [6]. Since all four nanoparticle formulations comprise of MAA and 
PEG, it is a strong possibility that they impact tight junctions in a similar manner, and 
may providing a pathway of explanation to the decrease in TEER values. Of notable 
mention is the inference that a nanoparticle concentration of 1 mg/ml is sufficient to 
saturate and reach the cell membrane layer and cause Ca
2+
 chelation, in contrast to 
microparticle formulations that typically result in attenuated TEER values at 
concentrations of about 20 mg/ml.          
Doxorubicin transport studies were performed with and without nanoscale 
hydrogels to evaluate the impact of the formulation on in vitro intestinal permeability of 
doxorubicin, and play a role in the determination of an optimal formulation for the end 
goal of improving intestinal permeability. As previously mentioned, nanoparticle 
formulations were pre-swollen in HBSS under sterile conditions at a concentration of 1 
mg/ml and doxorubicin at a concentration of 0.15 mg/ml (polymer:drug=1:0.15), an 
optimal ratio arrived at based on cytotoxicity studies, loading and release studies, and 
pharmacological feasibility calculations. 
The in vitro intestinal model of Caco-2 cells was seeded on Transwell
®
 plates, and 
their health and tight junction development monitored as mentioned in the TEER studies 
section. For the actual transport study, the nanoparticle solution and drug solution were 
added directly onto the cells on the apical side. Samples from the basolateral side were 
collected over a 3 hr time period and doxorubicin was analyzed using a UV-Vis plate 
reader.      
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Apparent permeability was determined using the following equation: 
 
Papp =
dQ(t)
dt
×
1
A × CA0
 
 
In this equation, A is the known area of the cell monolayer and CA0 is the initial apical 
concentration of doxorubicin added. dQ/dt is the slope of the linear regression model fit 
of the transport profile of doxorubicin concentration over the 3 hr period based on the 
basolateral concentrations. This equation is derived from the Fick’s first law of diffusion 
applied to a chemically homogeneous monolayer of known thickness. Q(t) is the 
cumulative amount of doxorubicin transported from the apical side to the basolateral side 
at time t. Lastly, apparent permeability Papp is defined as (K x D)/h, where K is the 
partition of distribution coefficient of doxorubicin within the cell monolayer, D is the 
diffusion coefficient of the doxorubicin within the cell monolayer (cm
2
/s), and h is the 
height or thickness of the cell monolayer.  
The apparent permeability values of doxorubicin in the presence of each of the 
four formulations are shown in Table. By far, the P(MAA-g-PEG-co-MMA) formulation 
is the best performing of them all with an apparent permeability of . The higher 
permeability in the presence of MMA could be attributed to the relatively optimal 
distribution of methacrylic acid moieties available for Ca
+2
 chelation and increased 
transport via tight junction opening, and methyl methacrylate hydrophobic groups that 
may allow the nanoparticles to come closer to the cell monolayer leading to increased 
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doxorubicin transport by passive diffusion. The apparent permeability of free doxorubicin 
without any nanoparticles was higher than with nanoparticles alone. This can be possibly 
ascribed to the solubility-permeability interplay we previously referred to in Chapter 7. 
Presence of nanoparticles with lipophilic moieties in the vicinity can cause some 
absorption of doxorubicin within the particle core. This reduces the free doxorubicin 
concentration available for transport on the apical side at the cell membrane interface, 
leading to a smaller concentration gradient than that when doxorubicin is present without 
any nanoparticles. Lower concentration gradient implies lower transport, and thus lowers 
apparent permeability. This is touted to be an inherent limitation of solubility improving 
nanoformulations, but we can be overcome by combining our amorphous solid 
dispersions with next-stage pharmaceutical processing techniques like spray drying that 
rely on supersaturation to mitigate the solubility-permeability interplay. Indeed, we note 
that the tight junction values for in vitro intestinal models indicate tighter junctions being 
formed in vitro than in vivo, and we anticipate the apparent permeability values for all 
formulations to be higher in vivo than the in vitro values obtained. Lastly, all apparent 
permeability values are in the range of 10
-6
 cm/s, and are consistent with values found in 
the literature involving transport studies with in vitro cell models.  
8.3.2 Transport Studies with PEGylated and Non-PEGylated Formulations 
To evaluate if there is any improvement in the permeation of doxorubicin in the 
presence and absence of PEGylation hydrogel formulation, we conducted transport 
studies using an in vitro intestinal cell model. In this study, we focus on the impact of 
PEG on doxorubicin. PEG has been shown to interact with tight junction proteins in 
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addition to interacting with P-glycoprotein as we have previously mentioned. 
Doxorubicin transport studies were performed with microparticles containing PEG and 
compared to transport with formulations without PEG. 
Caco-2 cells were cultured on Transwell
®
 plates for a period of 21-24 days to 
allow for development of tight junctions. Tight junction development was monitored for 
the 21-24 day period by TEER measurements performed using a chopstick electrode and 
an EVOM epithelial volt-ohm meter. The TEER values typically increase from 100 ohm-
cm
2
 (resembling blank HBSS control and undeveloped tight junctions) to 400-500 ohm-
cm
2
 at the end of the 21-24 day culture period. In contrast to human small intestinal 
epithelial cell monolayers that exhibit TEER values of 50-100 ohm-cm
2
, the in vitro 
intestinal cell model displayed TEER values of about 400-500 ohm-cm
2
 at the end of the 
21-24 day culture period. These tighter junctions obtained in an in vitro experimental 
setting are representative of colonic tight junctions and it is understood that the 
permeability values will be attenuated/underestimated as compared to actual in vivo 
permeability values.  
Permeation studies were performed under same conditions for the two 
formulations namely, P(MAA-co-NVP-g-PEG) and P(MAA-co-NVP). To investigate the 
impact of each formulation on the in vitro intestinal transport of doxorubicin in the 
presence of the nanoparticles, the formulation was incubated with doxorubicin on the 
apical side of the Transwell
®
 for a 3 hr period, with doxorubicin concentration analyzed 
regularly on the basolateral side. TEER measurements were also taken to monitor tight 
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junction integrity throughout the experiment. All formulations were used at a 
concentration of 1 mg/ml to allow for proper comparison between formulations. 
The in vitro intestinal model of Caco-2 cells was seeded on Transwell
®
 plates, and 
their health and tight junction development monitored as mentioned in the TEER studies 
section. For the actual transport study, the nanoparticle solution and drug solution were 
added directly onto the cells on the apical side. Samples from the basolateral side were 
collected over a 3 hr time period and doxorubicin was analyzed using a UV-Vis plate 
reader. The apparent permeability values of doxorubicin in the presence of each of the 
four formulations are shown in Table. By linear-fitting the mass of doxorubicin 
transported from apical-to-basolateral side versus time, we obtained a slope or apparent 
permeability for doxorubicin to be 6.805 x 10
-6
 cm/s for the PEGylated formulation, 
while the slope obtained for the non-PEGylated formulation was 4.472 x 10
-6
 cm/s. Our 
measurements demonstrate and increased transport of doxorubicin from the apical-to-
basolateral side with PEGylated formulations. However, this study does not clearly reveal 
if the increased transport is due to interaction of PEG with P-gp receptors or the 
interaction of PEG with tight junction proteins that may lead to increased paracellular 
transport of doxorubicin, or a combination of the two [6, 7]. To more clearly elucidate the 
interactions of PEGylated nanoparticles with P-gp receptors we measured calcein AM 
retention with P-gp overexpressing cells as described further in section 8.3.4.1.     
8.3.3 Image Flow Cytometry  
Amnis IDEAS
®
 software was used to create the fluorescent compensation 
matrices, and to obtain images of in-focus cells using the Gradient RMS feature that 
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reviews image sharpness. Propidium iodide positive cells were ignored as they represent 
dead cells since propidium iodide can permeate only dead cells, and all attention was 
diverted to live cells (about 1000-2000 live cells were imaged). Any debris present was 
also gated according to side scatter that is capable of discriminating cell 
complexity/granularity from brightfield area. Single cells were honed in by surveying the 
brightfield aspect ratio in comparison to the brightfield area based on the fact that single 
cells have high aspect ratios. However, in case of Caco-2s single cells were hard to obtain 
since many of them adhered to each other forming clumps precluding an ideal number of 
cells for any in-depth analysis.  Pictured in Figure is a panel of representative fluorescent 
micrographs of Caco-2 cells. Channel 1 shows cell nuclei in blue, Channel 2 was used to 
collect fluorescent data from the natural fluorescence of doxorubicin, and while Channel 
5 was used to obtain brightfield images are displayed to show cellular granularity. 
Composite images of Channel 1 and Channel 2 show colocalization of doxorubicin and 
the nucleus visually verifying internalization and uptake of Caco-2 by doxorubicin. 
Composite of all three channels 1, 2, and 5, offers further evidence to the internalization 
of doxorubicin and Caco-2. 
8.3.4 Evaluation of P-glycoprotein inhibition  
8.3.4.1. Evaluation of P-glycoprotein Inhibition: Multidrug Resistance Assay  
An investigation of the influence of nanoparticles on P-gp mediated efflux was 
conducted using a Vybrant
®
 Multidrug Resistance Assay (Life Technologies). This in 
vitro assay compares the capacities of the nanoparticle formulations to interfere with the 
P-gp mediated efflux of a known fluorescent substrate, namely, Calcein AM 
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(acetoxymethyl calcein), and has been used extensively in the literature for screening 
drug compounds and inhibitors for their P-gp inhibitory effect [8-11].   To detect 
inhibition of calcein AM efflux in the presence of the nanoparticle formulations, we used 
a pair of cell lines- one multidrug resistant cancer cell line which overexpresses P-gp 
(H69/LX4) and the parental cell line (H69) which does not overexpress P-gp. As 
previously mentioned, the multidrug resistant cell line is derived from the parental cell 
line by exposure to increasing concentration of doxorubicin over a period 6-9 months and 
numerous replication cycles. Beyond the results described above, a kinetic understanding 
of the inhibition by these formulations is not facilitated by this assay, however given the 
possible non-specific nature of the interactions of PEG with P-gp, these formulations can 
be assumed to be interacting in the capacity of P-gp modulators, rather than competitive 
inhibition. Results of the assay were analyzed by normalizing fluorescence of treatment 
groups to that untreated parental cells as prescribed in the assay protocol. Relative 
fluorescence has also been used to analyze Calcein AM studies in other investigations. 
Formulations were ranked on the basis of effectiveness in inhibition of calcein AM efflux 
by comparing the amount of polymer concentration required to obtain a certain extent of 
P-gp inhibition and thus, calcein retention and increased fluorescence. A dose-response 
curve was plotted to evaluate the ability of the formulations to increase calcein retention 
in MDR cells. Specifically, we evaluated the polymer concentration of each formulation 
to attain 50% of calcein AM specific fluorescence in parental cells to compare 
effectiveness across all formulations, and the curves are shown in Figures 8.4 to 8.7. 
P(MAA-co-tBMA-g-PEG) formulation performed better than the other formulations in 
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this study, with concentration of 0.125 mg/ml being able to restore atleast 50% of 
calcein-specific fluorescence compared to similarly treated parental cells as shown in 
Figure 8.4. This result can be attributed to the smaller size of these nanoscale hydrogels, 
since higher surface area-to-volume ratio can allow for better presentation of the PEG 
grafts (which are believed to modulate Pgp-mediated behavior) to the Pgp proteins 
expressed on the cell membrane surface. It is also possible that the relatively hydrophobic 
nature of this formulation was able to enhance proximity to the cell membrane surface, 
allowing for interaction with P-gp receptors. P(MAA-co-nBA-g-PEG) nanoscale 
hydrogels also exhibited favorable behavior at increasing calcein retention in MDR cells 
as compared to parental cells. P(MAA-co-MMA-g-PEG) nanoscale hydrogels were only 
able to restore 20-30% of the calcein-specific fluorescence and performed inadequately 
as compared to all other formulations. P(MAA-co-nBMA-g-PEG) nanoscale hydrogels 
showed some increase in retention, although the increase was not sufficient to 
appreciably restore greater than 50% of the relative fluorescence.  
8.3.4.2 Evaluation of P-glycoprotein Inhibition: Cellular Proliferation 
In order to further elucidate the effects of the nanoscale hydrogels on Pgp-
mediated efflux, we measured the cytotoxic or anti-proliferative effect of doxorubicin on 
the multidrug resistant H69/LX4 cells and the parental H69 cells, in the presence of the 
formulations. As previously mentioned, the H69/LX4 cells used in this study are resistant 
to doxorubicin, and exclude doxorubicin from the cytoplasm through a Pgp-mediated 
efflux. We hypothesized that the presence of the nanoscale formulations would sensitize 
the doxorubicin resistant cells by interacting with P-gp receptors. As another way to 
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compare the effectiveness of these formulations, the anti-proliferative effects of 
doxorubicin were measured for all formulations with H69/LX4 cells and H69 cells. 
While such sensitization studies have been conducted for parenteral formulations [8-13], 
this is the first study of its kind where drug sensitization studies are being conducted with 
orally deliverable nanoparticle formulations to understand their interactions with P-gp 
receptors. Formulations were compared for their capacities to facilitate the anti-
proliferative effect of doxorubicin on the multidrug resistant cell lines. Cell proliferation 
was measured using an MTS assay and is shown in Figures 8.8-8.11. At the end of four 
hours, there were no significant differences among treatment groups for the cellular 
proliferations obtained for the formulations. Similarly, we did not observe a dramatic 
sensitization of the cells to doxorubicin at the end of the four hours when we measured 
the relative proliferation of the MDR cells. It is possible that a four hour time point may 
be insufficient to highlight the differences among the formulations to mediate P-gp 
efflux, and improve the anti-proliferative potential exerted by doxorubicin upon 
multidrug resistant H69/LX4 cells. The four hour period was chosen keeping consistent 
with the time these formulations will potentially spend in the small intestine, but further 
studies may be conducted on a 3-4 day time period to reflect the doubling time of these 
cells as has been seen elsewhere in the literature.  
8.4  CONCLUSIONS 
Nanoscale hydrogel formulations were investigated for their capacity to modulate 
transport and permeability of hydrophobic therapeutic, doxorubicin in vitro. Transport of 
 270 
doxorubicin in the presence of nanoparticles was studied to assess the impact of the 
formulation on doxorubicin permeability across an intestinal cell model. The P(MAA-g-
PEG-co-MMA) formulation was observed to showed highest permeability improvement 
of doxorubicin across the intestinal epithelial cell model as indicated by transport studies. 
Similarly, the role of PEG in influencing doxorubicin permeability in vitro was 
investigated. PEGylated particles showed an increase in transport as opposed to non-
PEGylated formulations. This may be attributed to an interaction of PEG with tight 
junctions that results in opening of the junctions or/and possibly interaction of PEG with 
P-gp efflux pumps. Further studies to understand the interaction of these nanoscale 
hydrogel formulations with P-glycoprotein were conducted using a calcein AM assay and 
cellular proliferation assay. In the calcein AM study, multidrug resistant H69/LX4 cells 
exhibited greater calcein AM retention when incubated with P(MAA-co-tBMA-g-PEG) 
nanoscale hydrogels, demonstrating atleast 50% restoration of calcein-specific 
fluorescence. In addition, the cellular proliferation assay was used to evaluate the ability 
of the hydrogel formulations to sensitize doxorubicin-resistant H69/LX4 cells to the anti-
proliferative ability of doxorubicin. However, none of the formulations showed a large 
decrease in cellular proliferation of H69/LX4 cells at the end of the four-hour study. 
Results from the calcein AM study, in combination with the transport studies support the 
hypothesis that the panel of nanoscale hydrogel formulations synthesized can influence in 
vitro permeability of doxorubicin, and can potentially exhibit favorable behavior 
anticipated from nanoscale hydrogels to be used for oral delivery of hydrophobic 
therapeutics. Lastly, the set of in vitro studies described in this chapter serve as a novel 
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paradigm or set of tests that can be used together, as part of an integrative 
physicochemical and biological approach for in vitro testing or screening of nanoscale 
oral formulations. 
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Table 8.1 Doxorubicin transport with nanoscale hydrogel formulations 
 
 
Table 8.2 Doxorubicin transport with hydrogel formulations containing PEG and 
hydrogel formulations without PEG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Apparent Permeability (Papp) (x 10
6
 
cm/s) 
P(MAA-g-PEG-co-tBMA)  5.56 
P(MAA-g-PEG-co-nBMA)  2.77 
P(MAA-g-PEG-co-nBA)  3.53 
P(MAA-g-PEG-co-MMA)  6.94 
Formulation Apparent Permeability (Papp) 
(x 10
6
 cm/s) 
[P(MAA-co-NVP) w/ PEG] 
Microparticles + DOX 
6.805 
[P(MAA-co-NVP) w/o PEG] 
Microparticles  
4.472 
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Figure 8.1: A schematic of the set-up for the transport studies conducted using 
Transwell® plates. 
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Figure 8.2: Doxorubicin transport with nanoscale hydrogel formulations. Studies were 
conducted with 1 mg/ml nanoscale hydrogel formulations incubated with 
Caco-2 cells and 0.15 mg/ml doxorubicin. n=4, Data points represent mean 
+/- SD.  
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Figure 8.3: Transport of doxorubicin in the presence of PEGylated formulation vs non-
PEGylated formulations. Studies were conducted with 1 mg/ml hydrogel 
formulations incubated with Caco-2 cells and 0.15 mg/ml doxorubicin. n=4, 
Data points represent mean +/- SD.  
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Figure 8.4: Representative fluorescent micrographs of doxorubicin uptake by Caco-2 
cells. Channel 1: cell nuclei in blue, Channel 2: doxorubicin, Channel 5: 
brightfield images.  
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Figure 8.5: Relative calcein retention in P-gp overexpressing multidrug resistant cells 
(H69/LX4) and parental cells (H69) upon incubation with calcein AM (a P-
gp substrate) and P(MAA-co-tBMA-g-PEG) nanoscale hydrogel 
formulation. Increase in calcein retention can be observed beyond a 
concentration of 0.125 mg/ml. Relative calcein retention calculated by 
normalizing calcein fluorescence for sample to untreated parental cells. n=3, 
data points represent mean +/-SD.   
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Figure 8.6: Relative calcein retention in P-gp overexpressing multidrug resistant cells 
(H69/LX4) and parental cells (H69) upon incubation with calcein AM (a P-
gp substrate) and P(MAA-co-nBMA-g-PEG) nanoscale hydrogel 
formulation. Relative calcein retention calculated by normalizing calcein 
fluorescence for sample to untreated parental cells. n=3, data points 
represent mean +/-SD.   
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Figure 8.7: Relative calcein retention in P-gp overexpressing multidrug resistant cells 
(H69/LX4) and parental cells (H69) upon incubation with calcein AM (a P-
gp substrate) and P(MAA-co-nBA-g-PEG) nanoscale hydrogel formulation. 
Increased calcein retention was observed beyond a concentration of 0.5 
mg/ml. Relative calcein retention calculated by normalizing calcein 
fluorescence for sample to untreated parental cells. n=3, data points 
represent mean +/-SD.   
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Figure 8.8: Relative calcein retention in P-gp overexpressing multidrug resistant cells 
(H69/LX4) and parental cells (H69) upon incubation with calcein AM (a P-
gp substrate) and P(MAA-co-MMA-g-PEG) nanoscale hydrogel 
formulation. No significant increase in calcein retention was observed. 
Relative calcein retention calculated by normalizing calcein fluorescence for 
sample to untreated parental cells. n=3, data points represent mean +/-SD.   
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Figure 8.9: Cellular proliferation MTS assay with P(MAA-g-PEG-co-tBMA) and 
doxorubicin against doxorubicin-resistant H69/LX4 cells. n=4, data 
expressed as mean +/- SD.  
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Figure 8.10: Cellular proliferation MTS assay with P(MAA-g-PEG-co-nBMA) and 
doxorubicin against doxorubicin-resistant H69/LX4 cells. n=4, data 
expressed as mean +/- SD. 
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Figure 8.11: Cellular proliferation MTS assay with P(MAA-g-PEG-co-nBA) and 
doxorubicin against doxorubicin-resistant H69/LX4 cells. n=4, data 
expressed as mean +/- SD. 
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Figure 8.12: Cellular proliferation MTS assay with P(MAA-g-PEG-co-MMA) and 
doxorubicin against doxorubicin-resistant H69/LX4 cells. n=4, data 
expressed as mean +/- SD. 
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Chapter 9:  Conclusions and Future Recommendations  
In this thesis, novel pH-responsive, nanoscale hydrogels capable of delivering 
hydrophobic therapeutics orally were developed. The nanoscale hydrogels described here 
were evaluated for design criteria desirable from an effective oral delivery system that 
can potentially improve the solubility and GI tract permeability of hydrophobic 
therapeutics, and makes an original and significant contribution to the existing literature 
on using nanotechnology for oral delivery of hydrophobic therapeutics. Lastly, the set of 
in vitro studies described in this chapter serve as a novel paradigm and a comprehensive 
set of tests that can be used together, as part of an integrative physicochemical and 
biological approach for in vitro testing or screening of nanoscale oral formulations.  
Four nanoscale hydrogel formulations with unique hydrophobic monomers at the 
same nominal feed composition were synthesized using a robust, reproducible 
photoemulsion polymerization method. These novel nanoscale hydrogels were then fully 
characterized for their physicochemical and biological characteristics. Composition of the 
copolymer was varied by incorporating four different hydrophobic monomers, namely, 
tert-butyl methacrylate, n-butyl methacrylate, n-butyl acrylate, and methyl methacrylate. 
A combination of 
1
H-NMR and FTIR verified the unique composition of each 
formulation. All four nanoparticle formulations underwent a transition in size in response 
to an increase in pH from 4 to 7.5 in physiologically relevant buffer with a critical 
swelling of around 4.9, as measured by dynamic light scattering measurements. 
Depending upon the hydrophobic monomer incorporated within the polymer network, 
dynamic light scattering revealed a compositional trend as the size of the formulations 
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ranged from about 100-500 nm at the relevant pH.  Incorporation of methyl methacrylate 
in the copolymer resulted in the formation of nanoparticles with the largest size transition 
as demonstrated by dynamic light scattering measurements. Higher nanoparticle size can 
be attributed to the emulsion characteristics, while the swelling behavior is likely the 
result of interplay between reactivity ratios of component monomers as well as emulsion 
properties. Negative zeta potential as determined by electrophoretic light scattering 
measurements is attributable to the presence of deprotonated carboxylic acid groups on 
the polymer backbone, and is in good agreement with literature and the design rationale.  
We analyzed cytocompatibility of the nanoparticles with an in vitro intestinal cell 
model. Despite considerable changes in swelling properties with a change in the 
hydrophobic monomer, all formulations displayed appreciable cytocompatibility in the 
presence of an in vitro intestinal cell model. The viability data from the LDH assay was 
supported by an MTS assay that confirmed healthy cellular proliferation in the presence 
of the nanoparticles. By displaying amenable physicochemical properties and agreeable 
cytocompatibility, the pH-responsive nanocarriers thus, exhibited the key characteristics 
expected from a potential oral drug delivery system. Both the size and swelling response 
of the nanoscale hydrogels could be controlled by varying the hydrophobic monomer 
component of the formulation. Incorporation of a different hydrophobic monomer did not 
appear to affect the . However, incorporation of did result in a fold increase in the 
swelling response. Relate molecular and nanoscale structure to function 
We examined and compared the capacity of the nanoparticle formulations to load 
and release the hydrophobic therapeutic, doxorubicin. The physicochemical and 
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structural properties of the nanoparticles were ideal for the encapsulation of hydrophobic 
therapeutics. Doxorubicin, a broad spectrum hydrophobic chemotherapeutic was chosen 
as the model delivery payload to test the loading capacity of nanoscale hydrogels.  
Loading studies were performed at pH 7.4 when the hydrogel networks are fully swollen. 
The capacity of loading hydrophobic therapeutics into the nanoscale hydrogel 
formulation is expected to be influenced by the hydrophobic interactions between the 
drug and the hydrogel, and the ability of the hydrogel to swell and permit diffusion of the 
drug during the loading procedure. By changing the hydrophobic comonomer in the 
nanoparticle formulations, we were able to successfully load doxorubicin, with loading 
efficiencies ranging from 40-70%, with the P(MAA-g-PEG-co-MMA) formulation 
showing the highest loading efficiency. Further, we investigated the ability of these 
formulations to perform favorably under pH conditions similar to those encountered 
during transit through the GI tract. Specifically, we examined their ability to retain 
doxorubicin at an acidic pH expected to be found at the site of the stomach, and release 
the drug in response to alkaline conditions of the small intestine. P(MAA-g-PEG-co-
tBMA)  released most of the loaded drug, about 95.55% of the loaded drug after about 6 
hours at pH 7 (total 8h). P(MAA-g-PEG-co-MMA) released about 74.71% of the drug in 
6 hours at pH 7. The almost linear release response of P(MAA-g-PEG-co-tBMA) may 
suggest surface or close to surface loading of doxorubicin in these nanoscale hydrogels 
despite considerable surface washing. It could also mean that small size of these 
hydrogels imply minimal diffusion path length for doxorubicin to diffuse out assuming 
similar tortuosity in all nanoscale hydrogel formulation pores.  Powder X-ray diffraction 
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analysis revealed the amorphous nature of the drug formulations suggesting an increase 
in the solubility of doxorubicin under conditions mimicking the site of drug release. 
Solute diffusion and permeation were explored indirectly through the use of membrane 
hydrogel networks with the same monomer feed composition as the nanoscale hydrogel 
formulations, although little or no correlation exists between the behavior of the 
nanoscale and macroscale networks. It is, however, worthwhile to note that partitioning 
of the solute in the membranes increased over time, while permeation is believed to 
proceed with a lag phase that can be attributed to size exclusion phenomena. Nanoscale 
hydrogel formulations exhibited the capacity to load and release the hydrophobic 
therapeutic doxorubicin, and varying the hydrophobic comonomer keeping the same 
nominal feed composition can play a role in modulating drug loading/release efficiencies. 
Nanoscale hydrogel formulations were investigated for their capacity to modulate 
transport and permeability of hydrophobic therapeutic, doxorubicin in vitro. The P(MAA-
g-PEG-co-MMA) formulation was observed to showed highest permeability 
improvement of doxorubicin across the intestinal epithelial cell model as indicated by 
transport studies. Similarly, the role of PEG in influencing doxorubicin permeability in 
vitro was investigated. PEGylated particles showed an increase in transport as opposed to 
non-PEGylated formulations. This may be attributed to an interaction of PEG with tight 
junctions that results in opening of the junctions or/and possibly interaction of PEG with 
P-gp efflux pumps. Further studies to understand the interaction of these nanoscale 
hydrogel formulations with P-glycoprotein were conducted using a calcein AM assay and 
cellular proliferation assay. In the calcein AM study, multidrug resistant H69/LX4 cells 
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exhibited greater calcein AM retention when incubated with P(MAA-co-tBMA-g-PEG) 
nanoscale hydrogels, demonstrating atleast 50% restoration of calcein-specific 
fluorescence. In addition, the cellular proliferation assay was used to evaluate the ability 
of the hydrogel formulations to sensitize doxorubicin-resistant H69/LX4 cells to the anti-
proliferative ability of doxorubicin. However, none of the formulations showed a large 
decrease in cellular proliferation of H69/LX4 cells at the end of the four-hour study. 
Results from the calcein AM study, in combination with the transport studies support the 
hypothesis that the panel of nanoscale hydrogel formulations synthesized can influence in 
vitro permeability of doxorubicin, and can potentially exhibit favorable behavior 
anticipated from nanoscale hydrogels to be used for oral delivery of hydrophobic 
therapeutics. Lastly, the set of in vitro studies described in this chapter serve as a novel 
paradigm or set of tests that can be used together, as part of an integrative 
physicochemical and biological approach for in vitro testing or screening of nanoscale 
oral formulations. The observed interactions can be subsequently explored for more 
information regarding the interactions between PEGylated nanoparticles and P-
glycoprotein receptors.   
The work described in this thesis specifically focused on improving solubility and 
permeability of a small molecule hydrophobic therapeutic for the treatment of liver 
cancer. For oral administration based treatment of a cancer such as liver cancer, it is 
essential that the drug be released at the site of the small intestine, and that it is 
transported across the GI tract into the blood stream. To facilitate the oral delivery of the 
hydrophobic therapeutics, we looked at design parameters and material properties of 
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polymeric hydrogels that can be modulated. Despite the success in formulating a delivery 
system for a poorly water-soluble drug, some concerns remain - mainly, local 
cytotoxicity of doxorubicin to the intestinal lining, and lack of a mechanism to guide the 
small molecule chemotherapeutic to the site/organ of action. These two concerns are 
separate projects that need a dedicated undertaking of their own, and the synthetic 
chemistry involved in accommodating these modifications depend largely on the type of 
therapeutic being delivered, and the afflicted organ being targeted.  In addition, owing to 
the small size of the nanoparticles, they can also be passively uptaken by intestinal cells 
such as M cells. Finally, we speculate on some of the modifications that could help 
bridge the mismatch between perceived shortcomings and desirable performance for 
reaping potential clinical benefits.  
To mitigate these concerns, several areas of this work can be pursued as future 
work. For instance, conjugation of doxorubicin or any other model hydrophobic drug, to 
permeation enhancers such as bile acids, surfactants can further reinforce the transport of 
the drug across the intestinal cell wall. Depending on the cancer being treated using these 
nanoscale oral delivery formulations, the drug can be conjugated with a suitable targeting 
ligand to guide delivery to tumoral / sub-cellular site of action. Moreover, to further 
enhance the loading capacity of these hydrogels, several other hydrophobic monomers 
may be investigated to observe variations in size and swelling behavior. The use of 
microparticles can also increase loading ability and be a good safeguard against marginal 
passive uptake of carriers by intestinal M cells.  
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Additionally, other diverse approaches for cancer therapy can also be pursued. 
The field of nanomedicine for cancer therapy, especially, has seen a drastic increase in 
research focus and publications in the past 5 years or so. The following approaches are 
representative of some of the more recent work in the field for the treatment of primary, 
metastatic and multidrug resistant cancers. Peptide/aptamer ligand conjugation for 
improved targeting ability of nanoparticles can be used to overcome physiological 
barriers to oral drug delivery. In addition, switching the charge on the hydrogels by 
varying the hydrophilic monomer, these nanoscale hydrogels can be used for the 
intravenous delivery for treatment of metastatic cancer/ anti-angiogenic therapy using 
nanotechnology. Concomitant gene therapy or delivery of multiple drugs can be used to 
normalize the tumor microenvironment and improve treatment outcomes. Finally, 
subsequent evaluation of these nanoscale hydrogels for the oral delivery of hydrophobic 
therapeutics should involve in vivo studies in an appropriate animal disease model to 
obtain a truer assessment of hydrophobic drug bioavailability.   
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APPENDIX B: BACKGROUND – MULTIDRUG RESISTANT PROTEINS  
 
Multidrug resistance proteins have always played an important in regulating the 
influx and efflux of drug entities through cells. Multidrug resistance proteins such as P-
glycoprotein (P-gp) and multidrug resistance-associated proteins (MRP) are typically 
found in epithelial cells and endothelial cells of the gastrointestinal tract, liver, kidney, 
blood brain barrier, choroid plexus and other organs. Interestingly, these “difficult-to-
deliver” organs are characterized by such multidrug resistance gate keepers, necessitating 
their thorough experimental investigation and formulating general strategies to overcome 
their impact, be profoundly studied. There is no doubt that the implications of evaluating 
their molecular action and methods to pre-empt their otherwise protective function, could 
be of tremendous prognostic import by improving bioavailability of orally administered 
drugs, as well as, the outcome of chemotherapy in metastatic diseases. In this review, we 
present an overview of recent biological findings about regarding MRPs and outline 
strategies to target these proteins for a therapeutic advantage for oral delivery and cancer 
therapy. A synergy that combines approaches to tackle these two conditions may appear 
to be materially taxing but can be therapeutically beneficial. 
Analogies can be drawn between drug resistance in chemotherapy to antibiotic 
resistance in microogranisms and weed resistance in genetically-modified crops. A foray 
into investigating the causes of resistance to drugs on a cellular level led to an emerging 
consensus that implicated two chief mechanism of action. One way cells become resistant 
to cancer drugs is by eliciting alterations in their cell replication cycles to combat the 
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apoptosis-inducing nature of most cancer drugs. The second way drug resistance is 
achieved by chemotherapeutic-exposed cancer cells is by way of drug efflux – a tactic 
that greatly reduces intracellular drug concentration by recycling apoptotic drug 
molecules out of the cell, thereby, pre-empting cell death. Research conducted since the 
1970s has convincingly demonstrated that cytotoxic cancer drugs typically used in multi 
regimen chemotherapy are evacuated from the cytosol using a family of energy-
dependent transporters known as ATP-binding cassette (ABC) transporters. The most 
commonly purported culprit of this family of transporters is P-glycoprotein (Pgp, also 
known as ABCB1 or MDR1). While largely over-expressed in a wide range of cancer 
cell types, these are the same transporters naturally prevalent in epithelial and endothelial 
cells of various organs in the gastrointestinal tract, renal clearance system and hepatic 
system of the body to mediate movement of nutrients, drugs and toxic substances. The 
key difference between the two being that in case of resistant cancers, these are over-
expressed in response to chemotherapy, whereas in epithelial and endothelial cells they 
are present naturally. Despite this subtle difference, pharmacological approaches have in 
the two distinct fields have intuitively borrowed heavily from each other to combat this 
unintentional resistance to accumulation/uptake of drugs by cells, and attenuated 
therapeutic outcomes. We begin by elucidating the multifarious components of the ABC 
transporter family, mentioning the current strategies to overcome resistance, and 
outlining future trends in this field that can be enabled by the growing body of literature 
in nanomedicine.     
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Multidrug resistance proteins, a class of proteins first discovered in the 1970s in 
tumor cells with a multidrug resistant phenotype (hence the name), play a pivotal role in 
maintaining the selectivity of the intestinal epithelial cell layer and ensuring extraction of 
needed nutrients, electrolytes, minerals and water. Intestinal enterocytes express this 
group of transporters/ plasma membrane transporters to modulate solute and fluid 
transport between the gut and the bloodstream, by serving as a final physiological barrier 
at the molecular level. Intriguingly, some members of this protein group are also found to 
play a pivotal role in regulating transmembrane transport of substrates across cell 
membranes of the epithelium in the liver, kidney, and the endothelial lining/ capillary cell 
surface of the blood-brain barrier. This large presence of MDR protein transporters at 
strategically important locations suggests their importance in body’s natural 
detoxification mechanism, an argument subsequently underscored by strong evidence in 
its favor. 
 These “pumps” remove substrates from the cell cytosol in an energy-dependent 
manner, resulting in decreased intracellular concentrations of the substrate and foiling 
further transport of the substrate downstream. While this works when the aptly named 
efflux pumps facilitate removal of unwanted toxins, bacteria, and antigens, it in fact, 
reduces the concentration of cytotoxic drugs germane for improved chemotherapeutic 
efficacy. Since this family of transporters was implicated for conferring resistance to a 
wide range of chemotherapeutics and reduced bioavailability of a number of other 
therapeutics, substantial research attention has been dedicated to enhancing our 
understanding of how these work and can be overcome.  
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Concerns regarding this rather undesirable role played by MDR efflux pumps were 
amplified upon realization of the fact that these transmembrane receptors identify and 
selectively remove hydrophobic molecules, a structural characteristic of many a cancer 
drugs. The dawn of this realization has fomented considerable research in developing 
drugs, and/or combination approaches that involve evasion of efflux or inhibition of 
transporter function to deliver chemotherapeutics to their subcellular site of action. 
Broadly, these approaches have included, (a) development of entirely new 
chemotherapeutics/ appropriately modified renditions of existing chemotherapeutics that 
are not substrates to the MDR protein receptors, (b) concomitant use of drugs that inhibit 
the receptors, while allowing chemotherapeutics to pass through successfully, and (c) use 
material-based approaches to evade/inhibit drug efflux receptors.  
Each of the aforementioned approaches have been accompanied by challenges 
owing to the broad substrate specificity of these receptors and the sheer number at the 
multiple physiological checkpoints a drug typically encounters. Compelling evidence 
supports the implication of these MDR proteins in the abysmal permeability and 
subsequent bioavailability of chemotherapeutics in bioequivalence studies. Orally 
delivered substrates undergo significant efflux, first at the site of the intestinal epithelium, 
which is followed by clearance from the liver and kidneys. Understanding the mechanism 
of action of these transporters can help further inform and elucidate strategies to 
overcome the unwelcome effect of MDR protein transporters. This section is of particular 
importance given the vast importance that is typically given to synthesis of nanocarriers 
to achieve greater degree of control over molecular architecture, while grossly neglecting 
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several other physicochemical and physiological obstacles that need to be surmounted to 
achieve favorable prognostic outcomes in anticancer therapy.            
 MOLECULAR BIOLOGY OF ABC TRANSPORTERS 
ABC transporters function through a pair of two distinctive domains- two transmembrane 
domains (TMD) and two nucleotide binding domains (NBD), each serving a unique 
purpose. Structural evidence suggests that the two nucleotide-binding domains (NBD) 
sequester ATP to empower the efflux of the drugs by forming a common binding site, 
while the two transmembrane domains (TMD) trace a porous path utilizing 
transmembrane helices within the cell membrane to allow for efflux of drugs out of the 
cytosol. This structure is consistent with most members of the ABC transporter family, 
except the ABCG2 (or mitoxantrone-resistance protein MXR) or breast cancer resistance 
proteins (BCRP), which exhibit only a one half set that combines with another half set to 
achieve full functionality.  
The evacuative phenotype of the ABC transporters and the wide range of substrates that 
they eliminate from the cytosol, are considered to be strong proof of their role in the 
general detoxification and protection of the body from foreign bodies and substances. 
This understanding is supported by compelling evidence uncovering the structure and 
function of these receptors, and their extensive presence on the surface of key 
pharmacological barriers that regulate substrate transport at a cellular level such as, the 
intestinal cells, hepatocytes, proximal tubules of the kidney, and the blood-brain barrier. 
Additional regulation at the cellular level by these transporters can thus further attenuate 
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the effective delivery of drug molecules despite optimal design in terms of 
physicochemical properties and chemical/metabolic transformations [5 of targeting 
multidrug]. This fact has ushered in a growing body of literature, not just aimed at 
developing high throughput screening of their tissue distribution levels, but also finding 
strategies that address delivery challenges associated with overcoming ABC transporters 
by assessing the predisposition of early stage, candidate drug molecules to act as 
substrates. Techniques developed by the pharmaceutical industry to screen drugs for their 
susceptibility to ABC transporter clearance are described in detail in subsequent sections.  
The ABCB  subfamily 
While the manifestations of multidrug resistance have recently been shown to be driven 
by atleast 12 ABC transporters belonging to four subfamilies, the ABCB subfamily has 
been implicated with the highest and the broadest resistance to compounds. In particular, 
the Pgp transporter especially plays the most significant role in impeding transport in 
both intestinal epithelial cells, as well as multidrug resistant cells [10 from targeting 
multi]. While a direct correlation between Pgp expression and poor patient prognosis in 
response to chemotherapy in multidrug resistant cancers is still lacking, tissue culture 
studies and in vivo experiments have demonstrated that Pgp expression can significantly 
reduce favorable outcomes in chemotherapy. In fact, the first ever study showing 
multidrug resistance in cancer cells involved the use of Pgp inhibitors such as verapamil 
to stop the efflux of chemotherapeutics. Recent evidence points to certain molecules and 
structural families that may be more susceptible to efflux than others. Substrates for Pgp 
transporters are a wide range of molecules which include but are not limited to 
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anthracyclines, vinca alkaloids, epipodophyllotoxins and taxanes. Typically, Pgp has 
been found to transport unmodified neutral or positively charged hydrophobic 
compounds more prominently than others.  
 What makes tackling Pgp resistance intriguing, challenging and simultaneously 
slightly less daunting, is its wide substrate specificity. This promiscuity in substrate 
recognition, works against achievement of ideal, desirable outcomes in chemotherapy, 
but also open a window of opportunity to examine the use of a wide range of 
modulators/inhibitors of Pgp activity that can potentially reverse the detrimental efflux of 
chemotherapeutics by Pgp.  
The ABCC subfamily 
In addition to neutral or positively charged molecules, ABCC subfamily members 
are also denoted by the term multidrug resistance associated-proteins (MRPs) and are 
known to translocate organic anions and metabolic products generated by 
conjugation/chemical modification of toxins entering cells. Recent discoveries have 
indicated an active removal of compounds such as glutathione (GSH), glucuronate or 
sulfate conjugates of organic anions, and unconjugated bile acids. In line with the 
previously mentioned unfortunate effect of otherwise strategically important transporters, 
MRPs capacity to selectively remove therapeutic molecules that fit these molecular 
characteristics can lead to unwanted drug elimination. Combined with a strong 
enzymatic/metabolic system such as the cytochrome 450 (CYP450) that tags molecules 
for subsequent elimination, MRPs present another potent mechanism for drug elimination 
prior to their demonstration of therapeutic effect.  
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 ABCC1, ABCC2, ABCC3, ABCC6, and ABCC10 comprise a portion of the 
ABCC subfamily, which display an additional group that contains an amino-terminal 
transmembrane domain and a cytoplasmic linker, which is also found in all other 
members of the ABCC subfamily like ABCC4, ABCC5, ABCC11, and ABCC12. 
ABCC1 or MRP1 is the most notorious subfamily member of the ABCC family with the 
evidenced reputation of conferring resistance to multiple hydrophobic compounds that 
are already substrates to Pgp, and further buttressing efflux of potent drug molecules 
already associated with multidrug resistance. Whether this association with substrates for 
Pgp transporters is a causal effect or a mere incidental result of having a similar 2 TMD 
and 2 NMD receptor structure, is not known with clarity at this point. While MRP1 is 
predominantly present in cancer cells displaying a MDR phenotype (based on 
observations in both clinical cancers and cancer cell lines), its homologue and close 
family member MRP2, is located in the apical membranes of polarized cells of the 
intestine and liver. This is an important observation implicating the role of MRP2 in the 
associated efflux of Pgp substrates that are orally administered, while MRP1 plays a 
synonymous role in augmenting the removal of Pgp substrates in MDR cancer cell lines. 
Another ABCC subfamily member of notable mention is MRP3 which is expressed in the 
kidney, liver and gut, and has shown propensity towards removal of several anticancer 
drugs and bile acid species. Additionally, gene transfection studies have revealed that 
MRP-6 transfected cells become resistant to anticancer agents like etoposide, teniposide, 
doxorubicin and daunorubicin, while MRP7 increases resistance to taxanes such as 
paclitaxel.      
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The ABCG subfamily 
The ABCG subfamily is the final family member with any evidence implicating its role 
in the efflux of anticancer or orally ingested drug molecules either in vitro or in vivo. The 
most notable chemoresistance-causing member of this family is the ABCG2 transporter 
(also known as the mitoxantrone resistance protein (MXP) and breast cancer resistance 
protein (BCRP), which has shown clear demonstration of drug efflux in cancer cell lines. 
In cell lines engineered to overexpress these transporters, substrates were rapidly and 
completely removed, and included a broad range of molecules such as cytotoxic drugs, 
tyrosine kinase-based/anti-angiogenesis inhibitors, toxins and even carcinogens found in 
food.     
SIGNIFICANCE OF ABC TRANSPORTERS IN ANTICANCER DRUG DELIVERY AND ORAL 
DRUG DELIVERY 
 
Emergence of the role played by efflux transporters in both oral drug delivery and 
anticancer drug delivery has been a crucial advance, despite the fact that a stronger 
broadening of the database of substrates as well as implicated transporters that can 
contribute to undesirable drug efflux continues to grow. There are also ongoing studies 
looking to further develop critical experiments that can establish a correlation between 
reduced drug sensitivity in clinical studies and the direct impact of regulating transporter 
function. Thus far, evidence suggests that there are approximately 31 ABC transporters 
(out of 48) that could be impacting drug chemosensitivity and oral bioavalability. Other 
non-ABC transporters that have revealed their role in affecting oral absorption, are also 
being investigated for their role in inducing chemoresistivity. As previously mentioned, 
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only Pgp, ABCG2, and MRP1 transporters have been evaluated for their role in abating 
chemosensitivity in clinical trials so far. Among these, Pgp has the highest capacity and 
the widest substrate specificity for elimination of drugs, and as a consequence the effect 
of evading Pgp associated drug efflux has been most extensively studied, both in 
improving chemosensitivity as well as increasing drug bioavailability. Clinically 
speaking, trials that have co-delivered Pgp-transport inhibitors to patients alongside first- 
or second-line chemotherapy have demonstrated a definite benefit over simply 
chemotherapeutic delivery. Although it is important to note that the broad specificity of 
ABC transporters and lack of a comprehensive list of transporters make it difficult to 
conclusively confirm inhibition of Pgp-mediated efflux alone. Cross-resistance or 
inhibition of multiple transporters that may be structurally similar to Pgp is a possibility 
across the entire gamut of clinical tumor types/level of progression. Clinical evidence 
also points out to the fact that drug substrates triggering Pgp efflux in a set of cancer 
cells, end up selecting for proliferating cancer cells capable of surmounting 
chemosensitivity by non-Pgp-mediated transport. Given the heterogeneity of various 
solid tumors and the fact that resistance can be acquired by Pgp expressing cells to non-
Pgp cells as well (by cross-resistance), has made establishment of a direct connection 
between high Pgp expression and poor clinical prognosis all the more difficult. On the 
contrary, the adverse impact of Pgp overexpression on patient survival has been more 
evident in haemotological malignancies like leukemia, due to the ease with which protein 
expression can be identified and quantified in a reproducible manner, as compared to 
solid tumors. Whether expression of other ABC transporters are just as widely relevant in 
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influencing patient survival post-MDR as Pgp remains to be clarified with confidence. 
There have been reports of ABCG2 being overexpressed in cancer stem cells that may 
play a role in tumor relapse subsequent to first-line chemotherapy, but once again, the 
degree to which ABCG2 transporters are utilized in inducing and exhibiting the final 
MDR phenotype second-line chemothterapy has to combat remains unclear.          
OVERCOMING MULTIDRUG RESISTANCE WITH INHIBITORS 
 
Studies associated with determining appropriate inhibitors for ABC transporters 
are crucial for both overcoming multidrug resistance to improve patient survival as well 
as, pinpointing new paradigms to link the exact effect of these transporters on clinical 
outcomes. Insights have been brought by using several inhibitors of Pgp, obtained by 
screening for molecules/structures that act as substrates to the Pgp receptor. In the past, 
such structure-based approaches have spawned generations of superior therapeutics for 
the treatment of neointimal hyperplasia in atherosclerosis, finding structural analogues to 
suboptimal chemotherapeutics, and finding mechanisms for receptor-mediated 
endocytosis of nanoparticles. 
Identification of genes coding for multidrug resistance, and the synthesis of multidrug 
resistant cell lines is carried out by a process, which selects for surviving cells continually 
exposed to cytotoxic drugs (Targeting multidrug resistance in cancer). Using this 
approach, a number of cell lines are available for commercial testing and validation of 
multidrug resistance inhibition for drug formulations. The following table summarizes 
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some of the multidrug resistant cell lines that are available for in vitro research and the 
mechanism by which resistance is acquired.  
In general, there are three established methods of acquiring drug resistance: 
1. Decreased uptake of drugs that are substrates for uptake transporters 
2. Anti-apoptotic mechanisms that alter cancer cell cycles and lead to increased 
repair of DNA damage 
3. Increased energy-dependent efflux of hydrophobic drugs that would otherwise 
permeate easily through the plasma membrane 
 In this work, we investigate the inhibition of pathway number 3, owing to its 
significance in the role played for multidrug resistance towards doxorubicin and other 
hydrophobic drugs that we wish to encapsulate within our system. We specifically seek to 
explore the ability of our nanoformulation to inhibit P-glycoprotein receptors that are 
typically overexpressed in intestinal cells. P-gp is reported to have shown increased 
transport of unmodified neutral or positively charged hydrophobic compounds. Some of 
the common examples of chemotherapeutics transported by P-gp include but are not 
limited to doxorubicin, etc. We examine the inhibition of P-gp receptors using a 
multidrug resistant MDR1-Pgp assay kit (SOLVO Biotech), and a multidrug resistant 
calcein AM assay (Life Technologies). Furthermore, we observe the uptake of 
doxorubicin by multidrug resistant lung cancer cells using scanning confocal microscopy. 
We had a wide variety of cell lines to choose from as far as multidrug resistant cell lines 
go. Eventually, we settled on a metastatic, multidrug resistant lung cancer cell line 
because of the similarity between mucus covered lung epithelial cells and intestinal 
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epithelial cells, and because the cell line was characterized to have acquired multidrug 
resistance by an overexpression of P-gp receptors. Some other cell lines that can act as 
models for multidrug resistant cancers are presented in the tables below. 
 
Cell Line Disease Cell type Cell line type References 
ATCC® CCL-119™ 
[CCRF CEM] 
Acute 
lymphoblastic 
leukemia 
Human: 
T lymphoblast 
Parental - 
Transfection
able 
http://www.atcc.or
g/Products/All/CC
L-
119.aspx#generali
nformation 
CEM/C2 ATCC® 
CRL-2264™ 
Acute 
lymphoblastic 
leukemia 
Human: 
T lymphoblast 
Drug 
Resistant 
(atypical: 
toposiomeras
e mutation) - 
Transfection
able 
http://www.atcc.o
rg/Products/All/C
RL-2264.aspx; 
http://www.ncbi.nl
m.nih.gov/pubmed
?cmd=Retrieve&li
st_uids=7579731&
dopt=AbstractPlus 
HL-60 (ATCC® CCL-
240™ 
acute 
promyelocytic 
leukemia 
Human: 
Promyeloblasti
c- myeloblastic 
Parental - 
Transfection
able 
http://www.atcc.or
g/Products/All/CC
L-
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(morphology) 240.aspx#generali
nformation 
HL-60/MX2 (ATCC® 
CRL-2257™ 
acute 
promyelocytic 
leukemia 
Human: 
lymphoblast 
MDR 
(atypical- 
altered 
topoisomeras
e catalytic 
activity) 
http://www.atcc.or
g/Products/All/CR
L-
2257.aspx#general
information 
MES-SA (ATCC® 
CRL-2274™) 
Uterine 
sarcoma 
Human: 
Epithelial – 
morphology 
fibroblast 
Parental - 
Transfection
able 
 
MES-SA/MX2 
(ATCC® CRL-2274™) 
Uterine 
sarcoma 
Human: 
Fibroblast 
morphology 
(non epithelial 
origin) 
MDR (over 
expression of 
P-gp) 
http://cancerres.a
acrjournals.org/c
ontent/43/10/4943
.long; 
http://www.atcc.or
g/Products/All/CR
L-
;http://www.ncbi.n
lm.nih.gov/pubme
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d?cmd=Retrieve&l
ist_uids=4028002
&dopt=AbstractPl
us2274.aspx#histor
y 
 
EMT6/AR1 (Mouse) 
mammary 
tumor  
Mouse: 
Epithelial-like 
morphology 
MDR 
(classical- 
over 
expression of 
P-gp) 
http://www.sigma
aldrich.com/catal
og/product/sigma/
96042327?lang=e
n&region=US 
 
EMT6/P (Mouse) 
Mammary 
tumor 
Mouse: 
Epithelial-like 
morphology 
Parental  
COR-L23/R Large cell lung 
cancer 
Human: 
Epithelial-like 
MDR 
(typical but 
not P-
gp/MDR1; 
instead MRP 
– Multi-drug 
Overexpression of 
MRP. Also, 
reduced levels of 
glutathione and 
glutathione-S-
transferase 
 326 
resistance-
associated 
protein) 
activity; 
http://www.sigmaa
ldrich.com/catalog/
product/sigma/960
42339?lang=en&re
gion=US 
http://www.sigmaa
ldrich.com/catalog/
papers/3011054 
COR-L23 Large cell lung 
cancer 
Human: 
Epithelial-like 
Parental http://www.sigmaa
ldrich.com/catalog/
papers/3011054 
MDR1 Knockout 
C2BBe1 
Colon 
adenocarcinom
a (Caco-2 
subclone) 
Human: 
Epithelial-like 
MDR: 
MDR1 
knockout/lac
king in P-gp 
 
NCI-H69/LX4 Small cell lung 
cancer 
Human: 
floating 
aggregates/ 
epithelial like 
MDR 
(classical- 
over 
expression of 
P-gp) 
http://www.phe-
culturecollections.
org.uk/products/c
elllines/generalcel
l/detail.jsp?refId=
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96042329&collect
ion=ecacc_gc 
http://www.sigma
aldrich.com/catal
og/papers/131369
0 
http://www.sigma
aldrich.com/catal
og/papers/301105
4 
http://www.sigma
aldrich.com/catal
og/papers/202220
53 
http://europepmc.o
rg/articles/PMC20
01423?pdf=render 
NCI-H69 Small cell lung 
cancer 
Human: 
floating 
aggregates/ 
epithelial like 
Parental http://www.phe-
culturecollections.
org.uk/products/c
elllines/generalcel
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l/detail.jsp?refId=
91091802&collect
ion=ecacc_gc 
 
 
 It is well established that the multispecificity in transmembrane protein 
transporters drives variations in the pharmacokinetics of myriad drugs, even becoming 
the root cause of undesirable drug-drug interactions owing to multidrug resistance 
resulting from resistance that initially emerged against one drug [6,7 of in vitro methods 
in drug transporter interaction assessment]. Stringent guidelines for drug formulation-
transporter interactions expected from drug manufacturers by regulatory authorities such 
as the FDA and EMA, have driven a foray into the development of in vitro tools that can 
help better predict and understand the structural basis for drug-transporter interactions. 
Moreover, the ubiquitous presence of these transporter proteins in several tissue linings 
that serve as pharmacological check-points for membrane transport indicates the extent of 
their importance in the development of effective early-stage product development 
screening tools. Given the changing landscape of the regulatory environment and the 
exorbitant costs associated with in vivo studies and clinical trials, it also makes 
unequivocal fiscal sense to prescreen drug formulations predictably prior to launching in 
vivo studies and clinical trials. Here we present some of the routinely conducted, 
prescribed drug-transporter studies that can aid in the forecasting of in vivo and clinical 
behavior arising from drug-transporter interactions. Broadly, examination of drug 
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formulations in the presence of entities that express properties associated with MDR 
function, (1) Live cell-based methods include, cancer cell lines overexpressing MDR 
transporters, or intestinal/hepatocytic cell monolayer models, (2) Indirect methods such 
as, ATPase assays (that ascertain if the drug competes with transporter proteins to utilize 
ATP), and membrane vesicles that overexpress transporter proteins [in vitro methods]. 
Each method has its merits and shortcomings, and as is the case with all in vitro methods, 
variability in actual clinical performance is to be presumed.  
Live cell-based Methods to evaluate drug-efflux transporter interaction 
These methods are best suited for hydrophobic compounds that can access the substrate 
binding sites of the efflux transporters located on the transmembrane domain ensconced 
within the lipid bilayer of the cells. As a result, free drug formulations of hydrophobic 
therapeutics that are able to passively come into contact with transmembrane domains of 
the protein can be evaluated for their interaction with transporters using this method. 
Hydrophilic drugs that may be unable to come into intimate contact with the substrate 
binding sites may be unable to elicit a robust efflux response from the transporters.   
Indirect Methods to evaluate drug-efflux transporter interaction 
Vesicular transport assays   
Membrane vesicles that display the substrate binding site to the solvent can prove to a 
crucial tool in the investigation of substrate binding to the transporters. This method can 
definitely minimize any variations in the concentration of substrate at the binding site that 
may rise from poor passive diffusion of the substrate into the lipid bilayer/cytoplasmic 
leaflet.   
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APPENDIX C: BUILDING VASCULAR NETWORKS 
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